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Abstract
Severe fever with thrombocytopenia syndrome virus (SFTSV) is a highly pathogenic emergent bunyavirus.
First isolated in 2009 in China, SFTSV is now endemic to several east Asian countries where high case
fatality ratios of 6-30% are reported. The primary tick vector of SFTSV, Haemaphysalis longicornis, has a
large range and is a well reported invasive species throughout the world. This, in addition to SFTSV’s
ability to spread in the absence of its vector in nosocomial and veterinary settings, suggests SFTSV is
well suited to cause widespread lethal outbreaks. Currently no vaccines or therapeutics against SFTSV
exist, prompting health agencies to list SFTSV as a high priority pathogen. Here, we first develop a single
dose recombinant vesicular stomatitis virus (rVSV) encoding the SFTSV glycoproteins Gn/Gc as a virus
vectored vaccine. We demonstrate that this vaccine (rVSV-SFTSV) is safe in immunocompromised mice
and not neuropathogenic when delivered intracerebrally. Additionally, this vaccine induces robust antibody
responses that are protective from lethal challenge. Furthermore, we demonstrate that this vaccine elicits
cross-protective responses against the closely related Heartland virus. We then developed an mRNA
vaccine encoding SFTSV Gn/Gc and compared this platform with our rVSV-SFTSV vaccine in single dose,
homologous prime-boost, and heterologous prime-boost regimens. We found that mRNA immunizations
in single dose and homologous prime-boost regimens achieved the highest neutralizing antibody titers.
Immunizations with rVSV-SFTSV also reached high antibody titers though they were the lowest titers of
any immunization regimen, with heterologous prime-boost having intermediate titers. When T-cell
responses were analyzed, mRNA immunization achieved robust CD4+ and CD8+ responses in single dose
and homologous prime-boost regimens. Heterologous vaccine regimens elicited similar responses to
homologous mRNA strategies despite weak cellular activity after rVSV-SFTSV prime. Despite some
differences in immunogenicity, all vaccines were protective from lethal SFTSV challenge. Overall, this
work demonstrates the effectiveness of two vaccine platforms in their ability to elicit robust protective
responses against SFTSV.
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ABSTRACT
DEVELOPMENTOF NOVEL VACCINATION STRATEGIES AGAINST EMERGING
BUNYAVIRUSES
Tomaz Berquo Manzoni
Paul Bates, PhD
Severe fever with thrombocytopenia syndrome virus (SFTSV) is a highly
pathogenic emergent bunyavirus. First isolated in 2009 in China, SFTSV is now endemic
to several east Asian countries where high case fatality ratios of 6-30% are reported.
The primary tick vector of SFTSV, Haemaphysalis longicornis, has a large range and is
a well reported invasive species throughout the world. This, in addition to SFTSV’s ability
to spread in the absence of its vector in nosocomial and veterinary settings, suggests
SFTSV is well suited to cause widespread lethal outbreaks. Currently no vaccines or
therapeutics against SFTSV exist, prompting health agencies to list SFTSV as a high
priority pathogen. Here, we first develop a single dose recombinant vesicular stomatitis
virus (rVSV) encoding the SFTSV glycoproteins Gn/Gc as a virus vectored vaccine. We
demonstrate that this vaccine (rVSV-SFTSV) is safe in immunocompromised mice and
not neuropathogenic when delivered intracerebrally. Additionally, this vaccine induces
robust antibody responses that are protective from lethal challenge. Furthermore, we
demonstrate that this vaccine elicits cross-protective responses against the closely
related Heartland virus. We then developed an mRNA vaccine encoding SFTSV Gn/Gc
and compared this platform with our rVSV-SFTSV vaccine in single dose, homologous
prime-boost, and heterologous prime-boost regimens. We found that mRNA
immunizations in single dose and homologous prime-boost regimens achieved the
highest neutralizing antibody titers. Immunizations with rVSV-SFTSV also reached high
antibody titers though they were the lowest titers of any immunization regimen, with
vi

heterologous prime-boost having intermediate titers. When T-cell responses were
analyzed, mRNA immunization achieved robust CD4+ and CD8+ responses in single
dose and homologous prime-boost regimens. Heterologous vaccine regimens elicited
similar responses to homologous mRNA strategies despite weak cellular activity after
rVSV-SFTSV prime. Despite some differences in immunogenicity, all vaccines were
protective from lethal SFTSV challenge. Overall, this work demonstrates the
effectiveness of two vaccine platforms in their ability to elicit robust protective responses
against SFTSV.
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CHAPTER 1: Introduction
1.1 – Emerging Bunyaviruses
As humans come into increasingly close contact with wild animals due to urban
sprawl, the likelihood of encountering emergent viruses, newly discovered viruses with
increasing incidence, increases concurrently1. In the last several decades there have
been many new pathogenic viruses including Middle East respiratory syndrome virus,
severe acute respiratory syndrome coronaviruses 1 and 2 (SARS-CoV-1 and SARSCoV-2), and Nipah virus, among many others, have caused significant impact to
humans. Indeed, many of the major epidemics and pandemics of the last century,
including Ebola virus (EBOV), human immunodeficiency virus (HIV), and various
coronaviruses (CoV), have been associated with zoonotic transmission from animal
reservoirs2-4. Among the recent emergent viruses are the viruses in the Bunyavirales
order which pose serious public health and economic threats5.
1.1.1 Introduction to Emergent Bunyaviruses
The Bunyavirales order encompasses a large and diverse set of viruses found
throughout the world (Figure 1.1). These viruses are generally characterized by having
multisegmented, single stranded RNA genomes that are either ambisense or negative
sense6. The genomes of these viruses are generally comprised of three segment (with
the exception of the Arenaviruses, which have two segments and are a recent addition
to the order Bunyavirales)6,7. Most viruses in this order are spread by arthropod vectors
such as mosquitos, flies, or ticks; the two exceptions to this are the Hantaviruses, which
are spread by aerosolization of rodent feces, and the Arenaviruses which cause chronic
asymptomatic infections in their rodent hosts (due to their significant differences in
virology, Arenaviruses are not discussed further)6. This order of viruses includes many
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Figure 1.1 Global Distribution of Pathogenic Bunyaviruses The distribution of
various pathogenic bunyaviruses discussed in the text are shown. RVFV and CCHFV
share a similar distribution throughout much of Africa and reaching into the Arabian
Peninsula. CCHF extends to western Asia and southeast Europe. SFTSV is endemic
to much of east Asia while it’s closely related counterpart, HRTV, is found in the
midwest of the United States. Also shown are the locations of three New World
hantaviruses, SNV, ANDV, and BCCV; and three Old World hantaviruses, HTNV,
DOBV, and PUUV. Figure created in BioRender.com
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important pathogens with high economic and health burdens associated with livestock
and human disease.
Many bunyaviruses pose public health and economic hazards including Rift
Valley fever virus (RVFV), Crimean-Congo hemorrhagic fever virus (CCHFV), and
severe fever with thrombocytopenia virus (SFTSV). One of the first identified
bunyaviruses was RVFV which was first isolated in the 1930’s during a large outbreak
that led to the death of many livestock animals and hemorrhagic fever in humans8,9.
Since this outbreak, retrospective studies have identified suspected RVFV outbreaks
dating as far back as 1912 and outbreaks continue to this day8,9. A member of the
Phenuiviridae family, RVFV is spread by mosquitos. In mosquitos, it infects the midgut
after a blood meal from an animal carrying the virus at a high enough viremia6. Once the
virus replicates in the midgut it eventually travels to the salivary glands of the mosquito
where, upon the next blood meal, it is injected into the skin of the bitten animal6. As is
seen in many other bunyaviruses, RFVF can be transmitted transovarially and is
seasonal/cyclical according to conditions favoring its vector8. RVFV is endemic to subSaharan Africa and the Arabian Peninsula where it represents a major economic and
health hazard (Figure 1.1)8,9. The virus infects domestic ruminants causing high rates of
mortality and abortions or fetal malformations in pregnant animals8,9. In humans, RVFV
generally causes a self-limiting febrile illness but in some cases can cause severe
disease including hemorrhagic fever, neurologic disorders, and blindness8,9. These
symptoms, including hemorrhagic fever and neurologic disorders are common
symptoms of many other bunyaviruses6. The potential for RVFV to cause large
outbreaks and significant economic damage cannot be overstated. Since the discovery
of RVFV, many more deadly bunyaviruses have been identified which often share similar
disease manifestations and life cycles to those of RVFV.
3

Many other bunyaviruses represent public health threats. The hantaviruses
include several species such as Sin Nombre virus (SNV) and Andes virus (ANDV) which
are spread by aerosolized mouse feces (Figure 1.1)6. Human infection by hantaviruses
often manifests itself through hemorrhagic fever with renal syndrome (HFRS) or
hantavirus cardiopulmonary syndrome (HPS)10. HFRS is caused by old world
hantaviruses, such as Hantaan virus (HTNV), Dobrava-Belgrade virus (DOBV), and
Puumala virus (PUUV), with reported cases in China alone reaching as high as 100,000
cases a year10. New world hantaviruses, such as SNV, ANDV, and Black creek canal
virus (BCCV), cause HPS which has a case fatality ratio of 40-50%10. Infection by new
world hantaviruses is less common with 816 cases reported from 1993 to 2019 by the
Centers of Disease Control11.
The tick-borne virus CCHFV is another source of significant health and economic
burden. Disease caused by CCHFV was originally described in 1944 and the virus was
later identified in 196812,13. CCHFV has a high case fatality rate of approximately 30%
and shares a similar disease course and range to RVFV13. Like many bunyaviruses, the
burden of disease for CCHFV remains understudied due to it primarily impacting rural
farmworkers. More recently discovered bunyaviruses include SFTSV and heartland virus
(HRTV), identified in 2009 and 2011 respectively14-16. HRTV was discovered in the
Midwest of the United States and is transmitted by the lone-star tick16. Despite the
prevalence of the HRTV tick in the Midwest, the disease remains uncommon with few
recorded cases. Its Asian counterpart, SFTSV, on the other hand has become
commonplace in East Asia and is considered an endemic seasonal disease (Figure
1.1)17,18. SFTSV has quickly become a major public health concern due to its high case
fatality ratio, lack of treatment options, and the expanding range of its tick vector. A
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common theme among the Bunyaviruses is the pervasiveness of high case fatality ratios
and a lack of effective treatment and preventative therapies.
1.1.2 SFTSV Epidemiology
SFTSV first emerged in 2009 in the rural Hubei and Henan provinces of China15.
An unknown illness with a case fatality ratio (CFR) of 30% was observed in patients
presenting with fever, thrombocytopenia, leukopenia, and gastrointestinal symptoms15.
After ruling out anaplasmosis and other suspected pathogens, a virus was isolated by
culturing a variety of cell lines with patient serum15. Sequencing of viral RNA identified a
novel Bunyavirus, SFTSV15. Since the initial report of SFTSV in China, several other
countries including Japan, Vietnam, and South Korea, have reported CFRs ranging from
6-30%17,19,20. These numbers are likely overestimates of actual CFR due to SFTSV
incidence in rural areas and the likelihood of unreported asymptomatic cases.
Clinical disease of SFTSV is characterized by fever, leukopenia, and
gastrointestinal symptoms including nausea, vomiting, and diarrhea21,22. These initial
symptoms generally occur 3-7 days after a tick bite or other exposure21,22. In general,
patients with mild disease recover from these symptoms after approximately a week and
see viral titers decrease over 2 weeks after initial disease onset21. In patients with severe
disease, however, virus titers continue increasing and new symptoms manifest. These
symptoms are far more serious including hemorrhagic manifestations such as
disseminated intravascular coagulation and pulmonary and gastrointestinal bleeding,
central nervous system (CNS) disorders such as tremors, convulsions, and comas, and
acute respiratory distress21,22. Patients with severe illness often experience multiorgan
distress which may be reversible in some patients, however, this often leads to
multiorgan failure and death21. Infection by the closely related HRTV induces similar
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disease manifestations23. Currently no approved therapeutics exist against SFTSV, thus,
patients can only be treated for manifested symptoms, not the underlying disease.
Like other viruses in the Phenuiviridae family, SFTSV is a tick-borne disease.
The primary vector of SFTSV is the Asian long-horned tick, Haemophysalis longicornis,
though other tick species have been found to be positive for SFTSV24. Work with the
closely related HRTV suggests that these viruses can be transmitted among ticks
transstadially and transovarially25,26. Additionally, cofeeding of ticks allows uninfected
ticks to acquire the virus, though this transmission method appears to be rare26. It
remains unknown whether ticks, mammals, and/or birds are reservoir species for SFTSV
and HRTV. Several serologic studies have found a wide range of animals to be seropositive for SFTSV, including sheep, cattle, dogs, and chickens27. As a tick-borne
disease, SFTSV incidence increases seasonally from early spring to late fall.
Additionally, environmental predictors of tick populations including cattle density,
temperature, rainfall, and forest coverage correlate with incidence of SFTSV22. Of
particular concern is the expanding range of the invasive H. longicornis tick. Originally
endemic to China, Japan, Korea, and eastern Russia, H. longicornis was introduced to
Australia, and New Zealand in the 19th century and has been recently identified in
eastern United States28,29. Spatial modeling of climates suitable for H. longicornis
suggest a potential for the tick to greatly expand its range leading to ecologic, and
economic damage28. Indeed, tick surveys in New Jersey have found all immature life
stages of H. longicornis suggesting a viable population30. Currently, no ticks outside of
eastern Asia have been found positive for SFTSV, yet the expanding presence of this
vector threatens to increase SFTSV incidence around the world.
Though primarily tickborne, SFTSV has been shown to be infrequently
transmitted by other means. Ferret studies have shown that SFTSV can be transmitted
6

in the absence of ticks when animals are co-housed or co-housed with a separator31.
This transmission is thought to be due to contact with bodily fluids, as SFTSV was
detected at high titers in ferrets’ saliva, urine, and feces31. Indeed, several cases of
nosocomial transmission have been reported in humans that have been exposed to
blood from infected individuals32. Additionally, zoonotic transmission from cat bites have
been reported in veterinary settings33,34. Due to the potential for severe disease,
evidence of human-to-human transmission, the ever-increasing range of the SFTSV
vector, and a lack of vaccines or therapeutics, SFTSV is classified as a Category C
Priority Pathogen by the National Institutes of Health and is often included in lists of high
priority pathogens by other health organizations35,36.
1.1.3 SFTSV Biology
As with other members of the Phenuiviridae family of viruses, SFTSV has a
tripartite RNA genome composed of a large (L), medium (M), and small (S) segment
(Figure 1.2)15. Both the 6.3 kilobase-pair (kb) L and the 3.3 kb M segments are negative
sense and encode the RNA dependent RNA polymerase (RdRp) and the glycoproteins
(Gn/Gc) respectively15. The 1.7kb S segment is ambisense with the nucleocapsid (N)
encoded in one direction and a non-structural protein (NSs) encoded in the opposite
orientation15. Each RNA segment has terminal complimentary regions and thus each
segment is predicted to form a noncovalently closed loop (Figure 1.2)6. The N protein
encapsidates the viral genome and is essential for transcription and replication by the
RdRp, which is found in complex with the viral RNA and N6. The glycoproteins Gn/Gc
are found on the membrane of the virus and confer specificity and enables viral entry
into cells6,37. The NSs protein is an interferon (IFN) antagonist38. Fully formed SFTSV
virions are pleiomorphic and range from 80-100nm15.
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Figure 1.2 STSV Virion Structure and Genome Organization SFTSV is an
enveloped virus with a pleiomorphic structure. Its surface is coated with the
glycoprotein complex Gn/Gc. The virion carries the three segmented negative sense
RNA genome. The large segment (L) encodes the polymerase, the medium segment
(M) encodes the glycoproteins as a polyprotein, and the small segment (S) encodes
the nucleoprotein and NSs. Unlike other segments, the S segment is ambisense.
Created with BioRender.com
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The infection cycle of SFTSV and other Bunyaviruses begins with interaction of
the glycoproteins, Gn/Gc, and their receptor, which induces receptor-mediated
endocytosis6,39. As endosomes acidify, Gn/Gc mediated fusion of viral and endosomal
membranes occurs, releasing viral nucleoproteins into the cytoplasm where SFTSV and
other bunyaviruses replicate6,39. The RdRp mediates viral transcription and replication
within the cytoplasm, which is thought to be membrane associated. Replication and
transcription are dependent on both the presence of RdRp and N6. The SFTSV
glycoproteins Gn/Gc are produced as a single polyprotein which is then cleaved by a yet
to be identified protease6,39. In cells, the uncleaved precursor of Gn/Gc is not observed,
indicating that cleavage occurs co-translationally6. Once cleaved, Gn and Gc remain
associated as dimers within the endoplasmic reticulum (ER) and golgi compartments
due to the presence of ER and golgi localization signals40. Interestingly, Gn can exit the
ER when expressed alone, but Gc cannot6. This indicates that oligomerization of the two
glycoproteins is necessary to overcome the ER retention signal found in Gc6. The Gn/Gc
complex is capable of budding and is sufficient for the formation of virus like particles6.
Viral particles are made when Gn/Gc bud into the golgi with S, M, and L fragments.
Once in the golgi the virus is transported out of the cell by vesicles.
SFTSV entry is mediated by Gn/Gc presenting a potential target for therapeutic
and vaccine development. It is unclear which glycoprotein subunit is responsible for
imparting specificity; both proteins are likely involved in binding. Multiple studies have
failed to isolate an SFTSV receptor, and entry factors remain poorly characterized.
Several studies have indicated that the lectin dendritic cell-specific intercellular adhesion
molecule 3-grabbing nonintegrin (DC-SIGN) is likely involved in SFTSV entry, as
knockout cells showed decreased viral infection37. While DC-SIGN is involved in SFTSV
entry it cannot be the sole receptor, as cell types lacking DC-SIGN can be infected by
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SFTSV37. After receptor-mediated endocytosis, fusion is then mediated by the Gc
subunit37,41. This has been shown to occur in late endosomes and is pH dependent with
fusion occurring at a pH of approximately 5-5.542. Proteins associated with viral entry are
also poorly characterized, though studies show that UDP-glucose ceramide
glucosyltranferase (UGCG) is a contributing factor. In UGCG-knockout cells, SFTSV
virions are unable to fuse and fail to exit late endosomes, preventing viral replication43. It
is known that antibodies against either Gn or Gc can neutralize virus37,44,45. This
indicates that both subunits likely play a role in interacting with receptors. Neutralization
of Gn/Gc thus presents a potential target in the development of vaccines, although
further work is needed to identify key entry factors on the host cell.
Although the receptor for SFTSV is unknown, several groups have investigated
the cellular and tissue tropism of the virus. In one study in humans, it was found that in
fatal disease the primary target organs for SFTSV were the lymph nodes46. High levels
of SFTSV were also detected by immunohistochemistry and real-time quantitative
polymerase chain reaction (RT-qPCR) in the spleen and bone marrow46. The primary
cell types infected by SFTSV were macrophages and class-switched B cells46. Mouse
models of SFTSV have shown similar targets with virus detected in the spleen, lymph
nodes, liver, and kidney of infected animals47. The targets of infection in mice appear to
be primarily macrophages and B cells, resembling human infections47. Another similarity
between infections in mice and humans is the high levels of virus detected in the lymph
nodes in fatal disease47. Notably, a difference between infection in mice and humans is
the absence of hemophagocytosis in the mouse model47. This symptom is characteristic
of fatal cases in humans but not observed in mice. This is perhaps due to the lack of IFN
signaling in the most commonly used SFTSV animal models.
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1.1.4 Animal Models for SFTSV
The development of efficacious vaccines and therapeutics is dependent on the
availability of good animal models to test potential therapies. Quality animal models must
meet several criteria, among them: achieving similar disease course as in humans,
reasonable cost of use, and availability of tools to assess immune responses. In general,
all animal models currently employed to study of SFTSV are lacking in at least one of
these areas (Table 1.1). The current animal models of SFTSV infection are aged ferrets,
cats, and immunosuppressed or newborn mice and hamsters (Table 1.1).
One of the better models at recapitulating human disease is the SFTSV aged
ferret model31,48. In a study with various mouse strains as well as aged and young ferrets
it was found that aged ferrets (³4 years old) succumbed to SFTSV by 8 days post
challenge48. In contrast, young ferrets challenged equivalently exhibited no lethality and
only minor clinical symptoms48. Aged ferrets showed a variety of clinical symptoms of
disease that mimicked what is seen in human patients; this included fever, severe
thrombocytopenia, decreased white blood cell count, and increases in both aspartate
aminotransferase and alanine aminotransferase48. High viral titers were detected in the
spleen, liver, and serum of aged animals48. Overall, this model captures clinical
manifestations of SFTSV well, despite a lack of CNS symptoms and a lack of any
mortality in young animals (despite a higher mortality in older humans, SFTSV can be
fatal in younger individuals). Notably, an aged ferret model is unlikely to gain traction as
a widely used animal model. Very few vendors offer ferrets ³4 years old, and when they
are available these animals carry a significant financial cost. Labs are also unlikely to
purchase and maintain ferrets until they are old enough to manifest clinical symptoms,
again due to the overwhelming cost associated with such an experiment. Finally, few
tools are available for the analysis of immunological responses limiting the ability to
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Animal

Strain/Age

Immunocompetence

Lethality

Mouse

WT
Newborn

Incompletely
developed immune
system

Lethal

WT Adult

Immunocompetent

Non-lethal

WT Aged

Immunocompetent

Non-lethal

IFNAR Ab

Temporarily
immunocompromised

Lethal

Ifnar-/-

Immunocompromised

Lethal

Stat1-/-

Immunocompromised

Non-lethal

Stat2-/-

Immunocompromised

Lethal

WT
Newborn

Incompletely
developed immune
system

Non-lethal

WT Adult

Immunocompetent

Non-lethal

Stat2-/-

Immunocompromised

Lethal

≤2 Years
Old

Immunocompetent

Non-lethal

≥4 Years
Old

Immunocompetent

Lethal

Russian
blue,
American
shorthair

Immunocompetent

Lethal

Rhesus
macaque

Immunocompetent

Hamster

Ferret

Cats

Non-Human
Primates

Immunologic tools

Not a good model for
vaccine studies

Readily
available

Table 1.1 Current animal models of SFTSV
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Expense of IFNAR Ab
Lacks full immune
capabilities useful for
vaccine studies

Lacks full immune
capabilities useful for
vaccine studies

Somewhat
available
Lacks full immune
capabilities useful for
vaccine studies

Lacking

Lacking

Non-lethal

Accessibility/barriers
to use

Somewhat
available

Not readily available;
Expensive; Risk of
bites and scratches;
Known transmission of
SFTSV in absence of
tick
Expensive; Risk of
bites and scratches;
Known transmission of
SFTSV in absence of
tick; Ethical concerns

dissect responses elicited by potential vaccines. Taken together, ferrets recapitulate
human SFTSV disease well, but are limited in their use for the development of treatment
strategies. This model may however become useful in the end-stages of development of
therapeutics.
Another animal that shows clinical symptoms mirroring what is seen in humans is
the SFTSV cat model. It has been widely reported that cats (including domestic cats and
in one case a cheetah) can be infected by SFTSV and manifest clinical symptoms49,50. A
small study of 6 cats experimentally infected with SFTSV demonstrated a 66% fatality
rate50. All animals showed severe thrombocytopenia and decreased white blood cell
counts, surviving animals began recovery at approximately day 14 post infection50.
Additionally, cats infected with SFTSV developed high fever, extensive gastrointestinal
symptoms, and hepatic and renal damage consistent with what is seen in humans
infected with SFTSV50. As previously discussed with the ferret model, an SFTSV cat
model has many shortcomings such as cost and lack of tools for deep analysis of
immune responses. Both ferrets and cats are also far more difficult to handle and pose a
danger to researchers who must conduct these studies in animal biosafety level 3
facilities (ABSL3). Transmission of SFTSV through a cat bite has been documented and
ferrets have been shown to transmit SFTSV to cohoused animals33. Both animal models
have been shown to contain high titers of SFTSV in their bodily fluids48,50. Therefore, a
bite or scratch from a challenge animal could prove fatal making these animal models
potentially dangerous and unlikely to become commonplace.
The most common animal used as a model in research is the mouse. Extensive
work has been done to identify mouse models that effectively recapitulate human
SFTSV disease. The mouse model is ideal for research and development of novel
vaccines and therapeutics due to the short lifespan, rapid reproduction, and ease of
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handling, as well as their affordability and availability of extensive genetic and biological
tools. Unsurprisingly, due to the ease of use of this animal model various groups have
attempted to find mouse strains that recapitulate with reasonable accuracy human
SFTSV disease. One study analyzed 12 immunocompetent mouse strains (including
aged mice in these strains) and found that none of the tested immunocompetent mouse
strains succumbed to lethal disease47. This study demonstrated that wild type C57/BL6
mice did have some weight loss upon challenge despite no lethality47. SFTSV has been
shown to cause lethal disease in wild type mice only when mice are newborn47. This is
likely due to newborn mice lacking a developed immune system capable of mounting a
significant response to infection. As such, newborn mice are not useful in vaccination
studies or for the analysis of pathologic responses.
Due to the lack of lethality of SFTSV in wild type mice, most groups rely on
immunocompromised animals. The primary immunocompromised mouse model is the
IFN alpha/beta receptor knockout (Ifnar-/-) mouse47,51,52. Most studies developing novel
SFTSV targeted therapies or vaccines have made use of Ifnar-/- mice as SFTSV causes
lethal disease that closely mimics SFTSV symptoms in humans. The caveat of studies
using Ifnar -/- mice in vaccine studies is that IFN signaling is critical in initiating immune
responses that lead to immunity. Regardless, even without an IFN response many
studies have been able to make strides in the development of SFTSV therapeutics.
Other immunocompromised animals that have been identified to be susceptible to lethal
SFTSV infection are mice and hamsters that are Stat2-/-53. Like Ifnar-/- mice, the IFN
signaling pathway is disrupted in Stat2-/- mice allowing them to succumb to SFTSV
infection.
The most recent SFTSV animal model is the use of wild-type mice treated with
an a-IFNAR monoclonal antibody (mAb)54. This group reported (and we later confirmed,
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see chapter 3) that use of this a-IFNAR mAb strategy led to complete lethality in all mice
given a sufficient challenge dose54. a-IFNAR mAb was administered at low doses on day
-1 and day 2 post infection54. The use of this mAb treatment likely stifles the animal’s
immune response, allowing the virus to rapidly expand and cause tissue damage. When
compared to Ifnar -/- mice, lethality in a-IFNAR mAb treated animals lagged and SFTSV
in mAb treated animals did not reach titers as high as those in Ifnar-/- mice54. This is likely
due to the inability of the mAb to control all IFN signaling resulting in weak immune
responses that slightly dampen SFTSV mediated disease. For vaccine work this model
represents a great improvement in available tools by allowing vaccine candidates to be
tested in immune competent animals, thereby enabling a better understanding of the
characteristics of the immune response elicited by vaccine candidates. Additionally, it
allows for challenge studies with animals that can mount a full immune response with the
caveat that this immune response is briefly dampened by the a-IFNAR mAb therapy.
1.2 – Vaccines
1.2.1 Vaccines Overview
Vaccines are the most effective public health intervention available and save an
estimated 2-6 million lives each year from preventable diseases55,56. Vaccination is a
powerful strategy to combat infectious diseases and has allowed for the elimination of
rinderpest and smallpox as well as the near elimination of polio virus56. The primary
function of vaccines is to expose an individual’s immune system to immunogens from
disease causing pathogens thereby eliciting protective immune responses55. An
immunogen here is defined as a component of a pathogen against which an immune
response can be directed, most commonly these are proteins, though sugars and lipids
are also potential immunogens. Successful vaccines drive an immune response that will
be recalled if the vaccinated individual ever encounters the immunogen again55.
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Immunization is safer than infection from the pathogen and once a sufficient portion of
the population is immunized, herd immunity can be achieved56. Achieving high vaccine
efficacy requires vaccination with appropriate immunogen using the ideal delivery
method for the chosen immunogen and eliciting the correct type of immune response.
Vaccines vary widely on how an immunogen is delivered, each delivery strategy
comes with benefits and drawbacks. Here, four classes of vaccines approved for human
use will be discussed, these include live attenuated pathogens, inert vaccines, virus
vectored vaccines, and nucleic acid vaccines, the most recently approved class of
vaccines. Historically, most licensed vaccines have used live attenuated or inert vaccine
platforms, however, these platforms present difficulties that underscore the need for new
vaccine platforms55. Broadly, live attenuated vaccines contain a version of the live
pathogen which has been weakened sufficiently to no longer cause significant disease in
humans55. Inert vaccines deliver one or more non-replicating immunogens55. New
vaccine technologies such as virus vectored and nucleic acid vaccines are becoming
more common and hold the promise of improving upon the historical vaccine platforms.
Virus vectored vaccines use live viruses that are non-pathogenic to humans to deliver an
immunogen from another pathogen55. Finally, nucleic acid vaccines deliver mRNA or
DNA (currently no DNA based vaccines are approved for human use) encoding an
immunogen which is then produced by cells in the vaccinated individual55.
The first vaccines developed were attenuated live vaccines57. These vaccines
are generally produced by passaging pathogens many times through various animals or
cell lines that are slightly permissive of pathogen replication or by using related
pathogens that do not cause disease in humans55,57. For example, the oral polio virus
vaccine was developed by passaging polio virus through rats and monkeys which are
not infected efficiently55,57. Due to this passaging, the virus accumulated various
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mutations that enabled it to adapt to growth in the animals where it was passaged. The
adaptation of the virus to infect these animals in turn resulted in a virus that is less
virulent in humans. Another example of an attenuated vaccine is the smallpox
vaccine55,57. The original smallpox vaccine used by Edward Jenner used the cowpox
virus, which is related to variola virus, the cause of smallpox57. Patients immunized with
the cowpox virus would develop immunity that cross-protects them from smallpox57. Live
attenuated vaccines continue to be widely used to this day, some examples of this
vaccine type include the measles, mumps, and rubella vaccine, rotavirus vaccine,
chickenpox vaccine, and the yellow fever vaccine57.
There are many advantages and disadvantages to consider in using live
attenuated vaccines. The primary advantages lie in the robust long-lived responses they
generate55,58. Because they are live viruses the immune polarization (see section 1.2.3)
is similar to what would be achieved by natural infection58. These vaccines thus elicit
powerful responses optimal for the pathogen they target while largely eliminating the risk
of severe disease55,58. The disadvantage of these vaccines, however, is the potential for
reverted virulence57. Because the immunogens in these vaccines are replicating, there is
the potential for the accumulation of mutations that revert the pathogen to a virulent
strain57. The oral polio vaccine is an example of the risks associated with live attenuated
vaccines. Every year a small number of children vaccinated with the oral polio vaccine
develop polio disease due to the virus reverting to wild type57,59. An additional
consideration that is needed for the use of live attenuated vaccines is the immune status
of patients. While attenuated vaccines are generally safe for immunocompetent people,
they can cause severe disease and even death in immunocompromised patients60-62.
Additionally, these vaccines are not recommended for pregnant women as their immune
systems are somewhat compromised, and they can pose a risk of crossing the placenta
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and infecting the baby which is largely unable to respond to infectious pathogens63.
Finally, the production of live attenuated vaccines can be complicated and time
intensive. It frequently takes many repeated passages through animals or tissue culture
cells to achieve a pathogen that is sufficiently attenuated57. Additionally, it is unclear
what cells or animals will yield the best results in attenuating pathogens or even if the
pathogen will be sufficiently attenuated57. Because of these drawbacks, live attenuated
vaccines may not always be optimal and alternatives should be considered.
The next and perhaps largest class of vaccines are inert vaccines. These
vaccines deliver an immunogen that is not capable of replicating and causing disease55.
These vaccines range from delivering a single immunogen that is sufficient to provide
protection up to delivery of a whole killed pathogen55. The immunogens delivered in
these vaccines can vary widely, in some cases, recombinant proteins are delivered to
target an immune response against a single protein that is essential for disease55.
Vaccines of this type are widely used to target bacterial toxins55. In toxoid vaccines, an
inactive version of the toxin is delivered to the patient creating immunity against the
virulence agent as opposed to the pathogen itself55. Polysaccharides, complex sugars
coating the exterior of many bacteria, can also be targeted with this vaccination type55. In
vaccinations against viruses, viral-like particles, which lack nonstructural proteins, or
whole killed virus may be used55. Some pathogens targeted by inert vaccines currently in
use include, tetanus, diphtheria, shingles, hepatitis B, and human papilloma virus55.
While inert vaccines are advantageous due to their safety in
immunocompromised individuals, their disadvantage lies in their inability to drive a
strong immune response alone55. Inert vaccines by nature of not replicating or being
virulent are unable to elicit the signals associated with infections and responsible for
initiating immune responses55,64. Because of this, inert vaccines are often delivered with
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adjuvants, which are compounds able to stimulate immune responses55,64. Unfortunately,
adjuvants may not always elicit immune responses that are ideal for controlling the
targeted pathogen58,64. Inert vaccines are generally associated with immune responses
that are not long-lived and thus may require booster immunizations.
A relatively new class of human vaccines are the virus vectored vaccines55,65,66.
This type of vaccine typically uses viruses that are non-pathogenic to humans to deliver
an immunogen65,66. While extensively studied, only recently have these vaccines
become more widely adopted with the development and approval for human use of the
vesicular stomatitis virus (VSV) vectored Ebola virus vaccine, and adenovirus vectored
SARS-CoV-2 vaccines66,67. Virus vectored vaccines are advantageous in their ability to
produce robust long-lasting immunity55,65,66. A major concern for viral vectored vaccines
is the potential for platform immunity66. Delivery of immunogens through a virus elicits
immune responses not only to the desired immunogen, but also to the proteins that
comprise the viral vector. Therefore, vaccination with a VSV vector may render future
immunizations with VSV platforms ineffective due to immune responses against the
vector itself66. Additionally, insertion of immunogens into a non-pathogenic virus may
alter that virus’s pathogenicity65,66. Because of these characteristics of virus vectored
vaccines, they often require more extensive testing to ensure their safety. Virus vectored
vaccines using the VSV platform are discussed in detail in section 1.2.4.
The most recent class of vaccines approved for human use are the nucleic acid
vaccines. Nucleic acid vaccines, both mRNA and DNA based, have been under
development for decades68,69. These vaccines rely on the delivery of nucleic acid
sequences encoding an immunogen. As an example, the two SARS-CoV-2 mRNA
vaccines, which are the only currently approved nucleic acid vaccines in humans,
encode the spike protein of SARS-CoV-270. Cells that take up the mRNAs produce the
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encoded immunogen, spike protein in this case, which leads to the induction of a strong
immune response69. The advantages of nucleic acid vaccines are that once the platform
is optimized and an immunogen is found to be protective, they are easy produce and
manufacture is scalable69. Once an immunogen’s nucleic acid sequence is known,
producing needed mRNA or DNA sequences for vaccination is a relatively fast process.
There are however some disadvantages to these vaccines, the primary challenge is
often delivery69. Nucleic acids need to be delivered into cells; in DNA vaccines this often
involves electroporation which can be painful to the patient68. Other concerns for DNA
vaccines are the potential for integration into the vaccinated patients’ chromosomal
DNA68. Delivery of mRNA vaccines has been largely addressed (see section 1.2.5) but
these vaccines require a strict cold chain to maintain effectiveness69. mRNA vaccines
must be maintained at -80 °C and once thawed for use they cannot be frozen again due
to degradation of the mRNA69. This can complicate delivery of vaccines to isolated rural
populations where maintaining a cold chain may be unfeasible. It is likely that in the
coming years more mRNA-based vaccines will become available due to their various
advantages and the robust responses they achieve. Section 1.2.5 delves deeper into
mRNA vaccines.
1.2.2 Characteristics of Immune Responses
Immune responses are generally characterized as either innate or adaptive
immunity. The innate immune system is non-specific, meaning innate immune
responses are not pathogen specific71,72. The innate immune system serves as a broadly
acting response that can slow infections while the adaptive immune system is
activated71,72. Innate immunity includes physical barriers, cellular populations, and
various proteins71. Physical barriers include skin and mucous membranes which serve
as a first line of defense preventing pathogens from entering the body71. The cellular
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populations involved in innate immunity are extensive and indeed can include all
nucleated cells71,72. The more commonly discussed cellular elements of the innate
immune system include macrophages, dendritic cells, natural killer cells, basophils,
eosinophils, and mast cells71,72. In brief, macrophages and dendritic cells are phagocytic
cells considered to be professional antigen presenting cells (APCs) 72. These cells
phagocytose proteins and pathogens in the extracellular milieu and present peptides,
short protein sequences (approximately 8-15 amino acids long) that are found within
protein sequences in pathogens, to B- and T-cells72. Natural killer cells cause cytotoxicity
to cells infected with pathogens72. Eosinophils, basophils and mast cells are associated
with tissue damage, large extracellular pathogens, and allergenic responses72. All
nucleated cells can be considered part of the innate immune system as these cells
encode proteins for the detection of pathogens and the initiation of the adaptive immune
response71,72. The protein components associated with innate immunity are vast and can
be constitutively active or activated by certain danger signals elicited by infections or
tissue damage71-73. Recognition of danger signals is done by pathogen recognition
receptors (PRRs) which recognize pathogen associated molecular patterns
(PAMPs)72,73. Many different PAMPs are recognized by the innate immune system
including various species of mRNA (ex. double stranded or uncapped mRNA),
cytoplasmic DNA, polysaccharides, and lipids72,73. Most PRRs are constitutively active
and once activated they initiate a cascade of protein interactions resulting in altered
transcription and the production of immune signaling proteins such as interferon (IFN),
and various cytokines and chemokines72,73. The subset of cytokines produced is
dependent upon the type of PAMPs, each PRR generally results in a slightly different
cytokine profile which is able to shape the adaptive immune response73. The cytokines
produced directly influence the type of immune response mounted, with detection of
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RNA PAMPs leading to different responses than polysaccharide PAMPS. Importantly,
the innate immune system is separate from the adaptive immune system but interactions
between the two systems are essential to mounting and shaping adaptive responses71.
The adaptive immune system is composed primarily of B- and T-cells which are
activated when they encounter their cognate peptide (Note that B-cells can also
recognize nucleic acids and sugars. T-cells have also been described to respond to
lipids instead of peptides)71,72,74-76. Each B- and T-cell is specific to one specific epitope
giving these cells very narrow specificities71,72. While innate immunity is important to
initiate an immune response to vaccines, the adaptive immune response is typically
examined when analyzing vaccine responses.
The adaptive immune system can be further broken down into humoral and
cellular immunity71,72. Humoral immunity is associated with immunoglobulins (Ig), which
are produced by B-cells71,72. Cellular immunity is associated with T-cells which are
broken into two subsets CD4+ helper cells, and CD8+ cytotoxic cells71,72. Both B- and Tcells share a similarity in having a receptor that is highly specific71,72. In the case of Bcells, this receptor is the B-cell antigen receptor (BCR). The BCR genes encode the
immunoglobulin proteins which are referred to as the BCR when anchored to B-cell
membranes, and antibodies when secreted71,72. In T-cells, the T-cell receptor (TCR) is
responsible for the detection of antigens presented by the major histocompatibility
complex (MHC) 71,72. Both these receptors are formed by somatic rearrangements of
germline-encoded elements. This somatic rearrangement allows for the recognition of
millions of epitopes with each having a unique specificity72. This vast repertoire of B- and
T-cell specificities allows almost any encountered immunogen to be recognized and an
immune response mounted.
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T-cells can be further subdivided into two main subtypes which are defined by
surface expression of CD4 or CD8. CD8+ T-cells are called cytotoxic T-cells and
function primarily to kill cells infected with intracellular pathogens, though they also
secrete cytokines thereby regulating immune responses71,72. CD4+ T-cells on the other
hand act primarily by regulating the immune cellular and humoral response through
cytokine secretion and are often referred to as helper T-cells (Th)71,72. There are many
subpopulations of CD4+ T-cells that have been described, these populations are
characterized by the cytokines they secrete and the types of pathogens that they help in
controlling.
T-cells must encounter their cognate epitope to be activated. For T-cells to
become activated they must form an interaction through the TCR and a peptide
containing MHC71,72,77. Notably, the TCR is not activated upon interaction with its
cognate peptide or MHC proteins alone; they must both be found in complex71. T-cell
activation is broken down into three signals (Figure 1.3). The first signal occurs when the
T-cell recognizes, through the TCR, its cognate peptide presented in an MHC (Figure
1.3). The initial activation of T-cells results in the CD4 or CD8 molecules then binding the
MHC to stabilize the complex72,77. Signal two includes a variety of protein interactions
that lead to further activation and clonal expansion of activated T-cells (Figure 1.3)72,77.
In the case of CD4+ T-cells, CD28 activation by B7.1(CD80) or B7.2(CD86) found on the
APC is critical in initiating proliferation72,77. To control T-cell expansion CTLA-4(CD152)
is produced to compete for CD28 interaction, thereby slowing the expansion of Tcells72,77. CD8+ T-cells also rely on CD28 signaling though to a lesser extent, other
costimulatory molecules which are used by CD8+ T-cells are CD70 and 41BB(CD137)72,77. To generate a strong response, pro-survival signals are given to Tcells at this stage through ICOS, 4-1BB, and OX4072,77. If co-stimulation does not occur
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at this stage, the T-cells become inactive again without replicating, thereby preventing
aberrant activation72,77. Once a T-cell has become active, it is then able to induce an
immune attack the next time it encounters its antigen without the need for further costimulation. Signal three occurs once the activated T-cell encounters cytokines, this
often occurs at the site of infection or tissue damage (Figure 1.3)72,77. These cytokines
shape the activity of the T-cell by polarizing it to best response for the type of damage
detected72,77,78. For further discussions on T-cell polarization see section 1.2.3.
As discussed above, T-cells are activated through interactions with MHC proteins
which are divided into two main classes. Class I are present in all nucleated cells and
present peptides from within the cell71,72. Class II presents internalized and proteolytically
digested peptides within specialized APCs71,72. Since MHC class I cells present
endogenous peptides (note, exogenous presentation can also occur for more
information see cited source), they are particularly important for protection from
intracellular pathogens71,72,79. Cells infected with intracellular pathogens present
proteolytically processed peptides on MHC class I proteins71,72,80. Upon recognition of
the MHC class I and it’s cognate peptide, CD8+ T-cells are activated secrete perforin
and granzyme which kills the infected cell and, in many circumstances, the infecting
pathogen71,72. In contrast, MHC class II proteins are primarily expressed on
“professional” APCs such as macrophages, dendritic cells, and B-cells71,72,80. During
inflammation epithelial and endothelial cells can also express MHC class II71. CD4 Tcells recognize MHC class II-presented antigens. Once CD4+ T-cells are activated, the
cytokines secreted by the APC or present at the site of infection or tissue damage
impacts their maturation and the cytokines that will be produced by the T-cell. Both
CD4+ and CD8+ T-cells can be categorized into subtypes that have different functions78.
CD4+ T-cells in particular have various subpopulations characterized by their secreted
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Figure 1.3 Signals 1, 2, and 3 in T-cell activation The first signal in activation of Tcells comes when the TCR interacts with an MHC molecule containing it’s cognate
peptide. This interaction is stabilized by CD4 or CD8. Co-stimulatory signal occurs
inducing survival and proliferation. Many co-stimulatory proteins exist, shown here
are CD28 and 4-1BB and their respective ligands. The presence of tissue damage or
pathogen associated cytokines is signal three. The presence of these cytokines
polarizes T-cells to have functions suited for the elimination of the pathogen they
respond to. Created with BioRender.com
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cytokine profiles78. Polarization into each subtype is largely dependent on the cytokines
present upon initial activation of the T-cell. Once polarized, T-cells secrete cytokines
which are important for instructing other aspects of the immune response78. One
consequence of T-cell polarization is the induction of antibody class switching by B-cells.
Further discussion into certain immune polarizations is described in the next section.
Production of antibodies is driven by B-cell activation. Several types, called
isotypes, of antibodies may be produced by B-cells. These isotypes in mice are IgM,
IgD, IgG (which is found in isotypes IgG1, IgG2a/c, IgG2b, and IgG3), IgA, and
IgE71,72,81. Humans have similar antibody isotypes, though functions are not necessarily
homologous between mouse and human antibodies of the same isotype. Some
differences between human and mouse isotypes include human IgA antibodies having
the subclasses IgA1 and IgA2, and IgG being split into IgG1, IgG2, IgG3, and IgG4 in
humans (all further antibody discussion focuses on mouse antibodies)81. These different
isotypes are structurally and functionally distinct, for example secreted IgM is pentameric
and cannot cross into mucosa72,81. In contrast, IgA antibodies are found as monomers or
dimers and are capable of crossing into mucosa when dimerized72,81. Naïve B-cells
generally produce antibodies of isotypes IgM and IgD. Once activated isotype switching
and somatic hypermutation of the variable region, the epitope sensing region of
antibodies, occur. This allows for selection of higher affinity antibodies and production of
antibodies in isotypes that have functions useful in the response against a
pathogen71,72,81. The process by which a B-cell is activated and matures is the
determinant of antibody isotype produced after class switching.
Activation of B-cells leads to class switching and production and secretion of
antibodies. B-cell activation may occur in a T-cell dependent or independent manner. In
T-cell dependent activation, a B-cell binds its cognate antigen by the BCR71. The antigen
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is then internalized and degraded for presentation on MHC class II proteins71. In this way
B-cells can act as antigen presenting cells which activate CD4+ T-cells. Activation of Bcells occurs in lymphoid organs in highly organized structures called germinal
centers72,82. In these structures B-cells interact primarily with a specialized subset of
CD4+ T-cells called follicular helper cells (Tfh)82. Upon recognition of the antigen by a
Tfh cell’s TCR, CD40 on the B-cell interacts with its ligand found on the T-cell and
cytokines secreted by the T-cell lead to activation of the B-cell and rapid clonal
expansion71,72. Cytokines secreted by the Tfhs induce and control isotype switching. Of
particular importance for later discussions, the cytokines interleukin (IL)-4 and IFNg are
associated with the induction of IgG1 and IgG2c, respectively, in C57/BL6 mice71,72,78,81.
Once B-cells are activated, a subset of cells differentiates into short-lived plasma cells
which produce large amounts of antibodies before their eventual death some weeks
after differentiation83. Another subset of cells undergoes affinity maturation, then
differentiates into either memory B-cells or long-lived plasma cells83. Memory B-cells
generally remain dormant until their cognate antigen is encountered again, allowing for
rapid response and increased antibody production83. Long-lived plasma cells reside in
the bone marrow and constantly secrete their antibody providing passive immunity from
further infection by its cognate pathogen83. Long-lived plasma cells can survive and
continue producing antibodies for decades.
Antibodies have several mechanisms of action during an infection. Most antibody
isotypes can neutralize a pathogen preventing further infection or virulence (Note that
neutralization is dependent not on antibody isotype but where on the immunogen the
antibody binds to)71,72,81. In viruses for example, neutralization occurs when an antibody
binds to the virus’s glycoprotein. This prevents the virus from infecting a cell by either
blocking recognition of the virus receptor or preventing conformational changes
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necessary for viral fusion. Another function important during viral infections is antibody
dependent cellular cytotoxicity (ADCC) where antibodies bind to antigens on the surface
of infected cells and recruit natural killer cells or CD8+ T-cells to kill the infected
cell71,72,81,84. Various antibody isotypes can activate the complement pathway leading to
complement-mediated cytotoxicity81,84. Finally, another important function of some
antibodies is the ability to drive opsonization81,84. Opsonization occurs when an antibody
binds it’s cognate antigen, the constant region of the antibody (Fc) is then bound by an
Fc receptor in a phagocytic cell (such as a macrophage) inducing phagocytosis81,84.
Taken together, the role of B-cells is to produce antibodies, the repertoire of secreted
antibodies provides passive protection from pathogens and aids in directing other
cellular responses.
1.2.3 Type 1 vs Type 2 Immunity
T-cell polarization can lead to different immune functions. Type 1 and type 2
immune responses are often discussed in vaccination due to their differing abilities to
provide protection against various pathogen types. It is accepted that a type 1 response
is important for clearance of intracellular pathogens and that type 2 immune responses
are more suited in directing responses to inflammation caused by large extracellular
pathogens and allergic responses (Figure 1.4)78,85. When developing vaccines, it is
important to drive a response best suited to the targeted pathogen.
Type 1 immunity is important for clearance of intracellular pathogens. Cytokines
that drive skewing towards type 1 immunity are the type 1 IFNs, IFNg, and IL-12 (Figure
1.4)78,85. These cytokines are initially produced during innate immune responses in
infected cells that have detected a PAMP from an infecting pathogen. CD4+ T-cells
activated in the presence of IFNg, and IL-12 cytokines become polarized to Th1 cells78,85.
Once polarized, Th1 cells start secreting pro-inflammatory cytokines, including IFNg, IL28

2, and tumor necrosis factor (TNF) (Figure 1.4)78,85. These cytokines upregulate antiviral
and intracellular pathogen sensing pathways such as PRRs and lead to increased
expression of MHC proteins in some cell types thereby allowing further detection of
pathogens by T-cells71,72. Secreted cytokines also impact other immune cells such as
dendritic cells by instructing them to increase phagocytosis71,72. Further effects are seen
with the dilation and increased leakiness of blood vessels, allowing innate immune cells
to access areas of inflammation more easily78,85. CD8+ T-cells are also polarized by
IFNs and IL-1271. Type I CD8+ T-cells act in a similar manner as Th1 cells by secreting
the pro-inflammatory cytokines IFNg, IL-2, and TNF71. In addition to cytokine secretion
CD8+ T-cells also kill infected cells by ADCC or releasing perforin and granzymes when
interacting with MHC class I proteins presenting its cognate antigen71,72. Perforin forms
pores in the target cell's plasma membrane allowing for the entry of granzyme which
leads to cell death72.
The skewing of an immune response by Th1 cells also has an impact on humoral
immunity. As previously discussed, naïve B-cells express antibodies of the isotypes IgM
and IgD. IgM antibodies offer high avidity with its pentameric structure but lacks high
affinity which is achieved by somatic hypermutation after class switching. Tfh cells,
which can be skewed to aTh1 or Th2 profile, interact with B-cells and the secreted IFNg
drives class switching to IgG2c (in C57/BL6 mice, in other mouse strains IgG2a may be
induced by IFNg) (Figure 1.4)81,86. IgG2c is important during intracellular infections by
efficiently activating the complement pathway and having a high affinity for Fc receptors
capable of mediating opsonization and ADCC85. Together, the various arms of the
immune system regulated by type 1 immune polarization can effectively control many
intracellular pathogens.
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Figure 1.4 Type 1 vs Type 2 Immunity Type 1 immunity is associated with
intracellular pathogens such as viruses and bacteria. Type 2 immune responses
detect large extracellular pathogens and are associated with tissue damage as well
as allergic responses. Different subsets of innate immune cells respond to these
infections and recognize PAMPs from the infecting pathogen. This induces APCs to
produce cytokines (signal 3) to polarize T-cells. Th1 polarization stimulates CD8+ Tcells and Th1 cells to produce IFN, TNF and other cytokines. Th2 cells produce IL-4,
IL-5 and other cytokines. These cytokines when secreted by polarized Tfh cells lead
to isotype switching, IgG2a/c in type 1 and IgE and IgG1 in type 2 immunity. Created
with BioRender.com
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In contrast to type 1 immunity, type 2 immunity is characterized by effective
responses against extracellular pathogens and for causing allergies when
overstimulated (Figure 1.4)71,85. The cytokine responsible for activating a type 2
response is IL-4, which is associated with tissue damage and repair85. Type 2 immunity
polarized CD4+ T-cells are called Th2 and secrete a wide variety of anti-inflammatory
cytokines such as IL-4, IL-5, IL-10, IL-13, and GM-CSF85. Th2 immunity is primarily
characterized by activation and increases in numbers of eosinophils, basophils, and
mast cells (Figure 1.4)71,85. Th2 responses lead to tissue infiltration by eosinophils and
basophils as well as mast cell degranulation. In some situations, an overabundance of
the Th2 cytokines is known to cause allergies and the airway inflammation seen in
asthma. Polarization of CD8+ T-cells to a type 2 profile also occurs. In these cases,
CD8+ cells can produce IL-4 and IL-5 and cytotoxicity of these cells by perforin and
granzyme is decreased71.
As in type 1 responses, Th2 polarized Tfhs interact with B-cells to induce class
switching78,85. The primary isotype induced by B-cell interaction with Th2 cells is IgE
(Figure 1.4)78,85. Class switching to IgE cannot occur without the presence of IL-4 or IL13. Degranulation of mast cells is associated with cross-linking of IgE, a process
associated with allergic reactions71. The presence of type 2 cytokines also drives some
IgG antibodies, primarily IgG1 (Figure 1.4)85. IgG1 antibodies activate complement
weakly and only bind inhibitory Fc receptors. Due to an inability to drive ADCC or
activate complement, IgG1 is not suited for elimination of intracellular pathogens85.
The polarization of the immune response is necessary for the effective clearance
of pathogens. BALB/c mice, which favor a type 2 response, are particularly susceptible
to infection by the intracellular parasite Leishmania, which is more effectively controlled
by type 1 responses87. Incorrect immune polarization is well described to worsen
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infections with respiratory viruses in humans and small animal models88-90. In these
infections, patients tend to have increased mucus production which leads to worsened
disease. The initial polarization of the immune response is thus clinically important in
determining infection outcomes. This is particularly important in the design of vaccines
as Th1 and Th2 cells counteract each other72. The presence of IFNg is inhibitory of Th2
cells and conversely IL-4 is inhibitory of Th1s72. Therefore, initial polarization is likely to
be reinforced and not shift over time. If a vaccine skews the response to the wrong
polarization, it could not only impact the effectiveness of the vaccine but patient safety.
This has been previously demonstrated in vaccines against respiratory syncytial virus,
these vaccines drove a strong Th2 immune polarization88-90. This led to vaccine
associated enhancement of disease making RSV infections worse. This highlights the
importance of immune polarization in the development of vaccines and the need for
vaccine platforms that are able to efficiently skew polarization to a desired profile.
1.2.4 Recombinant Vesicular Stomatitis Virus Vaccines
One of the more recently approved vaccine platforms, recombinant VSV (rVSV)
presents a strong candidate in eliciting potent immune responses against viral
glycoproteins. VSV is a member of the Rhabdoviridae family. It is a negative sense,
single stranded RNA virus with a simple genomic structure comprised of 5 genes.
Commonly seen as a livestock pathogen, VSV has low sero-prevalence in humans and
causes no known disease to immunocompetent individuals91,92. Researchers have used
VSV as a backbone to study glycoproteins of highly pathogenic viruses due to tractable
genetic systems and VSVs ability to incorporate foreign glycoproteins into its virion93-95.
Most rVSVs are designed with the removal of the wild-type glycoprotein (G) and addition
of a foreign glycoprotein95. The use of rVSV as a vaccine platform against viruses has
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several advantages such as the efficient elicitation of a type 1 immune response, and
the ease of producing large amounts of vaccine virus.
Currently the Ebola virus vaccine is the only FDA approved rVSV vaccine96. In
the 2016 outbreak of Ebola virus (EBOV) an rVSV-EBOV vaccine was deployed and
shown to give strong protection in ring studies97. While the vaccine did have strong side
effects including arthralgia, fatigue, and myalgia, this deployment successfully
demonstrated the capabilities of rVSV vectored vaccines97. Despite the rVSV-EBOV
vaccine being the only currently approved rVSV-based vaccine, researchers have
developed and tested rVSV vaccines for a wide variety of viral diseases94,98-102. Current
progress in the field has demonstrated that rVSV can elicit immune responses when
expressing the glycoproteins of Lassa fever virus, Marburg virus, various species of
Ebola virus, Zika virus, and more recently SARS-CoV-294,98-102. Another benefit of rVSV
vaccines is the ability to elicit rapid immunity. In non-human primate studies using an
rVSV expressing Marburg virus glycoprotein (rVSV-MARV), it was demonstrated that
protection upon vaccination can occur as soon as 3 days post-vaccination. Macaques
vaccinated with rVSV-MARV had 100% survival when challenged 7- or 14-days postimmunization103. Impressively, even when challenged 3 days post-immunization 75% of
animals were protected from lethal challenge103. Other studies with rVSV-MARV have
shown that post-exposure vaccination in rhesus macaques is fully protective when
administered 30 minutes post lethal challenge, and partially protective (83% of animals
survived) when administered 24 hours after challenge104,105. The rapid protective
responses elicited by rVSV vaccines make this platform powerful for the development of
vaccines against laboratory pathogens where vaccination post-needle-stick could
provide protection and useful in the context of controlling rapidly spreading epidemics
and pandemics.
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The immune response elicited by rVSV vaccines is favorable for immunization
against viral pathogens. Infection with VSV elicits high levels of IFNs which drive a type
1 immune response as expected in a viral infection95,102,106,107. This skewing ensures that
rVSV elicits the appropriate immune response for protection from viral diseases.
Vaccinations with rVSV elicit both high levels of antibodies and T-cell
responses95,102,106,107. Many studies have demonstrated that rVSV based vaccines are
particularly capable of eliciting high levels of neutralizing antibodies which are often
sufficient for protection in passive transfer models.
A major consideration in the use of vaccines to control epidemics and pandemics
is the ability to deliver vaccines to rural and hard to reach areas, and the necessity for
cold chains. The effective roll-out of the rVSV-EBOV vaccine in Africa demonstrated that
rVSV vaccines can be delivered in rural areas. Additionally, research shows that rVSV
can be lyophilized or dried and retain infectivity and immunogenicity108. This represents a
mechanism to eliminate the cold chain in delivery of rVSV based vaccines.
Two often cited downsides of rVSV vaccination are the neuropathologic effects
of VSV and the potential for platform immunity66,109,110. As a member of the
Rhabdoviridae family, VSV is closely related to the highly neuropathic rabies virus. Due
to this and the neuropathogenicity of VSV itself it is important to verify rVSV vaccines are
safe. In wild type VSV, neuropathogenicity has been conclusively linked to the virus’s
glycoprotein109,110. Therefore, most rVSV based vaccines have removed the innate risk
of pathogenicity from VSV with a deletion of the wild type VSV glycoprotein. However, it
is then important to consider the potential neuropathic effects of the newly inserted
glycoproteins. It has been shown that addition of certain viral glycoproteins into the VSV
genome leads to gain of neuropathogenesis98. In the development of novel rVSV based
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vaccines it is thus important to ensure that vaccine candidates do not cause neurologic
symptoms.
The concern of platform immunity is also an important consideration. Upon
vaccination with rVSV, immune responses develop not just to the foreign glycoprotein
but to the other viral proteins such as nucleoprotein and polymerase111. T-cell immunity
against these proteins has the potential to inhibit infection with following rVSV based
vaccines thereby leading to a less potent immune response that may not be protective.
Studies have shown that despite the potential for platform immunity, booster shots and
subsequent heterologous vaccinations are still effective94,112. Overall, studies have
demonstrated that vaccination against differing pathogens as well as booster doses of
rVSV are effective at eliciting immune responses to the foreign glycoprotein and provide
protection. These studies suggest that rVSVs are a powerful vaccine platform to deliver
viral antigens but must be thoroughly verified for safety.
1.2.5 mRNA Vaccines
The most recently approved vaccine platform is the mRNA platform. In light of
the SARS-CoV-2 pandemic (often referred to as coronavirus disease 2019, COVID19)
the FDA granted emergency use authorization to two mRNA vaccines in 2020, both of
which have since been given full FDA approval113,114. Despite only being recently
approved, mRNA vaccines have been in development for decades69,115. These vaccines
are safe, modular, and efficacious with an ability to induce high levels of antibodies. The
mRNA vaccine platform also has downsides that have prevented earlier use, these
include the instability of mRNA, considerations of delivery, and previous issues with
overstimulation of the immune system69,115,116. After decades of research and innovation,
many of these concerns have now been addressed to achieve a powerful vaccine
platform.
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mRNA vaccines mimic endogenous mRNA with a few modifications. Like
endogenous mRNA, mRNA vaccines encode a molecule with a 5’ cap, 5’ untranslated
region (UTR), open reading frame (ORF), 3’ UTR, and a polyA tail69,115. In brief, the 5’
cap is key in preventing recognition of the mRNA by cytosolic RNA sensors69,115. Without
this cap, the mRNA may be detected as viral and initiate innate immune responses. The
UTRs are important determinants of stability and half-life of mRNAs69,115. The polyA tail
together with the 5’ cap is critical for translation initialization and tail length is a
determinant of half-life117. The ORF is critical as this section encodes the desired
immunogen. To design an ORF, you must first select a protein that will be a suitable
immunogen at driving protective immune responses. The coding sequence of the
desired antigen must be known, due to advances in sequencing technologies, rapid
sequencing of novel pathogens is possible allowing for fast development of mRNA
vaccines. Modifications to the ORF are critical in optimizing immunogenicity of mRNA
vaccines. Some pathogens use rarely used codons in their genomic sequence,
modifying these to more commonly used codons is often done to increase efficiency of
translation115. The use of modified nucleosides is also critical in mRNA vaccines.
Unmodified nucleosides are markers of viral infections and elicit innate immune
responses shutting down protein production, thus modified nucleosides are often
included in mRNA vaccines118,119. Once delivered to a cell, mRNA vaccines function
similarly to endogenous mRNA and lead to production of the coded immunogen and an
eventual targeted immune response against the delivered immunogen.
RNA delivery and production are critical processes to consider when designing
mRNA vaccines capable of generating effective immune responses. DNA plasmids are
used as templates in the production of mRNA69,115. Plasmids encoding mRNAs allow for
the rapid production of vaccines at scale with relative ease. The primary concern when
36

preparing mRNA vaccines is the presence of double stranded (ds)RNA, a production
contaminant120. Many PRRs can detect the presence of dsRNA and initiate immune
responses preventing translation of the encoded antigen69. Additionally, exogenous
mRNA can also be detected by PRRs in endosomes, initiating antiviral pathways and
thereby preventing effective immunization121. To address these issues, thorough dsRNA
decontamination is done on synthesized mRNA by chromatographic methods prior to
delivery120. To ensure intracellular delivery of mRNA, several strategies have been
developed. The most widely used strategy is currently lipid nanoparticles (LNPs)69,115.
LNPs resemble commonly used lab reagents such as Lipofectamines that are used to
transfect cells in vitro. Clinically used LNPs are specially formulated to deliver mRNA
into cells in vivo and contain four components: an ionizable cationic lipid, cholesterol, a
lipid-linked polyethylene glycol (PEG), and phospholipids69,115. Briefly, ionizable cationic
lipids are important in the production of LNPs as they promote assembly of the particle,
their positive charge attracts negatively charged mRNA for inclusion in particles.
Ionizable cationic lipids are preferable to non-ionizable cationic lipids as the latter are
immunostimulatory122,123. Ionizable cationic lipids used are neutral at blood pH but
positively charged in acidic environments such as endosomes allowing for fusion and
delivery of mRNAs into the cytoplasm. Cholesterol helps stabilize the lipid structures.
Lipid-linked PEG increases the half-life of LNP particles and regulates particle size.
Finally, phospholipids are key for formation of a lipid bi-layer and modulate membrane
fluidity which aids in fusion at endosomes. Together, these developments in mRNA
production and delivery have made the mRNA platform viable for use in humans.
Vaccination with mRNA vaccines induce strong immune responses characterized
by robust antibody responses69,115. Recent work has indicated that mRNA vaccines
induce IFNs which skew immune responses towards type 1 immunity124-126. CD4+ T-cells
37

are stimulated to high levels and tend to be strongly Th1 polarized. Studies have shown
that mRNA vaccines are powerful inducers of Tfhs which are critical in controlling B cell
responses and inducing class switching124-126. Recent studies have shown that Tfh cell
polarization can be dependent on the antigen delivered124. Some antigens drive a strong
Th1 polarized response while other antigens can drive a mixed Th1/Th2 response124,127.
mRNA vaccines are widely lauded for their ability to induce high antibody titers which
remain stable for extended periods of time128,129. This is likely due to the strong induction
of Tfh cells and long-lasting germinal centers124. Due to the propensity of some antigens
to drive a mixed Th1/Th2 response, it has been noted that antibodies produced upon
vaccination likewise can have a mixed IgG1/IgG2 phenotype124,127. This mixed
phenotype has been posited as a potential benefit as IL-4 (a Th2 cytokine) is associated
with increased B-cell survival127. Notably, mRNA studies have not noted a strong Th2
response and thus there have been no reports of vaccine-induced enhancement of
infection as is common with some respiratory viruses127. The ability of mRNA to induce
CD8+ T-cells remains unclear. In mice, it has been shown that powerful CD8+
responses are elicited upon vaccination with SARS-CoV-2 mRNA vaccines125. However,
macaques immunized with mRNA vaccines against SARS-CoV-2 had no or poor
induction of CD8+ immunity except when high dosages were used130. In humans, few
studies have broken down T-cell responses into CD4+ and CD8+ subsets. Therefore, it
remains largely unclear what CD8+ responses are elicited in humans, though early
studies suggest that mRNA can in fact induce CD8+ T-cells. Overall, mRNA vaccines
elicit powerful immune responses well suited to protect against viral infections.
Despite improved mRNA vaccine technologies, these vaccines are still not widely
adopted and continue to be challenging in rural settings. The first approval of a novel
vaccine platform is often the most difficult due to the need to meet a high bar of safety.
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Due to the high efficacy of the COVID19 mRNA vaccines, it is likely that there will be an
increased prevalence of mRNA vaccines in the coming years. Indeed, many mRNA
vaccines to other pathogens including Zika virus, respiratory syncytial virus, and
influenza are already in clinical trials69,115,131-135.
Despite the widely understood efficacy and safety of mRNA vaccines by
scientists, certain populations of the public remain skeptical of mRNA vaccines. Nucleic
acid vaccines are misunderstood by the general public with a common misconception
that mRNA can alter a person's genes. Further public education is thus required to
highlight that mRNA is non-integrative and is incapable of genetic modification. Another
currently problematic property of mRNA is its instability and requirement for storage at 80° C. Delivery to hard-to-reach areas is currently difficult or impossible due to the
difficulty of maintaining this cold chain. Taken together, mRNA is a powerful vaccine
platform that is safe and efficacious and will likely see increased use in the coming
years.
1.2.6 Heterologous Vaccination Strategies
Heterologous vaccination, in the context of this work, refers to prime-boost
vaccination strategies where the first and second dose vaccines utilize different
platforms. Heterologous vaccinations have been studied for decades and the data
consistently shows that they can have beneficial effects on the immune response. As
previously described, different vaccine platforms have benefits and drawbacks in their
abilities to elicit specific immune responses. Heterologous vaccination offers the
potential for combining the benefits of each platform to attain a more well-rounded
response. Some of the first heterologous vaccine studies focused on human
immunodeficiency virus (HIV) vaccines where it was observed that immunization with
recombinant proteins elicited potent antibody responses but weak cellular responses136.
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Conversely, immunization with recombinant vaccinia viruses expressing HIV proteins
induced strong T-cell responses but low antibody titers136. These initial studies found that
combining these two platforms in a prime-boost model induced both strong antibody and
cellular immunity. The responses generated by heterologous immunization was stronger
than that of homologous prime boosts indicating that heterologous vaccinations may be
a useful vaccine regimen.
No currently approved vaccines have been designed for heterologous use,
however, during the COVID19 pandemic several governments around the world have
approved heterologous boosting with emergency use authorized vaccines137. Studies
around the world using either adenovirus based or mRNA based SARS-CoV-2 vaccines
have found that heterologous vaccination provides better protection and induces better
immune responses. In a Swedish study comparing heterologous vaccination (adenovirus
prime and mRNA boost) to adenovirus homologous vaccination, it was found that
heterologous vaccination was 68% effective compared to 50% for homologous
immunization138. These findings are corroborated in other studies that measured cellular
and humoral responses in homologous and heterologous vaccinated individuals139-141.
One such study from Hannover found that heterologous vaccination induced significantly
higher neutralizing antibody titers and T-cell activity than homologous vaccination139. In
mice, it has also been shown that heterologous vaccination (using adenovirus and selfamplifying RNA platforms) induced stronger humoral and cellular immune responses
than homologous vaccination142. While most studies show that differences exist between
heterologous immunization and homologous adenovirus-vectored regimens, these
differences are less pronounced when comparing heterologous immunization and
homologous immunization with mRNA140,141. Two studies in humans show that
homologous mRNA regimens induce higher levels of antibodies than heterologous
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immunization using adenovirus and mRNA platforms140,141. Conversely, cellular
responses are significantly better after heterologous vaccination140,141. Overall, current
data on SARS-CoV-2 heterologous mRNA vaccination suggests that immune responses
are superior or identical to homologous vaccination.
Heterologous vaccination using the rVSV platform has been done in the context
of HIV. These studies often combined a DNA vaccine platform prime with rVSV boosts.
One such study demonstrated that immunization with a plasmid encoding simian HIV
(SHIV) SIVgagp39 and IL-12 followed by a boost with an rVSV expressing env89.6P
gp160 and SIVmac239 gag p55 had improved immunogenicity and efficacy upon
challenge143. This was associated with preserved CD4+ cells in the peripheral blood, and
increased antibody titers143. Heterologous vaccination represents a clearly understudied
area with few pathogens having had experimental heterologous vaccines tested,
immune responses remain not fully characterized, and few vaccine platform
combinations have been tested.
1.3 – Current SFTSV Vaccine Candidates
Currently, no approved SFTSV vaccines exist. Several groups have developed
experimental SFTSV vaccines and tested for efficacy and immunogenicity in Ifnar-/- mice
or aged ferrets. A variety of vaccine platforms have been used to immunize animals,
these include DNA, protein subunit, and viral vectored vaccines. Most vaccines target
the SFTSV glycoprotein Gn/Gc, though some also target other viral proteins such as N
and NSs. The currently tested vaccines and characteristics of their responses are
discussed below.
1.3.1 DNA Vaccines
A DNA vaccine encoding SFTSV Gn, Gc, N, and NSs elicited weak immune
responses45. In this study, Kang et al. immunized Ifnar-/- mice with a single plasmid
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encoding several SFTSV proteins (Gn, Gc, N, and NSs)45. In this study, no antibody
responses were detected in vaccinated mice and only slight, not statistically significant,
increases were observed in T-cell activity. To elicit cellular responses, the authors added
IL-12 to the vaccine plasmid45. In mice immunized with the IL-12 containing plasmid,
antibodies were detected against SFTSV N, but no antibodies against Gn or Gc were
detected45. This suggests that immunization with this DNA vaccine would not lead to
antibody mediated neutralization of viruses, as Gn/Gc are the only viral proteins found
on the virion surface. Addition of IL-12 led to increased cellular responses as the authors
predicted45. The original plasmid protected only 40% of animals from lethal challenge
with SFTSV, while the IL-12 containing vector was 100% protective45. The lack of high
titer Gn/Gc antibodies indicates that protection was mediated by T-cells45. Overall, this
vaccine platform did provide protective immunity, though it failed to stimulate antibody
responses. Additionally, DNA vaccines are currently not approved for human use and
are problematic due to complications in delivery methods.
Another group tested a different DNA vaccine consisting of 5 plasmids encoding
SFTSV Gn, Gc, N, NSs, or RdRP144. This vaccine was initially tested in wild type BALB/c
mice with two doses given 21 days apart, each dose was given with electroporation to
induce more efficient take up of the plasmids. This vaccination protocol elicited potent
cellular immunity and modest levels of neutralizing antibodies144. To test whether this
DNA vaccine was protective, 3 doses were given to aged ferrets which were then
challenged with a lethal dose of SFTSV. Immunized animals were fully protected and
displayed strong cellular immunity particularly to the glycoproteins, Gn and Gc144. As
with the mouse model, vaccination elicited modest levels of neutralization. Experiments
using only plasmids encoding only SFTSV Gn and Gc demonstrated that these antigens
are sufficient for protection from lethal challenge. Furthermore, serum transfer from mice
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immunized against Gn and Gc to naïve mice was protective upon lethal challenge144.
Immunization with a combination of plasmids excluding Gn and Gc showed that full
protection occurred only when animals were immunized with all three plasmids
containing N, NSs, and RdRP144. Importantly, passive transfer of sera from these
animals to naïve ferrets did not impart protection. Several important conclusions can be
made from the data shown in this paper, the first being that SFTSV Gn and Gc are
sufficient to impart protection from lethal challenge. The second important finding of this
paper addresses the correlates of protection in SFTSV infection. Protection upon
challenge in mice that received passively transferred sera suggests that antibodies
against SFTSV are sufficient to prevent lethal disease. This protection is even more
impressive given the modest levels of neutralizing antibodies reached in vaccinated
mice. Additionally, full protection achieved by immunizing animals against N, NSs, and
RdRp suggests that cellular immunity may also be sufficient for protection, though this is
not directly tested. Therefore, future vaccine development against SFTSV can focus
primarily on antibody responses as this is sufficient for protection, but the presence of
cellular immunity is likely to provide a more thorough response that could be beneficial.
The downside of this vaccination platform is the requirement for electroporation which is
often painful. Despite that drawback, this SFTSV vaccine is quite promising.
1.3.2 Protein Subunit Vaccines
Only one study to date has investigated the immunogenicity of protein subunit
vaccines against SFTSV. This study fused SFTSV Gn or Gc to the Fc region of a human
antibody and immunized mice with each of these proteins using the adjuvant Alum45. As
expected from protein subunit vaccines, antibody titers in immunized animals reached
impressive levels of approximately 3,500 for both protein vaccines45. Interestingly,
neutralizing titers were higher in Gn immunized mice (mean titer = 929) than Gc
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immunized mice (mean titer = 209) 45. Total antibody titers were identical in both
vaccines, yet Gn produced higher levels of neutralizing antibodies suggesting the Gn
subunit may be a better target for vaccine development. Alternatively, this result may be
due to expression of these proteins individually as opposed to in complex as it is
naturally found in SFTSV infections. Expression of the proteins individually may lead to
Gn neutralizing epitopes being maintained, while misfolding or a lack of Gc-Gn
interactions leads to a loss of Gc neutralizing epitopes. When animals were challenged
with a lethal dose of SFTSV, all of the Gc immunized mice succumbed, with deaths
delayed 3 days compared to unimmunized mice, and half of the Gn immunized mice
succumbed to infection45. On the surface, these results seem to conflict with results from
other groups who have demonstrated that antibodies are sufficient for protection and
antibody titers elicited by these protein vaccines are higher than any currently discussed
vaccine has achieved. The explanation for this incongruency may be two-fold: protein
subunit vaccines are known to be poor inducers of cellular immunity, therefore
immunized mice likely did not have high levels of CD8+ T-cell activity. Additionally, Alum
is well described to drive a type 2 skewed immune response145. Therefore, antibodies
produced by this immunization are unlikely to drive opsonization, ADCC, or activation of
complement pathways effective for controlling viral infections. Cellular responses are
also unlikely to be optimized for responding to intracellular pathogens resulting in a lack
of protection. Overall, protein subunit vaccination against SFTSV appears to be an
ineffective platform.
1.3.3 Viral vectored vaccines
To date, three different studies have reported SFTSV immunization using viral
vectors. The virus vectors that have been studied so far include vaccinia virus, rabies
virus, and rVSV. The study with vaccinia virus used three different viruses for
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immunizations in a two-dose regimen, each virus was an LC16m8 strain of vaccinia virus
encoding either SFTSV N, Gn/Gc, or both N and Gn/Gc146. Immunization with either
virus encoding Gn/Gc led to high levels of total IgG (approximate titer of 4,000) but
incredibly low neutralizing antibody titers with serum at a dilution of 1:40 not neutralizing
50% of virus particles146. Despite low levels of antibodies these vaccines all were fully
protective against lethal challenge. Interestingly, these investigators determined that preexisting immunity to vaccinia virus inhibited protective responses. Ifnar-/- mice were first
inoculated with the vaccinia lister strain, then vaccinated one month later with each of
the three vaccines in a two-dose regimen. In this experiment, mice were only partially
protected from lethal challenge indicating that pre-existing immunity to vaccinia virus
negatively impacts immunization efficacy146. In this study, serum transfer only partially
protected against SFTSV disease. This was despite a two-dose serum transfer and a
low dose SFTSV challenge, further highlighting the weak neutralizing activity elicited by
this vaccine. To assess CD8+ contributions to protection, immunized mice were depleted
of their CD8+ T-cells through anti-CD8 antibodies. No change in lethality was observed
which is interpreted by the authors as CD8+ T-cells being unnecessary for protection
from SFTSV infection146. This interpretation however is confounded since the challenge
was done in immunized mice which had previously been shown to have high IgG titers
against SFTSV. The authors had previously shown that antibodies alone did provide
partial protection in a passive transfer model. Additionally, vaccinia virus is known to
induce robust type 1 immunity meaning antibodies present in these mice likely
neutralized low amounts of virus and carried out other protective functions such as
increased opsonization, activation of the complement pathway, and increased
cytotoxicity by natural killer cells through ADCC147,148. A better model to assess CD8+ Tcell contribution to infection would be an adoptive transfer which would exclude all
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antibody mediated immunity. Overall, the vaccinia virus SFTSV vaccine does induce
protective immunity though neutralizing antibodies are of relatively low titer. Additionally,
this vaccine platform may not be ideal as the authors demonstrated decreased efficacy
when pre-existing immunity to vaccinia virus existed. This is likely a downside of many
viral vectored vaccines, though this remains to be fully determined.
Another report describes SFTSV vaccine using an avirulent strain of rabies virus
as a vaccine platform149. Rabies virus is a close relative of VSV, however unlike VSV,
rabies virus infection is fatal in humans and highly neurotropic. A human vaccine using a
rabies virus vaccine is unlikely to ever pass FDA approval due to fears of neurotropism,
therefore the authors therefore present this as a veterinary vaccine designed for use in
dogs and cats to immunize against both rabies virus and SFTSV149. The virus platform
used does not remove the cognate glycoprotein as has been discussed with VSV
platforms. Instead, SFTSV Gn (note Gc is not present) is added to the rabies genome
after its cognate glycoprotein, thereby giving the virus an additional open reading
frame149. Single dose immunization of BALB/c mice with this vaccine led to high titers of
SFTSV neutralizing antibodies by 4 weeks after immunization149. These neutralizing
titers notably had high variability in immunized animals, and titers decreased rapidly over
the next 4 weeks. Immunization of mice with this vaccine was protective upon lethal
challenge with rabies virus however protection is unknown for SFTSV as the authors
used C57BL/6 mice which do not display lethal disease upon infection with SFTSV149.
The only protection data displayed was a significant decrease in SFTSV viral load in the
spleen 7 days after challenge in immunized animals relative to unimmunized mice149.
This vaccine is interesting as it presents the possibility of controlling both SFTSV and
rabies, however, it is unlikely to ever be used in humans and we currently lack
information of its efficacy against SFTSV.
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The final virus vectored SFTSV vaccine that has been evaluated in animals is an
rVSV based vaccine. This vaccine removes the cognate VSV glycoprotein and inserts
SFTSV Gn/Gc112. The authors demonstrate that insertion of SFTSV glycoprotein slows
replication of rVSV relative to a virus with the wild-type glycoprotein112. Single dose
immunization of Ifnar-/- mice with rVSV-SFTSV was completely protective against lethal
challenge with all vaccine doses used (lowest dose given was 2x101 focus forming
units)112. Passive transfer of sera was partially protective with 60% of challenged mice
surviving112. This group tested whether pre-existing immunity against VSV would prevent
effective immunization112. Mice were first immunized with an rVSV containing a
hantavirus glycoprotein, then vaccinated with rVSV-SFTSV, and finally the animals we
challenged with a lethal dose of SFTSV. It was found that pre-existing immunity did not
affect protection imparted by rVSV-SFTSV, as all challenged mice survived112. Finally,
this group showed that immunization of animals with rVSV-SFTSV produced high titers
of neutralizing antibodies against SFTSV as well as the closely related HRTV112. Overall,
this study demonstrated the power and efficacy of rVSV-SFTSV vaccines suggesting
that this is a powerful platform with good efficacy, although neuropathogenesis and
protection from HRTV challenge were not assessed.
1.4 – Experimental Questions
The goals of this dissertation are to develop novel vaccine platforms against
bunyaviruses, with a particular focus on SFTSV, and to assess the safety and
immunogenicity of these vaccine platforms. As previously discussed, there are currently
no approved vaccines or therapeutics against SFTSV in any country. Additionally, the
vaccines that have been reported in the literature to date often have immunological
short-comings, or the safety and immunogenicity are not fully characterized. To address
this, we developed an rVSV-SFTSV and an mRNA SFTSV vaccine. Both platforms are
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currently in use and approved for human use with a proven track record for other viral
diseases. We then sought to answer the broad question, are these vaccines safe and
protective, and do they stimulate a favorable immune response against SFTSV?
To begin addressing these questions, in chapter 2 we determine the safety and
efficacy of a single dose rVSV-SFTSV vaccine. While this study is similar to the
previously described study by Dong et al. which was published in the midst of our own
study, we add further data reinforcing the safety and cross-reactivity of the vaccine112.
We hypothesized that single dose immunization with rVSV-SFTSV would be fully
protective in Ifnar-/- mice and safe when injected intracranially. This would address
widespread concerns of safety for rVSV based vaccines, which can in some cases
cause neuropathogenesis, that have not previously been addressed in other studies.
Additionally, we hypothesized that immunization with rVSV-SFTSV would be fully
protective upon challenge with the related HRTV. While Dong et al. found that rVSVSFTSV vaccination induced cross-neutralizing antibodies, they did not assess survival
upon lethal challenge with HRTV.
In chapter 3 we use wild type C57/BL6 mice to dissect the immune responses to
rVSV-SFTSV and mRNA SFTSV vaccines in both single dose and prime-boost
regimens, including a heterologous strategy. Detailed analysis of both the humoral and
cellular adaptive immune responses were done to compare the different vaccination
strategies. This study is novel in not only in its use of mRNA as a platform for
immunization against SFTSV, but in the testing of heterologous vaccination strategies
and the use of wild-type mice treated with anti-IFNAR antibodies for our challenge
studies. We hypothesized that all immunization conditions would be protective, but that
heterologous rVSV-SFTSV + mRNA SFTSV would induce the most potent cellular
immune responses. These studies address important, unknown safety concerns for the
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rVSV vaccine platform, and carefully analyze the immune responses elicited by the
tested vaccine platforms, which have previously been unclear. Furthermore, we drive the
field forward by developing an mRNA vaccine, representing a novel vaccine platform
against SFTSV, and demonstrating the utility of an IFNAR antibody blockade mouse
model for immunological and challenge studies. Ultimately, the goal of this study was to
further our understanding of immune responses elicited by various vaccine strategies
with the hope that this work may further the development of safe and efficacious human
vaccines against SFTSV.
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2.1 – Abstract
Severe fever with thrombocytopenia syndrome virus (SFTSV) is a recently
emerged tickborne virus in east Asia with over 8,000 confirmed cases. With a high case
fatality ratio, SFTSV has been designated a high priority pathogen by the WHO and the
NIAID. Despite this, there are currently no approved therapies or vaccines to treat or
prevent SFTS. Vesicular stomatitis virus (VSV) represents an FDA-approved vaccine
platform that has been considered for numerous viruses due to its low sero-prevalence
in humans, ease in genetic manipulation and promiscuity in incorporating foreign
glycoproteins into its virions. In this study, we developed a recombinant VSV (rVSV)
expressing the SFTSV glycoproteins Gn/Gc (rVSV-SFTSV) and assessed its safety,
immunogenicity and efficacy in mice. We demonstrate that rVSV-SFTSV is safe when
given to immunocompromised animals and is not neuropathogenic when injected
intracranially into young immunocompetent mice. Immunization of Ifnar-/- mice with
rVSV-SFTSV resulted in high levels of neutralizing antibodies and protection against
lethal SFTSV challenge. Additionally, passive transfer of sera from immunized Ifnar-/mice into naïve animals was protective when given pre- or post-exposure. Finally, we
demonstrate that immunization with rVSV-SFTSV cross protects mice against challenge
with the closely related Heartland virus despite low neutralizing titers to the virus. Taken
together, these data suggest that rVSV-SFTSV is a promising vaccine candidate.
2.2 – Importance
Tick borne diseases are a growing threat to human health. Severe fever with
thrombocytopenia syndrome (SFTS) and Heartland viruses are recently recognized,
highly-pathogenic, tick-transmitted viruses. The fatality rates for individuals infected with
SFTSV or HRTV are high and there are no therapeutics or vaccines available. The
recent introduction of the tick vector for SFTSV (Haemaphysalis longicornis) to the
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eastern half of the United States and Austrailia raises concerns for SFTSV outbreaks
outside East Asia. Here we report the development of a potential vaccine for SFTSV and
HRTV based on the viral vector platform that has been successfully used for an Ebola
vaccine. We demonstrate that the rVSV-SFTSV protects from lethal SFTSV or HRTV
challenge when given as a single dose. We evaluated possible pathogenic effects of the
vaccine and show that it is safe in immune compromised animlas and when introduced
into the central nervous system.
2.3 – Introduction
Severe fever with thrombocytopenia syndrome (SFTS) is an emerging tickborne
disease caused by the SFTS virus (SFTSV, recently renamed Dabie bandavirus,
formerly known as Huaiyangshan Banyangvirus). First identified in 2011 in China,
SFTSV is a novel bunyavirus that can cause fever, thrombocytopenia, and
leukocytopenia in infected individuals 14,15. Subsequent reports later showed that SFTSV
had been causing human disease since 2009 with a high case fatality ratio of
approximately 30% 14,15. Retrospective studies have found SFTSV to be endemic to, and
causing disease in, South Korea, Japan, and Vietnam 17,19,150. Recent literature indicates
the case fatality ratios range from 6-20% depending on the country studied, and disease
progression is characterized by hemorrhagic tendency with fatal cases exhibiting multiorgan failure 151. In 2009 a novel related bunyavirus named Heartland virus (HRTV) was
discovered in Missouri exhibiting a similar disease progression and transmission cycle to
SFTSV 16.
The recently discovered SFTSV and HRTV are both bandaviruses in the order
Bunyavirales and family Phenuiviridae. These viruses have a trisegmented, singlestranded RNA genome encoding 4 proteins. The S segment is ambisense and encodes
the nucleoprotein (N) in the negative sense and a nonstructural protein (NSs) in positive
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sense 15. The L and M segments are negative sense and encode the RNA-dependent
RNA polymerase (RdRp) and envelope glycoproteins, respectively. The glycoprotein is
translated as a polyprotein which is proteolytically cleaved into two subunits, Gn/Gc 6,15.
The Gn/Gc complex recognizes its receptor or binding factor and entry is mediated by
the fusion peptide within Gc 37,41,152. While studies have failed to isolate a receptor for
SFTSV and HRTV Gn/Gc, some molecules have been identified as important binding or
entry factors, including DC-SIGN and UGCG 37,43,152. Antibodies against both Gn and Gc
have been shown to inhibit viral entry into cells 37,44,153.
The primary vector for SFTSV is the tick Haemaphysalis longicornis found
throughout eastern Asia 154,155. However, SFTSV has been found in other tick genera as
well including Ixodes and Amblyoma suggesting that numerous tick species might
transmit this pathogen 156,157. Due to transmission resulting from contact with ticks,
SFTSV generally infects rural farmworkers. In recent years, the geographic distribution
of H. longicornis has expanded and now includes Australia, New Zealand, and the
United States, presenting further opportunities for SFTSV to spread 28,158-160. Although
likely more rare, other transmission routes have been shown to be possible for SFTSV.
Ferret studies have shown that SFTSV can be transmitted in the absence of ticks
between co-housed ferrets or ferrets co-housed with a separator 31. The detection of
SFTSV in ferret saliva, feces, and urine suggests that these fluids are a likely route of
SFTSV transmission in the absence of ticks 31. Indeed, one report indicates that SFTSV
can spread between humans in a nosocomial setting through contact with patient blood
32

. Another case report showed likely zoonotic transmission to a human through the bite

of an infected cat 34. Due to the high potential of SFTSV to cause deadly outbreaks, it
has been categorized as a high priority pathogen for the development of vaccines and
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therapeutics by both the World Health Organization (WHO), and the National Institute of
Allergy and Infectious Diseases (NIAID) 35,36.
Currently no approved therapeutics or vaccines exist for use against SFTSV.
This is in part due to lack of adequate animal models. Wild-type mice do not develop
severe disease upon challenge thus alternatives must be used 47,161,162. Animals that
succumb to SFTSV infection include cats, aged ferrets, Stat2-/- hamsters, and Ifnar-/mice 47,48,50,52,53. Despite these difficulties, several groups have designed and tested
SFTSV vaccines, primarily using Ifnar-/- mice. Tested vaccine platforms include DNA,
virus-vectored, and attenuated recombinant SFTSV vaccines 112,144,146,149,163. These
vaccines vary in their effectiveness and come with drawbacks. Here, we focus on
developing and characterizing a recombinant vesicular stomatitis virus (rVSV) vaccine.
The livestock pathogen vesicular stomatitis virus (VSV) is generally nonpathogenic to humans and of low sero-prevalence 91,92. Additionally, VSV is a powerful
vaccine platform with genetically tractable models and a promiscuity to incorporate
foreign glycoproteins in the virion 93. An often cited detriment of rVSV vaccines is the
propensity for VSV to be neurotropic. It is, however, known that neuropathogenicity is
conferred by the tropism of the viral glycoprotein 109,110. Currently, the rVSV vaccine
platform is approved for use against Ebola virus (EBOV) and has been successfully
distributed in Africa during recent EBOV outbreaks 96,97. Due to the proven nature of the
rVSV platform, we made an rVSV-SFTSV virus containing the SFTSV Gn/Gc
glycoprotein in place of the cognate VSV glycoprotein VSV-G.
It has been previously reported by another group that rVSV-SFTSV confers
protective immunity to Ifnar-/- mice 112. To go beyond what has been previously shown,
we demonstrate that our rVSV-SFTSV is non-neurotropic and safe in
immunocompromised animals. We also show that a single administration of vaccine
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virus is sufficient to induce protection against SFTSV challenge. Additionally, rVSVSFTSV vaccination induces high levels of antibodies in wild-type animals suggesting it
can effectively be used in immune competent animals. Both therapeutic and prophylactic
passive transfer of sera from immunized animals leads to protection upon challenge of
unvaccinated animals suggesting antibodies correlate with protection against SFTSV.
Finally, we demonstrate that our rVSV-SFTSV vaccine is cross-protective upon lethal
HRTV challenge.
2.4 – Results
2.4.1 rVSV-SFTSV is attenuated in Ifnar-/- mice and exhibits a favorable safety profile
rVSV-SFTSV was launched in HEK293T cells as previously described43.
Expression of SFTSV Gn and Gc was confirmed by Western blot of cell lysates prepared
from VeroE6 cells infected with rVSV-SFTSV (Fig. S2.1A). Before performing in vivo
studies, we first determined if rVSV-SFTSV was attenuated in cell culture relative to
parental VSV. To evaluate growth kinetics, VeroE6 cells were inoculated at a multiplicity
of infection of 0.01 with rVSV-SFTSV or VSV. Cell supernatants were sampled every 24
hours and infectious virus was titrated by plaque assay. At 24 hours post infection,
infectious titers of VSV were nearly 90-fold higher than titers of rVSV-SFTSV (Fig.
S2.1B). Both viruses achieved similar maximum titers by 72 hours post infection. rVSVSFTSV caused cytopathic effect in VeroE6 cells as evidenced by cell rounding and
detachment, as well as the formation of plaques on VeroE6 cell monolayers by 48 hours
post infection (Fig. S2.1C). However, the plaques created by rVSV-SFTSV were
significantly smaller than those created by parental VSV (Fig. S2.1D). Taken together,
these results suggest that rVSV-SFTSV is attenuated in cell culture and replicates with
slower kinetics than parental VSV.
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One safety concern with rVSV vaccines is the potential for neurotropism 164,165.
VSV-G, the cognate glycoprotein of VSV, is sufficient to catalyze viral entry into neurons,
and VSV can replicate efficiently in neuron-like cells both in vitro and in vivo 166,167. In
addition, other rhabdoviruses such as rabies virus are known human pathogens that
cause lethal neurotropic infections 168. It is currently unclear whether neurons can be
infected by SFTSV or viruses harboring SFTSV glycoproteins. Neurologic symptoms
have been observed in human SFTS cases, but it remains unclear whether the SFTSV
glycoproteins can initiate entry into neurons in vivo 169. To test the neuropathogenic
potential of rVSV-SFTSV, we injected escalating doses of rVSV-SFTSV or VSV Indiana
strain intracranially into the right cerebral hemisphere of 4-week-old C57BL/6 mice and
observed the mice for 14 days. All groups of mice lost 2-5% body weight the day
following intracranial injection independent of inoculum composition (Fig. 2.1A). Weight
loss in mice injected with rVSV-SFTSV was reversed by 4 days post-infection (dpi). In
contrast, weight loss was more severe in mice challenged with VSV and survivors
exhibited slower recovery. None of the mice injected with rVSV-SFTSV met humane
endpoints during the experiment (Fig. 2.1B). In contrast, lethal disease was seen in mice
injected with VSV that trended with inoculum dose. Neurologic effects were quantified by
using a neurologic sign scoring scale that ranged from 0 (no neurologic signs) to 4
(severe neurologic signs). No neurologic signs were observed in mice inoculated with
rVSV-SFTSV or vehicle. In contrast, a range of neurologic manifestations were observed
in most mice injected with VSV (Fig. 2.1C). All the observed neurologic effects occurred
between 2-7 dpi (data not shown).
The rVSV-EBOV vaccine received FDA approval despite severe pathogenicity in
Ifnar-/- and Stat1-/- immunocompromised mice 164,165. To evaluate the pathogenicity of
rVSV-SFTSV, we challenged groups of Ifnar-/- mice with escalating doses of rVSV56
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Figure 2.1 rVSV-SFTSV has a favorable safety profile compared to rVSV-EBOV and parental VSV. (A) Weight change, (B)
survival proportions, (C) and maximal neurologic disease severity score in C57BL/6 mice challenged intracranially (IC) with 101,
102, or 103 PFU of parental VSV or rVSV-SFTSV into the right cerebral hemisphere (Mantel-Cox test and ordinary one-way
ANOVA; *, P<0.0332; **, P<0.0021; ***, P<0.0002; ****, P<0.0001) (D) Survival proportions and (E) weight loss of Ifnar-/- mice
challenged intraperitoneally with PBS or 101, 102, 103, or 104 PFU of either rVSV-SFTSV or rVSV-EBOV. Weight changes were
reported as percentages of body weight measured immediately pre-challenge. (Mantel-Cox test; *, P<0.0332; **, P<0.0021; ***,
P<0.0002; ****, P<0.0001)

SFTSV or rVSV-EBOV. All mice injected with rVSV-SFTSV were alive 14 dpi (Fig. 2.1D).
In contrast, at least 50% of mice infected with rVSV-EBOV met humane endpoints by 4
dpi, and all mice challenged with at least 103 PFU succumbed by 6 dpi. All groups of
mice challenged with rVSV-EBOV exhibited weight loss beginning 2 dpi which
progressed with time (Fig. 2.1E). The surviving mice challenged with rVSV-EBOV lost at
least 20% body weight prior to their recovery. Mice challenged with rVSV-SFTSV also
began losing weight by 2 dpi, but the weight loss was less severe compared to rVSVEBOV groups. Of the groups of mice challenged with rVSV-SFTSV, only the group
infected with 104 PFU lost more than 10% body weight. Recovery from weight loss
began between 4-5 dpi for all mice challenged with rVSV-SFTSV. Collectively, these
experiments showed that rVSV-SFTSV was not neuropathogenic and demonstrated a
significantly more favorable safety profile than the currently approved rVSV-EBOV
vaccine in immunocompromised mice.
2.4.2 Single vaccination with rVSV-SFTSV induces high levels of neutralizing antibodies
To functionally characterize humoral responses to rVSV-SFTSV vaccination we
assessed antibody neutralization potential by focus reduction neutralization titer of 50%
(FRNT50) in several animal models. To assess whether the lethal Ifnar-/- mouse model
could mount an antibody response, mice were immunized intraperitoneally (IP) with 102,
103, or 104 plaque forming units (PFU) of rVSV-SFTSV. At 21 dpi sera were collected
and analyzed for FRNT50. Approximately half of the animals vaccinated with 102 PFU
failed to seroconvert (Fig. 2.2A). Increasing the vaccination dose increased rates of
seroconversion and neutralization titers (Fig. 2.2A). These titers are promising given
thay previous work on influenza and SARS-CoV-2 suggest that neutralizing titers of 4080 are sufficient for protection 170,171.
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The high levels of neutralizing antibodies achieved with vaccination of Ifnar-/mice was somewhat surprising as interferons (IFN)s are important drivers of immune
responses. To determine whether mice deficient in both type I and type II IFN receptors
also elicit high levels of neutralizing antibodies, we immunized AG129 (IFN-α/β and γ
receptor-deficient) mice with 101-104 PFU of rVSV-SFTSV. Notably, 2 of 4 mice
immunized with 104 PFU rVSV-SFTSV succumbed to viral infection (Fig. 2.2B). Mice
receiving 10 PFU rVSV-SFTSV failed to generate a neutralizing antibody response (Fig.
2.2C). Animals receiving higher doses had mean neutralizing titers ranging from 60 to
240 with increasing dosage (Fig. 2.2C). These results demonstrate that rVSV-SFTSV
elicits humoral responses even in highly immunocompromised animals lacking type I
and II IFN responses.
It is well documented that VSV infection is highly sensitive to IFN responses
172,173

. To determine whether rVSV-SFTSV can induce a neutralizing antibody response

in immunocompetent mice, we immunized C57BL/6 mice with 104, 105, or 106 PFU of
rVSV-SFTSV. Dosages were increased relative to Ifnar-/- mice to account for IFN
responses interfering with rVSV-SFTSV replication and thus reducing the humoral
immune response in the immune competent mice. In contrast to what was seen with the
immune deficient mice, no weight loss was observed in the C57BL/6 mice at any vaccine
dose (data not shown). Additionally, despite the increased dosages, neutralizing titers
were far lower than those observed in Ifnar-/- mice suggesting that rVSV-SFTSV is
sensitive to IFN, consistent with previous reports (Fig. 2.2D). A dosage dependent
increase in FRNT50 titers was observed with mice receiving 106 PFU rVSV-SFTSV
achieving a mean titer of 113 (Fig. 2.2D). Notably, all mice immunized with 106 PFU
rVSV-SFTSV sero-converted (Fig. 2.2D). These data indicate that despite VSV’s
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Figure 2.2 rVSV-SFTSV induces neutralizing antibodies across different mouse
strains (A) Ifnar-/- mice were immunized with PBS, 102, 103, or 104 PFU rVSVSFTSV. Serum neutralizing antibodies were quantified by measuring 50% decrease
in pseudovirus foci, the reciprocal endpoint dilution is shown (Ordinary one-way
ANOVA; *, P<0.0332; **, P<0.0021; ***, P<0.0002; ****, P<0.0001). (B, C) AG129
mice were vaccinated with varying doses of rVSV-SFTSV and monitored for survival
(B) and had serum collected 21 days post vaccination and FRNT50 was assessed (C)
(Mantel-Cox test and ordinary one-way ANOVA; *, P<0.0332; **, P<0.0021; ***,
P<0.0002; ****, P<0.0001). (D) Wild-type C57/Bl6 mice were immunized with rVSVSFTSV and had serum neutralization titers determined at 21 days post treatment
(Ordinary one-way ANOVA; *, P<0.0332; **, P<0.0021; ***, P<0.0002; ****,
P<0.0001).
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sensitivity to IFN, rVSV-SFTSV induces responses in immunocompetent animals that
reach neutralizing titers predicted to be protective.
2.4.3 rVSV-SFTSV protects Ifnar-/- mice from lethal SFTSV challenge and reduces viral
titers in tissues
Because of the high neutralizing antibody titers measured in Ifnar-/- mice
vaccinated with rVSV-SFTSV, we hypothesized that the vaccine would protect these
mice against lethal SFTSV challenge. To test this hypothesis, vaccinated mice were
challenged subcutaneously with 10 PFU of SFTSV 23 days post-vaccination (2 days
after blood collection for neutralizing antibody titration). A single group of unvaccinated
mice received 8 days of 100 mg/kg/day of favipiravir therapy following SFTSV challenge
as a positive control for protection 174. As expected, all mice vaccinated with PBS
succumbed by 8 dpi (Fig. 2.3A). In contrast, only 60% of mice vaccinated with 102 PFU,
and all Ifnar-/- mice vaccinated with at least 103 PFU, survived the lethal SFTSV
challenge. Mice vaccinated with at least 103 PFU were protected from weight loss
following SFTSV challenge while rapid weight loss was observed in PBS-vaccinated
mice beginning by 3 dpi (Fig. 2.3B). Mild weight loss occurred post-challenge in mice
that received 102 PFU of vaccine, but this trend was driven primarily by the three
individuals that succumbed to disease. Vaccination-associated weight loss was also
observed in this experiment and was consistent in magnitude to that shown previously
(Fig. 2.1E).
To assess the effect rVSV-SFTSV vaccination has on SFTSV viremia and tissue
viral loads, groups of 4 mice were vaccinated and challenged in, parallel following the
timeline described above. These subsets of mice were sacrificed 5 days following
SFTSV challenge and serum, liver, spleen, and kidney were collected for SFTSV
quantification by endpoint titration on Vero E6 cells. All groups of vaccinated mice had
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Figure 2.3 Vaccination with rVSV-SFTSV protects Ifnar-/- mice from lethal SFTSV
challenge. (A) Survival proportions and (B) percent weight change in Ifnar-/- mice
challenged subcutaneously with 10 PFU SFTSV (blue arrow) 23 days after
intraperitoneal vaccination with PBS, or 102, 103, or 104 PFU rVSV-SFTSV (red
arrow). Weight change is reported as percentage change in body weight relative to
starting weight prior to vaccination. One group of mice received favipiravir daily for
eight days following SFTSV challenge to serve as a positive control for protection.
(Mantel-Cox test; *, P<0.0332; **, P<0.0021; ***, P<0.0002; ****, P<0.0001). (C)
SFTSV titers in serum liver, spleen, and kidney of mice five days post-challenge in
mice subjected to the same vaccination schedule as those in (A) and (B). Horizontal
dotted lines indicate the limit of detection of the assay (Ordinary one-way ANOVA; *,
P<0.0332; **, P<0.0021; ***, P<0.0002; ****, P<0.0001).
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significantly reduced SFTSV serum and tissue viral titers (Fig. 2.3C). In the liver
and kidney, there was a trend towards dose-dependence with mice vaccinated with the
highest dose of rVSV-SFTSV having the lowest viral titers. Favipiravir treatment also
reduced SFTSV titers compared to mice vaccinated with PBS. These data demonstrate
that rVSV-SFTSV does not provide sterilizing immunity to SFTSV challenge but rather
reduces replication in the vaccinated animals.
2.4.4 Passive serum transfer imparts protective immunity to naïve mice
Although our data demonstrate that rVSV-SFTSV vaccination induces
neutralizing antibody response and protects against lethal SFTSV infection, it remains
unclear if antibody-mediated immunity is sufficient to confer SFTSV protection. To
assess whether antibodies alone impart protection against lethal SFTSV infection, we
performed passive serum transfer. 60 µl or 20 µl of sera from rVSV-SFTSV-immunized
or negative control Ifnar-/- mice were administered to naïve Ifnar-/- mice either
prophylactically (2 days prior to challenge) or therapeutically (2 days post challenge).
The pooled sera used for passive transfer had an approximate FRNT50 titer of 450, while
the FRNT50 titer for negative control sera was below the limit of detection. Approximately
33% of Ifnar-/- mice receiving 60 µl of immune sera prophylactically were protected
against lethal SFTSV challenge (Fig. 2.4A). When 60 µl of immune sera was
administered therapeutically, 62% of mice survived (Fig. 2.4A). Animals given 20 µl of
immune sera were not protected from challenge regardless of when sera were
administered (Fig. 2.4A). All mice in the positive control group receiving 103 PFU rVSVSFTSV 7 days prior to challenge survived (Fig. 2.4A).
Animal weights measured daily during the study positively correlated with the
survival data (Fig. 2.4B). The most dramatic weight loss after the SFTSV challenge
occurred in the group treated with the non-immune sera and the groups treated with the
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Figure 2.4 Passive transfer of sera from immunized mice protects naïve mice
against SFTSV challenge. Survival (A) and weight loss (B) curves are shown from
naïve animals receiving immune sera either 2 days prior to or 2 days post challenge
with 10 PFU of SFTSV. Mice immunized with 103 PFU of the rVSV-SFTSV 7 days
prior to challenge served as the positive control. Blue arrow, immunization with rVSVSFTSV 7 days prior to challenge; Red arrow, passive transfer 2 days prior to
challenge; Yellow arrow, SFTSV challenge; Teal arrow, passive transfer 2 days post
SFTSV challenge. (Mantel-Cox test; *, P<0.0332; **, P<0.0021; ***, P<0.0002; ****,
P<0.0001).
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lower quantities of immune sera. All surviving mice treated with the 60 µl dose of
immune sera recovered fully from the infection after losing approximately 10% body
weight (Fig. 2.4B). The mice vaccinated with 103 PFU rVSV-SFTSV did not experience
any weight loss due to the vaccine virus or upon SFTSV infection (Fig. 2.4B).
2.4.5 rVSV-SFTSV vaccination cross protects against lethal HRTV challenge
Next, we evaluated whether vaccination with rVSV-SFTSV confers cross
protection against HRTV challenge. In AG129 mice, a dose of 104 PFU rVSV-SFTSV
was partially lethal (Fig. 2.2B). Thus, we modified immunization dosages to 102, 102.5,
and 103 PFU rVSV-SFTSV. Mice were then challenged with a lethal dose of a mouseadapted HRTV (MA-HRTV) 21 days post vaccination. A group of unvaccinated mice
were treated with 100 mg/kg/day favipiravir for 8 days following MA-HRTV challenge.
Eighty percent of the mice that received the two highest doses of 102.5 or 103 PFU rVSVSFTSV survived the challenge, with 60% of the mice vaccinated with the lowest dose
(102 PFU) also surviving (Fig. 2.5A). As expected, all PBS-vaccinated mice succumbed
to MA-HRTV disease by 8 dpi and all the favipiravir-treated animals were protected (Fig.
2.5A). Most of the infected mice experienced considerable weight loss beginning 4 to 6
days post MA-HRTV challenge (Fig. 2.5B). Surviving mice fully recovered and had
weight gain comparable to favipiravir-treated animals.
Subsets of 4 mice per experimental group were sacrificed on day 5 post MAHRTV challenge for collection of blood, liver, and spleen tissue for measurement of viral
loads by endpoint titration using an infectious cell culture assay. Mice immunized with
rVSV-SFTSV had significantly reduced MA-HRTV titers comparable to the favipiravir
positive control (Fig. 2.5C). In parallel, serum from vaccinated animals was analyzed for
FRNT50 to determine whether cross neutralization of HRTV occurred. Mice vaccinated
with 102 or 103 PFU rVSV-SFTSV had moderate SFTSV neutralization titers of 40 and
65

66

Figure 2.5 rVSV-SFTSV vaccination cross-protects animals against MA-HRTV challenge. AG129 mice were IP immunized
with escalating doses of rVSV-SFTSV then challenged with MA-HRTV 21 days post immunization. (A) Survival and (B) weight
loss curves are shown from immunization until completion of experiment. Black arrows indicate vaccination and challenge times
at -21 and 0 days respectively (Mantel-Cox test; *, P<0.0332; **, P<0.0021; ***, P<0.0002; ****, P<0.0001). (C) Four animals in
each vaccination group were sacrificed 5 days post challenge to assess serum, liver, and spleen virus titers (Ordinary one-way
ANOVA; *, P<0.0332; **, P<0.0021; ***, P<0.0002; ****, P<0.0001) (D) Sera was collected from subsets of animals 21 days post
immunization and prior to HRTV challenge. Sera was analyzed for neutralizing antibodies against HRTV using a pseudotyped
virus with the HRTV Gn/Gc glycoprotein (Ordinary one-way ANOVA; *, P<0.0332; **, P<0.0021; ***, P<0.0002; ****, P<0.0001).

60, respectively, with one mouse in each group failing to seroconvert (Fig. 2.2C). Mice
receiving 104 PFU immunization doses reached higher neutralization titers against
SFTSV but 2 of 4 animals succumbed the vaccine virus (Fig. 2.2B, C). Interestingly,
cross neutralization of HRTV was only observed in sera from 2 of 4 mice receiving 103
PFU immunizations and the surviving 104 PFU immunized animals from the safety and
immunogenicity study (Fig. 2.5D). In mice immunized with 103 PFU rVSV-SFTSV,
neutralizing titers against HRTV were at or just above the limit of detection indicating
weak cross reactivity (Fig. 2.5D). Sera from mice receiving lower immunization doses did
not have neutralization activity despite partial protection from MA-HRTV challenge (Fig.
2.5A, C, D). Lack of cross neutralization titers suggests that the protective effect in the
context of survival and reduced viral loads may be due to cell-mediated immunity or
other non-neutralizing antibody functions.
2.5 – Discussion
SFTSV is an emerging public health threat in southeast Asia with case fatality
rates ranging from 4 to 30%. This high variability in case fatality rates may reflect access
to health care, the genetic background of infected populations, and the virulence of the
infecting SFTSV strain 175-177. Given that no therapeutics or vaccines are available to
curtail or prevent an outbreak of SFTS and that the virus is transmitted by multiple tick
species with expanding geographic ranges, the threat SFTSV poses to public health is
significant 157,178. This has caused the WHO to list SFTSV in its prioritized pathogen
research blueprint and the NIAID to include it as a category C priority pathogen 35,36. In
response to the potential threat from SFTSV, many SFTSV vaccines are being
developed using a variety of different technologies including protein subunit, DNA, and
recombinant viral platforms 45,112,144,146,163,179.
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Ifnar -/- mice are susceptible to lethal SFTSV challenge and have therefore been
used to evaluate an array of SFTSV vaccines that use DNA, protein subunit, and
recombinant viral technologies 45,112,146,163. A DNA vaccine encoding the ectodomains of
Gn and Gc and a chimeric N-NSs fusion protein on a single plasmid only protected 40%
of mice from lethal challenge after three doses of vaccine 45. However, a similar vector
that contained an additional open reading frame encoding IL-12 was fully protective
using an identical vaccination schedule 45. Interestingly, neither regimen induced
neutralizing antibodies. This same group also developed a protein subunit vaccine by
fusing Gn and Gc to the Fc region of human immunoglobulin heavy chain to create GnFc and Gc-Fc, respectively 45. Vaccination of mice with either Gn-Fc or Gc-Fc in alum
induced neutralizing antibody titers greater than 1:100 in a FRNT50 assay. This
vaccination regimen, however, achieved only 50% and 0% protection from lethal SFTSV
challenge with Gn-Fc or Gc-Fc, respectively 45. Recombinant vaccinia virus and VSV
technologies have also been explored. LC16m8 strain recombinant vaccinia virus
vaccines encoding SFTSV N alone, SFTSV Gn/Gc alone, or both N and Gn/Gc in
combination fully protected against lethal SFTSV challenge 146. These vaccines however
failed to induce FRNT50 neutralizing titers greater than 1:40, and not surprisingly, the
vaccine encoding N alone failed to induce detectable neutralizing activity. Of the vaccine
platforms evaluated thus far in Ifnar -/- mice, recombinant VSVs induced the highest
neutralizing titers. In our study, mean FRNT50 neutralizing titers ranging from 282 to 642
were induced by a single dose of rVSV-SFTSV HB29 strain that ranged from 102 - 104
PFU. A similar rVSV encoding the SFTSV AH12 strain glycoprotein sequence elicited a
neutralizing titer of 682 following vaccination with a single dose of 2 x 104 PFU 112.
Aged ferrets have also been used as a lethal SFTSV model to study the efficacy
of both DNA vaccines and live-attenuated vaccines harboring mutations in NSs 144,163.
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Representative vaccines from these platforms that fully protected ferrets from lethal
challenge included a combination of two plasmids that encoded SFTSV Gn and Gc, a
combination of five plasmids that encode SFTSV Gn, Gc, RdRp, N, and NSs, a
recombinant SFTSV HB29 strain virus encoding the P102A substitution in NSs, and a
recombinant SFTSV HB29 strain virus encoding an NSs containing a truncated carboxyterminus of 12 amino acids. Both DNA vaccine platforms are given in a three dose
regimen and elicit modest levels of neutralizing antibodies. Passive transfers from
animals vaccinated against SFTSV Gn/Gc were protective suggesting neutralizing
antibodies are a correlate of protection 144. It remains unclear what contribution cellular
responses make to protection from SFTSV challenge. Unfortunately, the age-related
changes that render ferrets susceptible to lethal SFTSV challenge are unknown. This
makes it difficult to directly compare results obtained from aged ferrets to other SFTSV
animal models.
The only currently FDA-approved rVSV vaccine, rVSV-EBOV, is highly
pathogenic and lethal in Ifnar -/- mice. In contrast, rVSV-SFTSV only caused mild-tomoderate weight loss at doses that elicited protective immunity. Unlike the parental VSV
vector, rVSV-SFTSV did not cause neurologic disease when injected intracranially into
4-week-old C57BL/6 mice, suggesting that this vaccine strain is not neurotropic. Despite
these promising results, it is possible that rVSV-SFTSV may be too attenuated in
animals containing a functional IFN system. This possibility is supported by the lower
neutralizing antibody titers measured in vaccinated C57BL/6 mice compared to those in
Ifnar -/- mice. However, neutralizing serum levels in vaccinated C57BL/6 mice were
higher than titers that are typically expected to protect against other viruses such as
influenza 170. This uncertainty highlights the need for immune-competent animal models
to evaluate the efficacy of SFTSV vaccines and therapeutics.
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Neutralizing antibodies elicited in the context of a functional humoral response
are thought to be a correlate of protection against lethal SFTS in humans 180. As such,
passive transfer of sera from vaccinated animals has been previously shown to be
protective when used prophylactically in an Ifnar -/- mouse model of lethal SFTSV 112.
Extending these findings, our results demonstrated that serum from mice vaccinated
with rVSV-SFTSV could protect against lethal SFTSV challenge when used either
prophylactically or therapeutically suggesting the protective capacity of Gn/Gc-targeted
antibodies against SFTSV. In support of the role for antibodies in protection against
SFTSV disease, a monoclonal antibody recognizing Gn protects Ifnar-/- mice from lethal
challenge 181. The efficacy of neutralizing sera administered therapeutically has
implications for monoclonal antibody or antibody cocktail management of patients with
SFTS.
In addition to direct neutralization by elicited antibodies, our data also suggest
other mechanisms for protection against SFTSV pathogenesis. In our passive transfer
studies, following redistribution of transferred sera from the peritoneal cavity to the
circulation and subsequent dilution within the host’s blood, it is likely that the neutralizing
titer of the recipient’s sera would be below the limit of detection of our FRNT50 assay.
Still, the dose of antibodies contained within 60 μL of donor sera was sufficient to protect
mice under both prophylactic and therapeutic conditions. Surprisingly, we observed
better protection when sera were transferred therapeutically (2 dpi) compared to
prophylactically (-2 dpi). While the mechanisms underlying this observation are
unknown, it is possible that uncharacterized variables such as the pharmacokinetics and
bioavailability of the sera components responsible for protection at sites of virus
replication may be responsible. In addition, our results suggest that passive transfer
intervention may be beneficial in areas endemic for SFTSV within high-risk populations
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for severe SFTS that have reported recent tick bites but are yet to show symptoms.
Further studies using appropriate animal models should be conducted to better evaluate
the temporal relationship of passive transfer therapies with both infection (by
experimental inoculation or tick bite) and clinical disease onset.
Protection against lethal challenge in the absence of high neutralizing antibody
titers has been observed in SFTSV vaccines using recombinant vaccinia virus and DNA
technologies 45,146. These observations suggest that other mechanisms in addition to
neutralizing antibodies may also contribute to protection against SFTS. In this study, we
demonstrated that vaccination with rVSV-SFTSV either 7 or 21 days prior to SFTSV
challenge was fully protective (Figures 3A and 4A). Protection at 7 days, a time at which
humoral responses are not fully developed, suggests that mechanisms other than
antibodies can be protective. Since the T cell immune response peaks at approximately
7 days post-vaccination, it is possible that these cells also contribute to the protection
elicited by the vaccine 182,183. Additionally, we noted protection against SFTSV lethality in
some of the rVSV immunized mice where the neutralizing titer was below the limit of
detection. rVSVs are known to stimulate robust TH1 immune responses in vaccinated
animals and humans 102,106,107. The data presented here suggest that rVSV-SFTSV may
also confer protection by inducing type 1 immunity and CD8+ T cells. It is also possible
that NK cells or other components of the innate immune system are important mediators
of this early protective effect of the rVSV vaccine. More studies will be required to
elucidate the potential role of T cells following vaccination with rVSV-SFTSV or infection
by authentic SFTSV.
HRTV is an emerging bandavirus closely related to SFTSV that can cause lethal
disease 184,185. Previous studies have shown that sera raised by vaccination against
SFTSV glycoproteins can cross-neutralize viruses harboring HRTV glycoproteins 112. In
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addition, this same study showed that a rVSV-HRTV protects Ifnar -/- mice against lethal
SFTSV infection. The present study is the first to report that rVSV-SFTSV protects Ifnar /-

mice against a lethal HRTV challenge. Despite protection against lethal disease, sera

from rVSV-SFTSV-vaccinated mice neutralized viruses pseudotyped with HRTV
glycoproteins much less efficiently than viruses pseudotyped with SFTSV glycoproteins.
Of the four serum samples collected from AG129 mice vaccinated with 102 PFU of rVSVSFTSV, only one had a detectable neutralizing antibody titer (reciprocal dilution of 20)
against VSV pseudotyped with HRTV glycoproteins. Despite this, 60% of AG129 mice
that received this dose of vaccine survived MA-HRTV challenge. These data suggest
that other systems stimulated by rVSV-SFTSV vaccination, such as a TH1 response,
could have contributed to the protection against HRTV. Additionally, alternative effector
functions of antibodies beyond neutralization may contribute to the protective effect
described here. Further studies are needed to elucidate which immune system
components are responsible for cross-protection as the results of these studies could
inform future vaccine development for these recently emerged bandaviruses.
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2.8 – Materials and Methods
2.8.1 Cells, Viruses, and Mice
ATCC verified and mycoplasma free 293T and Vero E6 cells were maintained in
DMEM (Corning, #10-013-CV) containing 10% FBS (Corning, #35-010-CV), and 2mM Lglutamine (Corning, #25-005-Cl). Cells were passaged every 2-3 days.
Recombinant viruses harboring an additional open reading frame encoding
EGFP (refered to as VSV throughout this paper) in genomic position 5, or encoding
heterologous viral glycoproteins in genomic position 4 (rVSV-SFTSV and rVSV-EBOV)
were launched and described previously 43,186. rVSV-SFTSV and rVSV-EBOV also
contain an additional open reading frame in position five encoding mCherry. All
recombinant viruses were grown in Vero E6 cells by infecting a confluent T-175 flask at
an MOI of 0.3-0.5. Virus was collected at 48-72 hours post infection with the addition of
Hepes buffer pH7.4 to 25mM. Media was clarified by centrifuging at 6000 times gravity
for 5 minutes at 4 oC twice. Virus was then frozen at -80 oC until used for
ultracentrifugation. Virus was concentrated by ultracentrifuging virus-containing media
through a 20% sucrose gradient at 26,000rpm for 2 hours at 4 oC using SW-32 tubes in
a Beckman Coulter Optima XPN-80 ultracentrifuge. After removal of the sucrose and
media, pelleted virus was placed on ice with 500 µl hepes buffered saline overnight. The
next day virus pellets were resuspended and frozen at -80 oC. Viral titer was determined
by plaque assays on Vero E6 cells with a 1.25% Avicel RC-591 NF (DuPont, #RC591NFBA500) overlay and then stained with 1% crystal violet. Due to the size difference of
plaques created by VSV and rVSV-SFTSV, plates were processed at 36 or 72 hours
post infection, respectively unless otherwise stated.
SFTSV, strain HB29, was obtained from Dr. Robert Tesh (WRCEVA; World
reference Center for Emerging Viruses and Arboviruses at the University of Texas
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Medical Branch, Galveston, TX). The virus stock (5.6 x 106 PFU/ml; 1 passage in Vero
E6 cells) used was from a clarified cell culture lysate preparation. Virus stock was diluted
in sterile minimal essential medium (MEM) and inoculated by subcutaneous injection of
0.2 ml containing approximately 10 PFU.
The mouse-adapted HRTV (MA-HRTV) strain used was derived from the MO-4
strain obtained from Dr. Robert Tesh (WRCEVA). The MA-HRTV stock (4.7 x 108 50%
cell culture infectious dose (CCID50/ml); 1 passage in Vero E6 cells, 5 passages in
AG129 mice) used was prepared from clarified liver homogenate. The virus stock was
diluted in sterile MEM and inoculated bilaterally in two IP injections of 0.1 ml each for a
total inoculation of 40 CCID50.
C57BL/6 mice were ordered from Jackson Labs (Bar Harbor, ME). AG129 and
Ifnar-/- mice were obtained from breeding colonies at Utah State University. 4 week old
C57BL/6 mice were used for intracranial challenge experiments. 8 week old C57BL/6
mice or Ifnar-/- mice on the C57BL/6 background were used for all other experiments. All
mouse experiments were done using equal numbers of male and female mice. All mice
were given approximately 7 days to acclimate to their cages and vivarium prior to each
experiment. Mice were weighed immediately prior to all vaccination and infection
procedures. All mice were anesthetized using 1% isoflurane in air delivered by vaporizer
(Northern Vaporisers, Skipton, UK) to the anesthesia chamber. Injection sites were first
prepared by cleaning with a 70% ethanol pad. Intracranial injection experiments and
some vaccination experiments without authentic SFTSV challenge were performed
under animal biosafety level (ABSL) 2 conditions at the University of Pennsylvania. All
other vaccination experiments that included authentic SFTSV challenged were
performed in BSL3 conditions at Utah State University.
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All animals were treated ethically using complying with guidelines set by the
USDA and Utah State University Institutional Animal Care and Use Committee and the
University of Pennsylvania Laboratory Animal Resources guidelines.
2.8.2 Western Blot
Vero E6 cells were mock infected or infected with rVSV-SFTSV. At 24 hours post
infection cells were lysed, Laemmli buffer was added and samples were denatured at
95°C for 5 minutes. Samples were run on a 4-15% Biorad gel (Bio-Rad, #5671084).
Protein was transferred to a PVDF membrane (Millipore, #IPVH00010) and stained with
anti-SFTSV Gn (ProSci, #6647) or Gc (ProSci, #6651) polyclonal antibodies followed
with a secondary HRP conjugated antibody (GE Healthcare, #NA934V). Between
staining’s, membrane was stripped for an hour at room temp using restore western blot
stripping buffer (Thermo Scientific,#21059). Western blots were developed using
SuperSignal west pico PLUS chemiluminescent substrate (Thermo Scientific, #34580)
and read on an GE Healthcare Amersham 600 imager (Piscataway, NJ).
2.8.3 rVSV-SFTSV replication kinetics assay
Vero E6 cells were infected at a multiplicity of infection of 0.01 with rVSV-SFTSV
or VSV diluted in DMEM + 10% FBS for 2 hours. The inoculum was then removed and
cells were gently washed three times with PBS. Cells were then covered in fresh
complete growth medium and incubated at 37 oC. Every 24 hours, 5% of the growth
medium was removed and replaced with an equal volume of fresh growth medium.
Samples were clarified by centrifugation, transferred to fresh tubes, and frozen at -80 oC
until they were titrated by plaque assay as previously described.
2.8.4 Measurement of plaque area
Wells were imaged individually using a GelDoc XR+ with Image Lab Software
(Bio-Rad Laboratories, Hercules, CA) with Coomasie Blue settings. Images were
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analyzed using FIJI (ImageJ). First, images were thresholded using a pixel intensity
cutoff of 216. Thresholded images were then converted to binary masks. Regions of
interest were automatically drawn around plaques using the “Analyze Particles”
command. Regions of interest that contained two or more plaques were discarded and
redrawn using the “polygon ROI” tool such that regions of interest only included a single
plaque. The area of each region of interest was then measured using the “Measure” tool.
2.8.5 Immunization
Vaccines were diluted to the desired concentrations with sterile PBS just prior to
vaccination by IP injection. All immunizations were done with a 200 µl inoculum.
Favipiravir, the positive control for the rVSV-SFTSV vaccine efficacy study, was kindly
provided by the Toyama Chemical Co., Ltd. (Toyama, Japan) and prepared in a
meglumine solution for administration by IP injection.
2.8.6 Intracranial infection and neurologic sign scoring
To evaluate neuropathogenesis, 4-week-old C57BL/6 mice were injected
intracranially into the right cerebral hemisphere using a 1ml Hamilton syringe with
Repeating Syringe Dispenser (Hamilton Company, Reno, NV). Inocula contained 0, 101,
102, or 103 PFU of rVSV-SFTSV or rVSV-EGFP and were diluted to a total injection
volume of 10 μl with PBS. Mice we monitored during anesthesia recovery until they were
ambulatory. Mice were weighed daily and were observed for neurologic signs.
Neurologic signs were assigned a severity score ranging from 0-4. Mice scored “0”
showed no signs of illness and were bright, alert, and responsive when handled. Mice
scored a “1” showed mild signs of illness without clear signs of neurologic illness
including body hunching, depressed activity, or mild grimace. Mice assigned a “1” had
normal ambulation and responded normally to being handled. Mice assigned a “2” had
clinical signs consistent with mild encephalitis including hyperexcitability or altered gait
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that did not impair linear locomotion and used all four limbs. Mice assigned a “3” had
more severe neurologic signs which included paraparesis of one or two limbs, mild head
tilt, and altered gait that did impair linear locomotion (such as spinning). Mice assigned a
“4” had severe neurologic signs that were inconsistent with life including complete pelvic
limb paraplegia, ataxia, or tremors/seizures. Mice scored with a “4” were humanely
euthanized with CO2.
2.8.7 Blood collection
Mice were isofluorane anesthetized and blood was collected through the
submandibular route using Goldenrod lancets 5mm (Medipoint, Mineola, NY). Blood was
maintained on ice after collection. Serum was separated from blood by centrifugation at
8,000 RPM for 30 minutes at 4 oC in an Eppendorf 5424R centrifuge (Eppendorf, Enfield,
CT). Serum was heat inactivated by incubating at 56 oC for 30 minutes. While running
neutralization assays, serum was stored at 4 oC, for long term storage serum was frozen
at -80 oC.
2.8.8 Pseudovirus neutralization assay
Production of VSV pseudotype with SFTSV Gn/Gc: 293T cells plated 24 hours
previously at 2 X 107 cells per T-175 flask were transfected using Lipofectamine 2000
(Invitrogen, #11668-019) using manufacturers protocol. Briefly, tubes each containing
1.75ml optimem (Gibco, #31985-070) were made. In one tube 100ul of Lipofectamine
2000 reagent was added and gently mixed. In the other, 45ug of pCAG-SFTSV Gn/Gc
expression plasmid was added, tubes were allowed to sit for 5 minutes at room
temperature. Lipofectamine and DNA containing tubes of optimum were combined and
gently mixed, after 20 minutes incubating at room temperature. Solution was added to
flask of 293T cells, after 4 hours cells were fed with fresh media. Thirty hours after
transfection, the SFTSV Gn/Gc expressing cells were infected for 2-4 hours with VSV-G
77

pseudotyped VSVΔG-mNeon at an MOI of ~1-3 (Generated by deleting the cognate
VSV-G and linking mNeon to the n-terminus of P. Virus was launched as previously
described 43). After infection, the cells were washed twice with FBS-free media to
remove unbound virus. Media containing the VSVΔG-mNeon SFTSV Gn/Gc
pseudotypes was harvested 30 hours after infection and clarified by centrifugation twice
at 6000g then aliquoted and stored at -80 °C until used for antibody neutralization
analysis.
Antibody neutralization assay using VSVΔG-mNeon SFTSV Gn/Gc: Vero E6
cells were seeded in 100 μl at 2x104 cells/well in a 96 well collagen coated plate. The
next day, 2-fold serially diluted serum samples were mixed with VSVΔG-mNeon SFTSV
Gn/Gc pseudotype virus (100-200 focus forming units/well) and incubated for 1hr at 37
°C. Also included in this mixture to neutralize any potential VSV-G carryover virus was
1E9F9, a mouse anti-VSV Indiana G, at a concentration of 600 ng/ml. The antibody-virus
mixture was then used to replace the media on VeroE6 cells. 16 hours post infection, the
cells were washed and fixed with 4% paraformaldehyde before visualization on an S6
FluoroSpot Analyzer (CTL, Shaker Heights OH). Individual infected foci were
enumerated and the values compared to control wells without serum. The focus
reduction neutralization titer 50% (FRNT50) was measured as the greatest serum dilution
at which focus count was reduced by at least 50% relative to control cells that were
infected with pseudotype virus in the absence of mouse serum. FRNT50 titers for each
sample were measured in two to three technical replicates performed on separate days.
2.8.9 Virus titer determination
Virus titers were assayed using an infectious cell culture assay as previously
described187. Briefly, a specific volume of tissue homogenate or serum was serially
diluted and added to triplicate wells of Vero E6 (African green monkey kidney) cell
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monolayers in 96-well microtiter plates. The viral cytopathic effect (CPE) was determined
11 days after plating and the 50% endpoints calculated as described188. The lower limits
of detection were 1.67 log10 CCID50/ml serum and 2.43-3.14 log10 CCID50/g tissue. In
samples presenting with virus below the limits of detection, a value representative of the
limit of detection was assigned for statistical analysis.
2.8.10 Passive transfer
The immune sera from mice vaccinated with rVSV-SFTSV (approximate FRNT50
of 453), non-immune sera, and recombinant vaccine rVSV-SFTSV (7.12 x 107 PFU/ml)
were diluted with sterile PBS so that the volume of each treatment was 100 µl. Sera was
delivered by IP injection 2 days prior to or post challenge with SFTSV. Mice receiving the
rVSV-SFTSV vaccine were immunized 7 days prior to challenge. Monitoring of mouse
weight began at 7 days prior to challenge and continued 21 days post SFTSV challenge.
2.8.11 Statistical and Data Analysis
The Mantel-Cox log-rank test was used for analysis of Kaplan-Meier survival
curves. A one-way analysis of variance (ANOVA) with the Dunnett’s post test to correct
for multiple comparisons was used to assess differences in virus titers. A one-way
ANOVA with Tukey’s multiple comparisons post-hoc test was used to assess FRNT50
titers and maximum neurologic sign scores. Two-way ANOVA with Tukeys multiple
comparisons test was used for replication kinetics. Unpaired student’s t-test with unequal
variance was used to assess differences in plaque area. All statistical evaluations were
done using Prism 9 (GraphPad Software, La Jolla, CA).
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Figure 2.S1 rVSV-SFTSV expresses SFTSV glycoproteins and is attenuated in
vitro. (A) Expression of SFTSV Gn and Gc by cells infected by rVSV-SFTSV. (B)
Growth kinetics of rVSV-SFTSV and VSV in Vero E6 cells infected at a multiplicity of
infection of 0.01(Two-way ANOVA; *, P<0.0332, **, P < 0.0021). Images (C) and
surface area (D) of plaques created by VSV and rVSV-SFTSV on Vero E6 cell
monolayers 48 hours post infection. (Unpaired t-test with unequal variance; ****, P <
0.0001)
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3.1 – Abstract
Severe fever with thrombocytopenia syndrome virus (SFTSV) is a highly
pathogenic emergent bunyavirus first isolated in China in 2009. Since its discovery,
SFTSV has been shown to have a high case fatality rate and wide distribution
throughout eastern Asia where it is endemic in China, Japan, South Korea, and Vietnam.
Currently, no therapeutics or vaccines are available for the treatment or prevention of
SFTSV infection. Due to its pathogenicity, expanding range of its tick vector, and the
ability for person-to-person transmission, SFTSV is a high-priority pathogen for the
development of vaccines and therapeutics. Here, we develop a novel lipid nanoparticle
(LNP)-encapsulated nucleoside-modified mRNA-based vaccine targeting the SFTSV
glycoproteins, Gn and Gc. We compare this vaccine to the previously described
recombinant VSV SFTSV (rVSV-SFTSV) vaccine in single dose, homologous, and
heterologous prime-boost regimens. We conducted our immunizations utilizing a newly
described mouse model with an a-IFNAR antibody blockade allowing us to determine
vaccine immunogenicity in a non-immunocompromised animal model. We show that all
vaccine regimens used are protective from lethal challenge and elicit strong long-lasting
antibody responses. Furthermore, strong cellular immunity is elicited by mRNA-LNP
immunizations and by heterologous immunization with an rVSV-SFTSV prime and
mRNA-LNP boost. Cellular responses have a robust functional type 1 immune
polarization characterized by high levels of IFNg, TNFa, and IL-2. Immunization with
mRNA led to a mixed type 1/type 2 immune response, as determined by antibody
isotypes IgG1 and IgG2c, despite no detectable levels of the type 2 cytokines IL-4 and
IL-5 in spleenocytes. In comparing homologous immunization to heterologous strategies,
we found that homologous immunization leads to stronger antibody responses while
heterologous immunization drives a slightly stronger cellular response. Taken together,
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the vaccine platforms described here represent strong vaccine candidates for further
development.
3.2 – Introduction
Severe fever with thrombocytopenia syndrome virus (SFTSV, also known as
Dabie bandavirus, and formerly Huaiyangshan banyangvirus) is an emergent tickborne
bunyavirus. First identified in China in a 2011 study, SFTSV has since been identified
and is considered endemic to several southeast Asian countries including Japan, South
Korea, Vietnam, and most recently Taiwan14,15,17,19,150,189. Infection with SFTSV results in
a variety of disease symptoms including leukopenia, thrombocytopenia, fever, and the
presence of gastrointestinal symptoms14,15,151. In more severe cases hemorrhage and
multiorgan dysfunction can occur with patients generally succumbing to multiorgan
failure in fatal cases151. The initial discovery of SFTSV reported a case fatality ratio
(CFR) of 30%, more recent studies have found CFRs ranging from 6-20%14,15,151. The
wide distribution of SFTSV coincides with the range of its primary vector, the tick
Haemophysalis longicornis154,155. Other tick genera such as Ixodes and Amblyoma have
also been found positive for SFTSV though these are more uncommon156,157. The
geographic distribution of H. longicornis has been greatly expanding and now includes
Australia, New Zealand, and the United States presenting the opportunity for further
spread of SFTSV28,158-160. Additionally, though less common, SFTSV has been found to
be able to spread without its tick vector. Ferret studies show that the virus is can be
transmitted to co-housed animals in the absence of ticks, presumably through contact
with blood, feces, urine, or saliva which contain high viral loads31. Transmission from a
cat bite to a human, and human-to-human nosocomial transmissions have also been
reported32,34. Taken together, the high CFR and potential for rapid spread of SFTSV
along with a lack of approved therapeutics and vaccines have led to SFTSV being
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categorized as a high priority pathogen by both the National Institute of Allergy and
Infectious Diseases (NIAID) and the World Health Organization (WHO)35,36.
SFTSV is in the order Bunyavirales and the family Phenuiviridae. Like other
viruses in this family, SFTSV is a tri-segmented, single-stranded RNA virus with a
negative and ambisense genome. The three segments of the virus are named by their
sizes with a small (S), medium (M), and large (L) segment of which S is ambisense with
M and L being negative sense15. The S segment encodes the nucleoprotein (N) and a
non-structural protein (NSs) which antagonizes interferon (IFN) signaling15,38. The L
segment encodes the RNA-dependent RNA polymerase (RdRp) which is essential along
with N for virus replication. The M segment encodes the envelope glycoprotein which is
translated as a polyprotein and then proteolytically cleaved into its two subunits Gn and
Gc15. The Gn/Gc complex coats the exterior of the SFTSV virion and mediates receptor
binding and entry through the fusion peptide found in the Gc subunit37,41,152. The
receptors and entry factors for SFTSV remain poorly defined. It has been shown that
DC-SIGN may be a potential receptor with studies showing that cells refractive to
SFTSV infection can be made susceptible with the expression of DC-SIGN37,152.
Additionally, UGCG has been shown to be an entry factor with SFTSV virions becoming
unable to exit endosomes in UGCG knockout cells43. Studies have indicated that
antibodies directed against Gn or Gc are able to inhibit viral entry into cells making the
Gn/Gc complex the primary target for vaccine development44,45,153.
Currently there are no approved vaccines against SFTSV. In part, the lack of
vaccines and therapeutics can be attributed to the limitations of animal models. Infection
with SFTSV does not cause severe disease in wild-type mice so other mouse genotypes
or animals must be used for SFTSV vaccine development47,161,162. Currently the only
immunocompetent animal models with lethal SFTSV disease are cats and aged ferrets,
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the use of these animals for immunologic studies is limited due to lack of tools for the
analysis of immune responses and difficulty in handling48,50. This leaves small animal
models such as Stat2-/- hamsters, and Ifnar-/- mice which have been the primary animal
models used for vaccine development against SFTSV47,53,161. More recently, one study
has shown that using anti-IFNAR (a-IFNAR) antibodies in wild-type mice makes them
susceptible to lethal SFTSV challenge54. Previous vaccine development against SFTSV
has included platforms such as DNA, virus-vectored, and attenuated recombinant
SFTSV vaccines45,112,144,146,163. Here we focus on the development of a novel mRNA-LNP
based SFTSV vaccine and a heterologous prime-boost strategy with a recombinant
vesicular stomatitis virus (rVSV) vaccine we have previously described190.
Vesicular stomatitis virus (VSV) is a livestock pathogen that has been considered
as a vaccine platform for a wide variety of pathogens91,94,97. The primary draw of VSV as
a vaccine is the low sero-prevalence in humans suggesting most individuals would not
have a pre-existing immune response against the vaccine platform92. Many groups have
incorporated foreign glycoproteins into the VSV backbone due to the genetically
tractable models available and the inherent ability of VSV to incorporate foreign viruses
glycoproteins into virions93,94,97. Currently, an Ebola virus (EBOV) vaccine using an rVSV
platform is approved for use by the United States Food and Drug Administration (FDA)
and this vaccine has been successfully distributed to combat recent EBOV outbreaks in
Africa96,97. As a virus platform, rVSV-based vaccines also elicit strong type 1 immune
responses which are ideal for the elimination of intracellular pathogens such as
viruses85,102,106,107. A shortcoming of many vaccine platforms is the skewing of immune
responses to a type 2 response which is more suited to attack extracellular pathogens85.
Here, we use an rVSV-SFTSV vaccine previously shown to be safe and effective in
mice112,190.
85

The most recently FDA-approved vaccine platform utilizes mRNA. mRNA
vaccines use an in vitro transcribed mRNA strand, often including various modified
nucleosides, to elicit production of an antigen in the vaccinated individual69. This platform
is powerful, allowing the rapid design and manufacturing of vaccines against emerging
pathogens along with the benefits of no platform immunity and the potential to easily
modulate the immunogenicity of the delivered mRNA69. The biggest detriment of the
mRNA platform is the need for storage at -80°C. Recent vaccination campaigns against
SARS-CoV-2 have demonstrated the effectiveness of mRNA vaccines in controlling viral
infections191. Indeed, mRNA vaccines induce primarily a type 1 immune response with
high titers of antibodies and CD4+ T-cells124-126. Recent studies suggest the immunogen
used can impact antibody skewing to a mixed type 1/type 2 response and the ability to
elicit strong CD8+ T-cell responses is confounded by the strong responses induced in
mice but no responses in macaques124,127,130. This platform remains represents a
potential strong candidate for future vaccine development but remains unstudied in its
use against SFTSV. Here we designed an mRNA vaccine targeting the SFTSV Gn/Gc
glycoproteins to define its immunogenicity and efficacy.
In light of the SARS-CoV-2 pandemic, heterologous vaccination strategies have
come to the forefront of discussion in the scientific community. The draw of heterologous
vaccination strategies is the potential to combine the best aspects of different vaccine
platforms to get a superior response. In our study, we combined an rVSV platform
known to drive strong type 1 immune responses, and then boosted with an mRNA
vaccine to achieve high antibody titers69,107,125. Recent reports of heterologous
vaccination using an adenovirus platform followed by mRNA and vice versa have
indicated that an mRNA boost does increase antibody levels further than a heterologous
virus boost140-142,192. In regard to cellular immunity, current data indicates heterologous
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vaccination induces similar or better responses compared to homologous vaccination140142,192

. Currently, detailed analysis of immunologic phenotypes upon heterologous

vaccination remains largely undefined and attempts to analyze these responses are
limited to SARS-CoV-2 vaccines142. Here we utilize a novel mouse model using wild type
mice and a-IFNAR antibody blockade to develop a novel mRNA vaccine against SFTSV
and compare it to the previously described rVSV-SFTSV vaccine in single dose as well
as prime-boost studies. Additionally, we consider a heterologous prime boost strategy
and show that all vaccines tested elicit powerful antibody responses. Immunization with
homologous mRNA and heterologous vaccination yield comparable antibody and type 1
cytokine responses in T-cells with heterologous immunization being slightly superior in
eliciting CD4+ responses and degranulation of CD8+ T-cells. Furthermore, all
immunization strategies protect mice from lethal SFTSV challenge. Taken together, the
mRNA platform is a strong candidate for development of a human SFTSV vaccine and
heterologous prime-boost regimens may induce superior immune responses.
3.3 – Results
3.3.1 IFNAR antibody blockade recapitulates lethal infection in WT mice
Previous studies using various viruses have shown that using an a-IFNAR
monoclonal antibody blockade can lead wild type mice to succumb to infections that are
generally non-lethal193. Indeed, a previous study using a different strain of SFTSV (KH1
strain) showed that wild type C57BL/6 mice succumbed to SFTSV infection with similar,
but delayed, symptoms and disease manifestations as seen in the more commonly used
Ifnar-/- mouse model54. Since the Ifnar-/- model cannot mount a comprehensive immune
response, we optimized an a-IFNAR blockade model with SFTSV strain HB29 to fully
characterize our candidate vaccines in immunocompetent animals and then challenge
them with lethal SFTSV doses. Animals were given two doses of the a-IFNAR
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Figure 3.1 Determination of SFTSV LD50 in a-IFNAR blockade (A) Scheme for
LD50 studies. (B) Weight loss and survival (C) in mice challenged with 26, 260, 2,600,
or 26,000 CCID50 of SFTSV following a-IFNAR blockade. Panel A created using
BioRender.com
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monoclonal antibody, one dose on day -1 from challenge and one dose on day 2 post
infection (Figure 3.1 A). Several challenge doses were used ranging from 26 to 26,000
cell culture infectious dose 50% (CCID50) to determine the median lethal dose (LD50).
Challenge with SFTSV caused severe weight loss with animals beginning to succumb at
6 days post infection (dpi) (Figure 3.1 B, C). By day 9, all animals challenged with
26,000 CCID50 succumbed. (Figure 3.1 C). Interestingly, the lowest challenge dose (26
CCID50) achieved the second highest mortality with 50% of animals succumbing to
infection (Figure 3.1 C). From these data, the LD50 was determined to be 18,000 CCID50.
Based on these results, a challenge dose of 26,000 CCID50 was selected for future viral
challenges.
3.3.2 Prime-boost vaccination strategies induce powerful antibody responses against
SFTSV
To assess the efficacy and immunogenicity of an SFTSV mRNA vaccine relative
to the previously described rVSV-SFTSV, we immunized wild type C57BL/6 mice in
either single dose or prime-boost regimens (Figure 3.2 A)190. Single dose vaccine
conditions included SFTSV Gn/Gc mRNA (RS), rVSV-SFTSV (VS), and as negative
controls, firefly luciferase mRNA (RL), and rVSV-EBOV (VE). Prime boost regimens
included mRNA homologous regimens RS+RS and the negative control RL+RL, viral
homologous regimen VS+VS, the heterologous regimens VS+RS, and the negative
control VE+RL (Figure 3.2 A). A heterologous vaccination strategy using an mRNA
prime and rVSV boost was not considered due to rVSV-SFTSV containing SFTSV
Gn/Gc on the virion surface which would likely be neutralized by antibodies elicited by an
mRNA vaccination thereby preventing any significant boost. Singly vaccinated animals
were euthanized at 7 days post immunization for T-cell analysis and at 14 days for
antibody assays (Figure 3.2 A). For boosted animals, a boost dose was administered at
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Figure 3.2 Immunization with mRNA and rVSV-SFTSV platforms induce potent
humoral responses (A) Study schematic. (B) Weight loss in mice immunized in
single dose (top panel) or prime-boost regimens (bottom panel). Grey arrows indicate
dates of immunization. (C) Analysis of neutralizing antibodies by FRNT50 in single
dose (left panel) and prime-boost regimens (right panel). (D) Total IgG titers as
determined by ELISAS in single dose (left panel) and prime-boost regimens (right
panel). (E) Total IgG and FRNT50 titers plotted against each other from mice receiving
prime-boost immunizations at day 35. Simple linear regression r2=0.6599. (F)
Analysis of mouse sera in single dose (left panel) and prime-boost regimens (right
panel) for antibody serotypes IgG1 and IgG2c by ELISA. Each panel includes data
from 5-6 mice per group with equally split sexes. Limit of detection (LoD) of 20 and 50
for FRNT50s and ELISAs respectively are represented by a dashed line. Two-way
ANOVA with tukey’s multiple comparison test used in panels C, D, E, and F (p=
*<0.0332, **<0.0021, ***<0.0002, ****<0.0001). Panel A created using
BioRender.com.
21 days post prime, and animals were euthanized at day 28 post initial immunization for
T-cell analysis and day 35 for antibody assays (Figure 3.2 A). Immunization led to no
weight loss regardless of vaccination regimen (Figure 3.2 B). All mice showed a slight
drop in weight the day after immunization likely from handling stress. All mice recovered
by 2 days post immunization (Figure 3.2 B).
Using an SFTSV Gn/Gc ectodomain enzyme-linked immunosorbent assay
(ELISA), we then determined total IgG titers achieved by each vaccination strategy. In
single dose vaccinated mice, the total IgG endpoint titers reached were identical in both
RS and VS immunized mice (Figure 3.2 C). In sera from 21 days post immunization,
mice primed with RS and VS continued to have comparable endpoint titers though these
titers are approximately 2-fold higher than on day 14 suggesting continued antibody
class switching (Figure 3.2 C). After boost, homologous RS+RS and heterologous
VS+RS vaccinated mice had similar endpoint titers with geometric means of
approximately 129,000 and 100,000 respectively (Figure 3.2 C). Homologous VS+VS
immunized mice had the lowest titers at approximately 32,000 (Figure 3.2 C). Fold
changes in total IgG titers upon boost had a similar 15- and 14-fold titer increase upon
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boost between RS+RS and VS+RS groups respectively. Mice immunized with the
VS+VS regimen had a 3-fold increase in total IgG titers upon boost.
We next sought to characterize the neutralization ability of generated antibodies.
At 14 days post vaccination all single dose vaccinated mice had sero-converted, the
geometric mean titers reached were 500 and 170 for RS and VS respectively (Figure 3.2
D). Prime-boost vaccination regimens induced powerful neutralizing antibody titers from
all groups. At 21 days post vaccination serum titers were slightly increased from what
was observed at day 14 in singly vaccinated mice (Figure 3.2 D). Upon boost all mice
had increased neutralizing antibody titers (Figure 3.2 D). Homologous RS+RS
immunized mice had higher titers than all other groups with a mean neutralizing titer of
9,000, though this was not significantly higher than heterologous VS+RS immunized
mice with a mean titer of 7,240 (Figure 3.2 D). Homologous VS+VS vaccinated mice had
the lowest mean neutralizing titers (1,280) and the greatest variability in neutralizing
titers (Figure 3.2 D). Interestingly, heterologous VS+RS immunization had a 31-fold
increase in neutralizing titers upon boost, higher than the 23 and 11-fold increases seen
in RS+RS and VS+VS regimens respectively. These data suggest that homologous
mRNA and heterologous immunizations yield the best neutralizing responses though all
conditions tested, both as a single dose and as a prime-boost, induce neutralizing
antibody levels theorized to be sufficient for protection. Analysis of FRNT50 titers relative
to total IgG titers indicate a positive correlation (Figure 3.2 E). Taken together, these
data show that all vaccination strategies elicit strong antibody responses. As expected,
homologous RS+RS had the highest responses, however, heterologous boost induced
the greatest increase in neutralizing antibody titers.
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3.3.3 Homologous mRNA and heterologous immunizations stimulate powerful type I
CD4+ and CD8+ responses
To assess differences in T-cell responses from each vaccination strategy, mouse
spleens were harvested at 7 days post single dose vaccination or 7 days post boost (day
21 from experiment initiation). Spleenocytes were harvested and stimulated overnight
with either a peptide pool covering SFTSV Gn or SFTSV Gc. Cells were then analyzed
by flow cytometry for the type 1 cytokines interferon g (IFNg), tumor necrosis factor a
(TNFa), or interleukin 2 (IL-2) as well as for degranulation markers CD107a and
Granzyme B (GranzB). Flow data was analyzed flowing the gating strategy shown in
figure 3.3 A. In single dose immunization, only RS vaccinated animals showed strong
CD8+ T-cell activation with both the Gn and Gc peptide pools (Figure 3.3 B). Mice
receiving a single dose of VS also showed increases in type 1 cytokines above negative
controls RL and VE, though cytokine positivity was seen only in cells stimulated with the
Gc peptide pool (Figure 3.3 B). Stimulated CD8+ cells in both RS and VS mice showed a
large increase in INFg+ cells and modest increases in all other cytokines including
polyfunctional cells positive for multiple cytokines (Figure 3.3 B).
In CD4+ T-cells, single dose immunization only induced a detectable response in
animals immunized with RS (Figure 3.3 D). CD4+ T-cell activation in RS immunized
mice occurred with both the Gn and Gc peptide pools, interestingly, in higher activation
of CD4+ T-cells occurred with the Gn peptide pool as opposed to CD8+ T-cells which
were more potently activated by the Gc pool. (Figure 3.3 B, D). Activated CD4+ T-cells
showed increases in all cytokines tested and particularly large increases in IFNg and IL-2
(Figure 3.3 D). Taken together this data indicates that in single dose immunizations, RS
induces much more potent cellular immune responses than VS.
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Figure 3.3 Single dose RS and prime-boost regimens RS+RS and VS+RS induce
potent cellular responses (A) General gating strategy used for analysis of flow
cytometry data from spleenocytes stimulated overnight with SFTSV Gn or Gc peptide
pools 7 days after immunization. Cytokine profiling of CD8+ T-cells in single dose
immunized animals (B) and prime-boost immunized animals (C). Throughout figure,
Gn peptide pool stimulated cells are shown on the left and Gc peptide pool stimulated
cells are shown on the right. CD4+ T-cell cytokine profiling in single dose immunized
animals (D) and prime-boost immunized animals (E). Analysis of degranulation in
CD8+ T-cells by CD107a and Granzyme B are shown in single dose immunized
animals (F) and prime-boost immunized animals (G). Each panel includes data from
5-6 mice per group with equally split sexes. Ordinary one-way ANOVAs with tukeys
multiple comparisons test was used in panels B-G (p= *<0.0332, **<0.0021,
***<0.0002, ****<0.0001). In panels B-E analysis was run on total cytokine positive
cell percentage, not based on specific cytokine profiles.
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In prime-boost studies, CD8+ T-cell responses in RS+RS and VS+RS were
relatively comparable and were far superior to a homologous VS+VS strategy. Animals
immunized with RS+RS and VS+RS both had potent CD8+ immune responses when
stimulated with Gn and Gc peptide pools (Figure 3.3 C). Responses to Gn peptides were
of smaller magnitude to Gc stimulation consistent with observations of single dose
immunized mice. Interestingly, RS+RS and VS+RS achieved a similar response with
stimulation by the Gc peptide pool, with approximately 42% of cells being cytokine
positive; In contrast, VS+RS mice had a significantly lower response compared to
RS+RS when stimulated with the Gn peptide pool (Figure 3.3 C). As seen in mice
receiving a single vaccine dose, cytokine positivity is primarily attributed to the robust
production of IFNg and a large population that is IFNg+TNFa+IL2- (Figure 3.3 C).
Animals receiving a homologous VS+VS immunization regimen did not achieve a
detectable CD8+ T-cell response with Gn peptide stimulation and only achieved a mild
response over negative controls when stimulated with Gc peptides (Figure 3.3 C).
In contrast to CD8+ T-cells, cytokine profiling of CD4+ T-cells revealed a stronger
response in heterologous VS+RS immunization than homologous RS+RS treated mice,
though this was not statistically significant (Figure 3.3 E). CD4+ responses were
detected with both Gn and Gc peptide pools and were stronger in cells stimulated with
Gn peptides, consistent with single dose immunization data (Figure 3.3 D, E). Higher
induction of CD4+ T-cells in heterologous immunized mice is surprising due to no
detection of CD4+ T-cell responses with either peptide pool in mice receiving a single
dose VS immunization (Figure 3.3 D, E). Perhaps differing vaccination strategies lead to
different tissue homing for activated T-cells explaining the weak T-cell responses seen in
VS and VS+VS immunized mice. CD4+ responses had a cytokine profile featuring high
levels of both IFNg and IL-2 as well as a large population of triple positive cells producing
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IFNg, TNFa, and IL-2 (Figure 3.3 E). All trends shown here are consistent with analysis
of spleenocytes 14 days post immunization (Figure 3.S1) and when cells are stimulated
for only 6 hours (data not shown), though magnitudes of responses are decreased.
To determine CD8+ T-cell functionality we also assessed positivity to the
cytotoxic marker Granzyme B (GranzB) and the degranulation marker CD107a. In
animals receiving a single dose immunization only RS induced CD107a+GranzB+ cells
when stimulated with both the Gn and Gc peptide pool (Figure 3.3 F). Animals receiving
the VS vaccine appeared to have a very slight but statistically insignificant increase in
CD107a+GranzB+ CD8+ T-cells stimulated with the Gc peptide pool (Figure 3.3 F). In
Animals receiving a boost, RS+RS and VS+RS mice induced equivalent levels of
CD107a+GranzB+ CD8+ T-cells when stimulated with Gn peptides (Figure 3.3 G). When
stimulated with Gc peptides, VS+RS induced significantly higher levels of
CD107a+GranzB+ CD8+ T-cells than the homologous RS+RS strategy (Figure 3.3 G).
For mice immunized with VS+VS no significant induction of CD107a+GranzB+ CD8+ Tcells occurred (Figure 3.3 G). Taken together the T-cell analysis presented here
suggests that in single dose immunizations, RS is superior. However, when a boost is
given heterologous VS+RS vaccination generally performs equivalently or better than
homologous RS+RS.
3.3.4 Antibody isotype analysis indicate mRNA induces some type 2 associated
immunity despite lack of type 2 cytokines in stimulated T-cells
To further determine whether immunization strategies skewed responses to type
1 of type 2 immune profiles, we performed SFTSV Gn/Gc ELISAs to quantify IgG1 vs
IgG2c levels. In C57BL/6 mice IgG2c is associated with a type 1 immune response with
IFNg driving class switching to IgG2c81,194. In contrast, IgG1 is associated with a type 2
immune response and isotype switch to IgG1 is driven by IL-481,194. In single dose
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immunizations, VS drives primarily an IgG2c response with only low levels of IgG1 as
expected from a virus known to drive a type 1 response (Figure 3.2 F). Surprisingly,
immunization with RS led to approximately equal levels of IgG1 and IgG2c indicating a
balanced type 1 and type 2 response (Figure 3.2 F). Despite a mixed response RS and
VS immunized animals had similar titers of IgG2c (Figure 3.2 F). Upon boost, VS+VS
immunized animals had increased levels of both IgG1 and IgG2c though IgG2c titers
remained approximately 2 logs higher than IgG1 (Figure 3.2 F). Mice receiving the
RS+RS regimen had a slight boost to IgG1 though isotype IgG2c showed the biggest
boost in titer (Figure 3.2 F). Despite this small boost in IgG1 RS+RS mice had the
highest mean IgG1 titer of any group by approximately 1 log (Figure 3.2 F). Finally,
heterologous VS+RS vaccination had both IgG1 and IgG2c responses boosted by
approximately 1.5 logs. Heterologous VS+RS immunization had an intermediate
polarization compared to homologous RS+RS and VS+VS regimens (Figure 3.2 F).
To further determine immune polarization to type 1 or type 2 responses we
assessed peptide stimulated T-cells for the presence of the type 2 associated cytokines
IL-4 and IL-5 at 7 days post immunization. Confusingly, despite the presence of the IL-4
driven IgG1 antibody isotype in some vaccination groups no IL-4+ CD4+ T-cells were
detected in any vaccination regimen (Figure 3.4 B, C). Similarly, another type 2 cytokine
IL-5 was not detected in any immunization regimen (Figure 3.4 D, E). Type 2 cytokines
continued to not be detected when spleenocytes were analyzed 14 days post
immunization (Figure 3.S2). Perhaps different tissues, such as the lymph nodes, may
contain IL-4+ CD4+ T-cells or timing for the detection of these cytokines is crucial in our
vaccination strategies.
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Figure 3.4 Immunization with mRNA and rVSV platforms do not induce type 2
cytokines IL-4 and IL-5 (A) General gating strategy used for analysis of flow
cytometry data from spleenocytes stimulated overnight with SFTSV Gn or Gc peptide
pools 7 days after immunization. IL-4 cytokine profiling of CD4+ T-cells in single dose
immunized animals (B) and prime-boost immunized animals (C). Throughout figure,
Gn peptide pool stimulated cells are shown on the left and Gc peptide pool stimulated
cells are shown on the right. CD4+ T-cell IL-5 cytokine profiling in single dose
immunized animals (D) and prime-boost immunized animals (E). Each panel includes
data from 6 mice per group with equally split sexes. Ordinary one-way ANOVAs with
tukeys multiple comparisons test was used in panels B-E, no significant comparisons
were found.
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3.3.5 Prime-boost vaccination regimens are fully protective from SFTSV challenge
After characterizing the immune responses elicited by our various vaccination
strategies, we next sought to determine whether these vaccines would provide
protection from challenge with a lethal dose of SFTSV. Date of challenge was set as day
0, initial immunization occurred on days -35 for animals receiving two vaccine doses,
and day -14 for animals receiving a single dose as well as animals receiving a boost. On
day -1 and day 2 mice had a-IFNAR antibodies administered IP.
Animals receiving a single dose of eithers RS or VS lost no weight upon
challenge and were protected by immunization (Figure 3.5 A, B). A single mouse
receiving VS immunization succumbed on day 1 post challenge as a result of injury
during the virus challenge (Figure 3.5 B). Negative control immunized mice receiving RL
or VE had severe weight loss after challenge and high lethality in RL immunized mice
(Figure 3.5 A, B). Surprisingly, VE immunized mice appeared to be protected from lethal
challenge with 90% of mice surviving despite severe weight loss (Figure 3.5 A, B). In
prime-boost regimens, mice immunized with RS+RS, VS+RS, and VS+VS all were fully
protected from lethal challenge and exhibited no weight loss (Figure 3.5 A, B). As with
single dose immunized mice, RL+RL and VE+RL mice had severe weight loss and
RL+RL mice succumbed by day 6 post-challenge with a 30% survival rate (Figure 3.5 A,
B). Animals receiving a VE prime again appeared to be partially protected with an 80%
survival rate (Figure 3.5 A, B). Decreased lethality relative to what was seen in Figure
3.1 is hypothesized to be partially attributed to mice being older and more acclimated to
the animal facilities, due to a 35 day immunization protocol, as well as long lasting
antiviral responses elicited by initial VE immunization.
Two days prior to SFTSV challenge, sera were taken from immunized mice for
neutralizing antibody analysis. As previously reported, both single dose and prime-boost
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Figure 3.5 All immunization conditions are protective from lethal SFTSV challenge C57/Bl6 mice were
immunized according to previously described vaccination regimens. Mice received a-IFNAR antibody blockades
on day -1 and 2 post challenge with challenge (day 0) occurring 14 days after the last received immunization
dose. Weight loss (A) and survival (B) are shown for both single dose and prime-boosted animals. (C) Serum
was collected from all animals 2 days prior to challenge for neutralizing antibody titer determination. (D) SFTSV
titers in liver, spleen, and serum were determined in a subset of mice sacrificed at 4 days post SFTSV challenge.
Ordinary one-way ANOVAs with tukeys multiple comparisons test was used in panels C and D (p= *<0.0332,
**<0.0021, ***<0.0002, ****<0.0001).

immunized animals had high titers of neutralizing antibodies (Figure 3.5 C). In VS
immunization group, two animals failed to sero-convert, yet both of these animals
survived lethal challenge implying non-neutralizing antibodies or cellular responses
mediated protection from lethal challenge (Figure 3.5 C).
Lethal infections of SFTSV in humans are characterized by high viremia. To
determine the ability of our vaccine candidates to control SFTSV infection, 4 mice from
each immunization group were sacrificed at 4 days post challenge to determine viral
titers in the liver, spleen, and serum. In single dose immunized animals both RS and VS
immunization decreased tissue SFTSV titers equivalently (Figure 3.5 D). Similarly, all
three prime-boost regimens, RS+RS, VS+RS, and VS+VS, induced significant
decreases in SFTSV titers in the liver and spleen (Figure 3.5 D). Significant decreases in
titers in the serum were only observed in RS+RS and VS+VS immunized mice, though
VS+RS immunization did decrease serum titers relative to RL+RL (Figure 3.5 D).
Immunization with VE also led to significant decreases in SFTSV titers in liver and
spleen when given in single dose (Figure 3.5 D). In prime-boost studies, VE+RL mice
also had decreased SFTSV titers though these decreases were not significant and were
of lower magnitude than in single dose animals (Figure 3.5 D).
3.3.6 High levels of antibody are maintained for months after vaccination
An important factor in considering the efficacy of vaccines is the longevity of the
immune response. To determine whether our vaccine regimens could produce a longlived immune response, animals were immunized as described in figure 2A and
maintained with sera collections occurring approximately every one to two months.
Serum analysis by FRNT50 and ELISA showed that immunized mice had similar titers as
previously described at days 21 and 35 post immunization (Figure 3.2 C, 3.6 A, B). Over
time, animals receiving a single dose VS immunization had the lowest titers of all groups
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Figure 3.6 All immunization conditions elicit long lived antibody responses (A) Analysis of neutralizing antibodies by
FRNT50 in immunized mice over extended period. (B) Total IgG titers as determined by ELISA in immunized mice. Each
panel represents data from 5-6 mice per group with equal sex distribution. Limit of detection (LoD) of 20 and 50 for
FRNT50s and ELISAs respectively are represented by a dashed line.

which stabilized at approximately 100 and 2500 for FRNT50 and total IgG respectively
(Figure 3.6 A, B). Animals receiving a single dose RS immunization and the prime-boost
VS+VS regimen reached and maintained identical titers for both neutralizing antibodies
and total IgG (Figure 3.6 A, B). For animals receiving the RS+RS or the heterologous
VS+RS immunization regimens, titers peaked at day 35 at similar levels but VS+RS
animals had decreasing neutralizing titers while RS+RS animals maintained neutralizing
antibody titers of approximately 6,000 for 200 days before seeing decreasing titers
(Figure 3.6 A). For VS+RS receiving animals neutralizing titers began to plateau at
approximately 180 days post initial vaccination with neutralizing titers of 1100 (Figure 3.6
A). Interestingly, total IgG for both RS+RS and VS+RS had similar titers and a slight
downward trend over time despite VS+RS having a more substantial decrease in
neutralizing titers over the same period (Figure 3.6 A, B). Taken together, all vaccines
induce long lived antibody responses that plateau in the long term with neutralizing
antibody titers that are likely protective.
3.4 – Discussion
SFTSV is a recently emerged pathogen with a high case fatality ratio14,15. The
expanding range of the vector responsible for transmitting SFTSV and the ability of the
virus to spread in nosocomial and veterinary settings highlights the need for
development of targeted vaccines and therapeutics to this pathogen28,32,34,158. In light of
these factors, several health organizations including the NIAID and WHO have listed
SFTSV as a priority pathogen for the development of therapeutics35,36. This has led to
several vaccine platforms such as protein subunit, DNA, and recombinant virus
platforms to be explored45,112,144,146,149,190. Here we added the mRNA platform as a
potential candidate for an SFTSV vaccine. Previous work has shown that mRNA is able
to drive high antibody titers and strong T-cell activity124-126. Furthermore, we characterize
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and compare both rVSV and mRNA immunizations in single dose and prime-boost
regimens including a heterologous model with an rVSV prime and mRNA boost (the
reverse regimen was not considered due to the likelihood of mRNA induced antibodies
neutralizing the rVSV vaccine boost). Heterologous vaccination has recently come to the
forefront of vaccine research due to the approval for heterologous “mix-and-match” use
of the SARS-CoV-2 vaccines around the world192. This vaccine regimen offers the
potential to combine the strongest characteristics of each vaccine platform used to
impart the strongest possible immune response. Our data suggest that heterologous
immunization against SFTSV induces potent immune responses.
Most vaccine studies have thus far used Ifnar-/- mice as a challenge model to
evaluate vaccine efficacy45,112,144,146,149,190. While these models have been sufficient and
yielded data suggestive of vaccine efficacy, the model is not suitable for all studies due
to its immunocompromised status. IFN signaling is essential for innate immune functions
and for the development of adaptive immune responses. Following a previous study that
indicated an antibody blockade against IFNAR made wild-type mice susceptible to lethal
SFTSV infection, we were able to utilize a novel model wherein we immunized
immunocompetent mice for characterization of immune responses54. Utilizing an aIFNAR blockade, these mice could then be made susceptible to SFTSV infection for
vaccine efficacy studies. Currently the only other immunocompetent animals available
that exhibit lethal disease upon challenge with SFTSV are cats and ferrets48,50. While
both animal models are superior to the aa-IFNAR blockade in the sense of not needing
any immunomodulation, they have many draw backs. Both cats and ferrets are more
expensive to purchase and maintain, and both animals have increased likelihoods of
biting or scratching the researcher potentially leading to a transmission event in the
absence of a tick as previously described31,34. Ferrets only manifest lethal disease when
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aged >4 years, the reason for this age dependence remains unknown though it is likely
due to the natural weakening of immune responses as animals age48. Finally, there is a
lack of available reagents and tools for the analysis of immune responses in both cats
and ferrets, making detailed immunological phenotyping as presented in this work not
possible.
Currently developed and tested vaccines demonstrate inferior immune responses
than what was measured in our homologous mRNA and heterologous rVSV+mRNA
strategies. Current vaccine research against SFTSV includes a DNA vaccine encoding
the SFTSV Gn and Gc ectodomains along with an N-NSs fusion protein45. In a threedose immunization of Ifnar-/- mice, this vaccine imparted 40% protection from lethal
challenge45. When the authors added IL-12 to the vaccine plasmid, to aid in cellular
responses, full protection was observed45. Neither vaccination condition induced any
detectable neutralizing antibodies45. This group then analyzed responses to recombinant
protein vaccines by immunizing mice with Gn or Gc fusions to an Fc region with the
adjuvant Alum45. These immunizations led to a neutralizing antibody response with titers
ranging from 1:100 to 1:1000, interestingly this resulted in only 50% or 0% protection in
mice immunized with Gn or Gc respectively45. Another strategy used was a vaccinia
virus platform to deliver SFTSV Gn/Gc146. In this vaccine, high levels of total IgG are
reached but neutralization is severely lacking with vaccinated mouse sera unable to
neutralize 50% of virus at a 1:40 dilution146. In contrast to these and other studies, we
achieve higher total IgG and neutralizing titers. Additionally, we demonstrate that these
titers are maintained for almost a year after initial immunization. We and others have
previously shown, by passive transfer studies, that antibodies are a correlate of
protection against SFTSV112,144,146,190. The high levels of antibodies maintained over time
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thus suggest these vaccination regimens are likely to provide long lived immunity from
SFTSV infection.
T-cell responses and their contributions to protection from SFTSV remain largely
unexplored. One study using vaccinia virus immunizations has shown that CD8+ T-cell
depletion does not impact survival upon lethal challenge146. This data, however, is
confounding as depletion was done in mice that were immunized and thus had SFTSV
directed antibody responses146. Despite weak neutralizing titers, total IgG titers were
high and could mediate protection through opsonization, complement activation, and
natural killer cell mediated antibody dependent cellular cytotoxicity146. Indeed, CD8+ cell
depletion did not affect survival in mice immunized with a vaccinia strain encoding
SFTSV Gn/Gc but did have an impact in mice receiving just SFTSV N as an antigen146.
Since antibodies cannot bind to N which is only found within cells or virions, this
suggests that excluding antibody mediated protection T-cells do in fact contribute to
protection146. Other groups using DNA vaccine platforms have also demonstrated that
animals are protected when immunized with internal SFTSV proteins which do not
induce neutralizing antibodies144. These studies suggest that T-cells may be important in
the control and clearance of SFTSV upon infection. The cellular responses induced by
other SFTSV vaccines are poorly characterized. Here we showed that mRNA
vaccination as a single dose or in a prime-boost models potently induces polyfunctional
CD4+ and CD8+ T-cells. CD8+ responses in heterologous vaccinated animals is
comparable to homologous mRNA immunization though heterologous vaccinated
animals exhibit higher degranulation of Granzyme B in cells stimulated with the SFTSV
Gc peptide pool. Interestingly heterologous immunization consistently activates more
CD4+ T-cells than homologous mRNA vaccination, though these differences are not
statistically significant. Surprisingly, immunization with rVSV-SFTSV in a single dose or
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prime-boost regimen induced weak or no T-cell responses. This is perhaps due to VSV
being considerably attenuated by switching the cognate glycoprotein to SFTSV Gn/Gc
which is not abundant on the cell surface where VSV buds112,190,195. This attenuation
likely results in weak viral replication which is further controlled by VSV’s sensitivity to
IFNs. Taken together, heterologous and homologous mRNA immunizations displayed
the strongest T-cell responses which other studies suggest may be an important factor in
protection from SFTSV infections.
In designing vaccines, it is important to consider the polarization of immune
responses towards a type 1 or 2 response85. Previous studies have shown that improper
immune polarization may have deleterious impacts on the immunized patient90. This is
best demonstrated in respiratory syncytial virus studies that determined the tested
vaccines drove a type 2 response resulting in vaccine associated enhancement of
disease90. Viral diseases and other intracellular pathogens are best controlled by type 1
responses characterized by cytokines such as type I IFNs, IFNg, TNFa, and IL-2 along
with antibody isotypes IgG2a/c (depending on mouse strain) 85. In contrast, type 2
responses are suited for large extracellular pathogens and produce IL-4, IL-5, and IL-13
along with antibody isotypes IgE and IgG185. In antibody analysis of type 1 and 2
responses we found that mRNA immunization led to a mixed polarization with
approximately equal titers of IgG1 and IgG2c (Figure 3.2 F). Upon boost with mRNA
these animals saw increased titers in both isotypes. In contrast, immunization with the
rVSV platform led to a primarily IgG2c response. Heterologous immunization was a
mixed phenotype with high levels of IgG2c and intermediate IgG1 titers. Interestingly,
cellular analysis indicated a strong type 1 phenotype in mRNA immunized animals (for
single and prime-boost regimens) and heterologous immunized mice with no IL-4 and IL5 being detected. Perhaps this can be explained by mRNA vaccines being potent
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activators of T follicular helper cells, which have been previously shown to be driven to a
mixed polarization despite strong type 1 polarization in other CD4+ T-cells124,127. Further
characterization of T-cell subsets and lymphoid T-cells is necessary to ascertain the
reasons for a mixed polarization in antibody analysis versus a strong type 1 skewing in
analyzed T-cells.
Despite differences in immune profiling, all tested conditions were protective
upon lethal challenge. Interestingly our negative control mice immunized with VE and
VE+RL were also partially protected from lethal challenge with SFTSV. This is
presumably from activation and long-lasting effects of interferon stimulated genes upon
immunization with VE. Similar observations of long-lasting non-specific vaccine
responses have been reported after vaccination with the live attenuated polio virus
vaccine and the live attenuated pertussis vaccine196-198. Other studies have implied that
long-lasting non-specific immunity may be due to long-lived IFN responses, likely due to
upregulation of IFN stimulated genes, inhibiting subsequent infection199. Infections with
VSV induce strong IFN responses which are known to activate pathways that make an
animal refractory to subsequent infection. This has previously not been described in
other studies using similar rVSV negative controls, likely due to the use of Ifnar-/- mice
which cannot initiate the innate immune responses our wild type mice can. Despite this
protection in a negative control, we can still conclude that our VS immunizations induce
specific protective responses not due to innate immunity as no weight loss was seen in
VS or VS+VS immunized animals, in contrast VE and VE+RL immunized animals did
survive challenge but suffered severe weight loss. Additionally, a temporal effect can be
observed in tissue SFTSV titers in animals receiving a single dose VE immunization as
opposed to VE+RL animals. Challenge of VE immunized animals occurred 14 days post
immunization, in these animals SFTSV tissue titer was similar to titers in mice receiving
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RS or VS immunizations. In prime-boost VE+RL animals, challenge occurred 35 days
after the last RE dose was delivered. In these animals SFTSV tissue titers were
decreased relative to our RL+RL negative control but not as low as animals receiving
RS+RS, VS+RS, or VS+VS. This is consistent with the hypothesis of IFN mediated
protection as we would expect waning protection over time.
Overall, the data presented highlight the potential for both mRNA and rVSV
based vaccines against SFTSV. In homologous immunization, the mRNA platform
greatly outperforms rVSV in immunologic stimulation. However, immune characterization
cannot currently be directly correlated to protection. Due to this, extensive work is
required to determine whether the differences seen in immunologic responses will
translate to clinical differences. Additionally, other considerations must be considered
when choosing a vaccine platform. An mRNA platform suffers from necessitating a cold
chain which is difficult to maintain in isolated rural areas. Meanwhile, the rVSV-platform
is well proven in isolated rural areas as demonstrated by the effective rollout of the rVSV
based EBOV vaccine97. As has been suggested by other studies, heterologous
immunization induces a somewhat superior or equivalent cellular response to
homologous mRNA vaccination, and a somewhat weaker or equivalent humoral
response140-142,192. These data are supported by human and animal studies of SARSCoV-2140-142,192. Approval of vaccines designed to be delivered in heterologous strategies
faces approval hurdles due to the need to demonstrate safety for two platforms.
However, as we have recently seen in the SARS-CoV-2 pandemic, the use of
heterologous immunizations has great potential for use in emergency situations where
availability of different vaccine platforms may be lacking. Currently there are no
approved SFTSV vaccines, in this study we demonstrate two viable platforms for
potential development and three highly efficacious prime-boost regimens.
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3.8 – Materials and Methods
3.8.1 Ethics Statement
All animals were treated ethically complying with guidelines set by the USDA and
Utah State University Institutional Animal Care and Use Committee and the University of
Pennsylvania Laboratory Animal Resources guidelines. Animals were humanely
euthanized once approved endpoints were reached.
3.8.2 Cells, Viruses, and Mice
ATCC verified and mycoplasma free 293T and Vero E6 cells were maintained in
DMEM containing 10% cosmic calf fortified serum (HyClone, #SH30087.03), 2mM L-
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glutamine (Corning, #25-005-Cl), and 1mM Sodium Pyruvate (Gibco, #11360-070). Cells
were passaged every 2-3 days and maintained for no more than 20 passages.
Recombinant viruses encoding heterologous viral glycoproteins in genomic
position 4 (rVSV-SFTSV and rVSV-EBOV) were launched and described previously.
rVSV-SFTSV and rVSV-EBOV also contain an additional open reading frame in position
five encoding mCherry. All recombinant viruses were grown in Vero E6 cells by infecting
a confluent T-175 flask at an MOI of 0.3-0.5. Virus was collected at 48-72 hours post
infection with the addition of Hepes buffer pH7.4 to 25mM. Media was clarified by
centrifuging at 6000 times gravity for 5 minutes at 4 oC twice. Virus was then frozen at 80 oC until used for ultracentrifugation. Virus was concentrated by ultracentrifuging viruscontaining media through a 20% sucrose gradient at 115,500 times gravity for 2 hours at
4 oC using SW-32 tubes in a Beckman Coulter Optima XPN-80 ultracentrifuge. After
removal of the sucrose and media, pelleted virus was placed on ice with 500µl hepes
buffered saline overnight. The next day virus pellets were resuspended and frozen at -80
o

C. Viral titer was determined by plaque assays on Vero E6 cells with a 1.25% Avicel

RC-591 NF (DuPont, #RC591-NFBA500) overlay and then stained with 1% crystal violet.
SFTSV, strain HB29, was obtained from Dr. Robert Tesh (WRCEVA; World
reference Center for Emerging Viruses and Arboviruses at the University of Texas
Medical Branch, Galveston, TX). The virus stock (5.6 x 106 PFU/ml; 1 passage in Vero
E6 cells) used was from a clarified cell culture lysate preparation. Virus stock was diluted
in sterile minimal essential medium (MEM) and inoculated by intraperitoneal injection of
0.2 ml containing approximately 26, 260, 2,600, 26,000 CCID50 for LD50 studies, and
26,000 CCID50 in challenge studies. For challenge experiments, animals were given 1
mg of a-IFNAR1 monoclonal antibody clone MAR1-5A3 (Leinco Technologies, St. Louis,

111

MO, #I-1188) by intraperitoneal injection on days -1 and 0.5 mg of a-IFNAR1
monoclonal antibody on day 2 post challenge.
C57BL/6 mice were ordered from Jackson Labs (Bar Harbor, ME). All mouse
experiments were done using equal numbers of male and female mice. All mice were
given approximately 7 days to acclimate to their cages and vivarium prior to each
experiment. Mice were weighed immediately prior to all vaccination and infection
procedures. Mice receiving intradermal injections at the University of Pennsylvania were
anesthetized using 1% isoflurane in air delivered by vaporizer (Northern Vaporisers,
Skipton, UK) to the anesthesia chamber. Mice at Utah State University were
anesthetized for intradermal injections using a bell jar and open-drop method. Injection
sites were first prepared by cleaning with a 70% ethanol pad. Vaccination experiments
without authentic SFTSV challenge were performed under animal biosafety level (ABSL)
2 conditions at the University of Pennsylvania. All other vaccination experiments that
included authentic SFTSV challenge were performed in ABSL3 conditions at Utah State
University.
3.8.3 Production of mRNA-LNP Vaccines
The codon-optimized Gn/Gc glycoprotein gene from SFTSV and firefly luciferase
were synthesized (Genscript) and cloned into an mRNA production plasmid. A T7-driven
in vitro transcription reaction (Megascript, Ambion) using linearized plasmid template
was performed to generate mRNA with 101 nucleotide long poly(A) tail. Onemethylpseudouridine (m1Ψ)-5’-triphosphate (TriLink) instead of UTP was used to
generate modified nucleoside-containing mRNA. RNAs were capped using the m7G
capping kit with 2’-O-methyltransferase (ScriptCap, CellScript) to obtain cap1 as
described200. Cellulose-based purification of mRNAs was performed as described201. All
mRNAs were then tested on an agarose gel before storing at -20°C. The cellulose112

purified m1Ψ-containing mRNAs were encapsulated in LNPs using a self-assembly
process as previously described wherein an ethanolic lipid mixture of ionizable cationic
lipid, phosphatidylcholine, cholesterol and polyethylene glycol-lipid was rapidly mixed
with an aqueous solution containing mRNA at acidic pH202. The RNA-loaded particles
were characterized and subsequently stored at -80°C at a concentration of 1 mg/ml.
3.8.4 Enzyme linked immunosorbent assay (ELISA)
Production of SFTSV Gn and Gc ectodomains: The SFTSV Gn ectodomain
(amino acids 20-452) and Gc ectodomain (amino acids 562-996) were cloned from
pCAG-SFTSV Gn/Gc and put into the pHLsec expression vector which adds a secretion
signal and c-terminal His tag to inserted sequence. FreeStyle 293-F cells grown in
FreeStyle 293 Expression Media (Gibco, #12338018) were co-transfected using
293Fectin (Gibco, #12347019) with pHLSec-SFTSV Gn and pHLSec-SFTSV Gc
plasmids encoding ectodomains of SFTSV Gn or Gc. Supernatants were collected 4
days post-transfection and purified by nickel-nitrilotriacetic acid resin (Qiagen, #30210)
according to the manufacturers protocol. Eluted protein was concentrated and buffer
exchanged into PBS using an Amicon Ultra-15 Centrifugal Filter with a 30 kDa MWCO
(Millipore, #UFC903024) and frozen at -80°C.
ELISA: Immulon 2HB (Thermo Scientific, #3455) plates were coated with
0.75µg/ml of purified SFTSV Gn/Gc ectodomains in sodium carbonate at 4oC overnight.
The next day ELISA plates were washed with phosphate buffered saline containing 0.1%
Tween-20 (PBS-T) and blocked for an hour at room temperature with 3% milk in PBS-T.
Mouse sera was diluted in 1% milk in PBS-T and serialy diluted 2-fold with an initial
dilution of 1:50, 1:800, or 1:3200. Plates were incubated with diluted mouse sera for 2
hours at room temperature. Secondary HRP conjugated antibodies for total IgG (GE
Healthcare, #NA931), IgG1 (Cell Signaling Technologies, #96714S), and IgG2c (Cell
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Signaling Technologies, #56970S) were diluted in 1% PBS-T at 1:5000, 1:6000, or
1:4000 respectively and staining was done at room temperature for an hour. Prior to
experiments IgG1 and IgG2c antibodies were normalized against known concentrations
of their target antigens so comparisons between isotypes could be made. SureBlue TMB
1 component substrate (KPL, #52-00-01) was then added to plates and quenched after 5
minutes with 250mM HCl. Absorbance at 450nm was immediately read on a SpectraMax
190 microplate reader (Molecular Devices, San Jose, CA). Endpoints were determined
as OD values twice as high as the background on a negative control run on each plate.
Samples lacking absorbance at our lowest dilution of 1:50 were assigned a titer of 25
signifying titers below the limit of detection.
3.8.5 Immunizations
Vaccines were diluted to the desired concentrations with sterile PBS just prior to
vaccination by IP injection for rVSV based vaccines and intradermal injections for mRNA
vaccines. Viral vaccines were done with a 200µl inoculum and mRNA vaccines were
done with a 50µl inoculum.
3.8.6 Blood collection
Mice were isofluorane anesthetized and blood was collected through the
submandibular route using Goldenrod lancets 5mm (Medipoint, Mineola, NY). Blood was
maintained on ice after collection. Serum was separated from blood by centrifugation at
8,000 RPM for 30 minutes at 4 oC in an Eppendorf 5424R centrifuge (Eppendorf, Enfield,
CT). Serum was heat inactivated by incubating at 56 oC for 30 minutes. While running
neutralization assays and ELISAs, serum was stored at 4 oC, for long term storage
serum was frozen at -80 oC.
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3.8.7 Pseudovirus neutralization assay
Production of VSV pseudotype with SFTSV Gn/Gc: 293T cells plated 24 hours
previously at 2 X 107 cells per T-175 flask were transfected using Lipofectamine 2000
(Invitrogen, #11668-019) using manufacturers protocol. Briefly, tubes each containing
1.75ml optimem (Gibco, #31985-070) were made. In one tube 100ul of Lipofectamine
2000 reagent was added and gently mixed. In the other, 45ug of pCAG-SFTSV Gn/Gc
expression plasmid was added, tubes were allowed to sit for 5 minutes at room
temperature. Lipofectamine and DNA containing tubes of optimum were combined and
gently mixed, after 20 minutes incubating at room temperature. Solution was added to
flask of 293T cells, after 4 hours cells were fed with fresh media. Thirty hours after
transfection, the SFTSV Gn/Gc expressing cells were infected for 2-4 hours with VSV-G
pseudotyped VSVΔG-mNeon at an MOI of ~1-3 (Generated by deleting the cognate
VSV-G and linking mNeon to the n-terminus of P. Virus was launched as previously
described 43). After infection, the cells were washed twice with FBS-free media to
remove unbound virus. Media containing the VSVΔG-mNeon SFTSV Gn/Gc
pseudotypes was harvested 30 hours after infection and clarified by centrifugation twice
at 6000g then aliquoted and stored at -80 °C until used for antibody neutralization
analysis.
Antibody neutralization assay using VSVΔG-mNeon SFTSV Gn/Gc: Vero E6
cells were seeded in 100 μl at 2x104 cells/well in a 96 well collagen coated plate. The
next day, 2-fold serially diluted serum samples were mixed with VSVΔG-mNeon SFTSV
Gn/Gc pseudotype virus (100-200 focus forming units/well) and incubated for 1hr at 37
°C. Also included in this mixture to neutralize any potential VSV-G carryover virus was
1E9F9, a mouse anti-VSV Indiana G, at a concentration of 600 ng/ml. The antibody-virus
mixture was then used to replace the media on VeroE6 cells. 16 hours post infection, the
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cells were washed and fixed with 4% paraformaldehyde before visualization on an S6
FluoroSpot Analyzer (CTL, Shaker Heights OH). Individual infected foci were
enumerated and the values compared to control wells without serum. The focus
reduction neutralization titer 50% (FRNT50) was measured as the greatest serum dilution
at which focus count was reduced by at least 50% relative to control cells that were
infected with pseudotype virus in the absence of mouse serum. FRNT50 titers for each
sample were measured in two to three technical replicates performed on separate days.
3.8.8 Flow Cytometry
Mouse spleens were harvested and placed in RPMI (Gibco, # 11875-085) with
10% FBS (Corning, #35-010-CV). Spleens were smashed between two slides to make
single cells suspension. Cells were filtered through a 70um cell strainer (Biologix, Cat #
15-1070). ACK lysis buffer (Quality Biological, Cat # 118-156-101) was used to lyse red
blood cells. Remaining cells were then resuspended in RPMI containing 10% FBS,
glutamine (Corning, #25-005-Cl), and b-mercaptoethanol (Sigma-Aldrich, #M7522).
Peptide pools containing SFTSV Gn or SFTSV Gc peptides (GenScript, Piscataway, NJ)
were added to cells at 1.5ug/ml for an hour at 37 C in the presence of a-CD28 antibody
(BD, #553295). Golgi plug (BD, #555029) and golgi stop (BD, #554724) were then
added to cells and incubated overnight at 37 C. If staining for CD107a PE-Cy7 (BD,
#560647), antibody was added along with golgi plug/golgi stop and stained overnight.
Extracellular staining was then done in FACS buffer for 30 minutes at 4 C with L/D Aqua
(Invitrogen, #L34957), a-CD8 Pacific Blue (Biolegend, #100725), and a-CD4
PerCP/Cy5.5 (Biolegend, #100434). Cells were fixed using BD fix/perm solution (Cat
#554722) then stained intracellularly with a-IL-2 BV711(Biolegend, #503837), a-TNFa
PE-Cy7(BD, #557644), a-IFNg AF-700(BD, Ca#557998), a-CD3 APC-Cy7 (BD,
#557596), a-Granzyme B (BD, #560213). Cells were analyzed on a BD LSRII flow
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cytometer with high-througput system using FACSDIVA software (BD Biosciences). Flow
data was then analyzed and prepared for presentation with FloJo software (FloJo LLC).
3.8.9 Serum and Tissue Virus Titers
Virus titers were assayed using an infectious cell culture assay as previously
described187. Briefly, a specific volume of tissue homogenate or serum was serially
diluted and added to quadruplicate wells of Vero E6 (African green monkey kidney) cell
monolayers in 96-well microtiter plates. The viral cytopathic effect (CPE) was determined
10 days after plating and the 50% endpoints were calculated as described188. The assay
lower limits of detection were 1.67 log10 CCID50/ml serum and 2.27 log10 CCID50/g tissue.
3.8.10 Statistical and Data Analysis
All serological assays were analyzed with two-way analysis of variance (ANOVA)
with tukey’s multiple comparisons test. T-cell assays were analyzed with ordinary oneway ANOVAs with tukey’s multiple comparisons test. All statistical evaluations were
completed on Prism 9 (GraphPad Software, La Jolla, CA).
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Figure 3.S1 Single dose RS and prime-boost regimens RS+RS and VS+RS
continue having strong cellular responses 14 days after immunization Gating
strategies like those used in Figure 3.3 were used for analysis of flow cytometry data
from spleenocytes stimulated overnight with SFTSV Gn or Gc peptide pools 14 days
after immunization. Cytokine profiling of CD8+ T-cells in single dose immunized
animals (A) and prime-boost immunized animals (B). Throughout figure, Gn peptide
pool stimulated cells are shown on the left and Gc peptide pool stimulated cells are
shown on the right. CD4+ T-cell cytokine profiling in single dose immunized animals
(C) and prime-boost immunized animals (D). Analysis of degranulation in CD8+ Tcells by CD107a and Granzyme B are shown in single dose immunized animals (E)
and prime-boost immunized animals (F). Each panel includes data from 6 mice per
group with equally split sexes. Ordinary one-way ANOVAs with tukeys multiple
comparisons test was used in panels A-F (p= *<0.0332, **<0.0021, ***<0.0002,
****<0.0001). In panels A-D analysis was run on total cytokine positive cell
percentage, not based on specific cytokine profiles.

118

Figure 3.S2 No immunization conditions are positive for the type 2 cytokines IL4 and IL-5 at 14 days post immunization. Gating strategies like those used in
Figure 3.4 were used for analysis of flow cytometry data from spleenocytes
stimulated overnight with SFTSV Gn or Gc peptide pools 14 days after immunization.
IL-4 cytokine profiling of CD4+ T-cells in single dose immunized animals (A) and
prime-boost immunized animals (B). Throughout figure, Gn peptide pool stimulated
cells are shown on the left and Gc peptide pool stimulated cells are shown on the
right. CD4+ T-cell IL-5 cytokine profiling in single dose immunized animals (C) and
prime-boost immunized animals (D). Each panel includes data from 5-6 mice per
group with equally split sexes. Ordinary one-way ANOVAs with tukeys multiple
comparisons test was used in panels A-D, no significant comparisons were found.
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CHAPTER 4: Discussion
4.1 – Summary of findings
Severe fever with thrombocytopenia syndrome virus (SFTSV) is an emerging
bunyavirus with a high case fatality ratio, posing considerable risk of causing large,
deadly outbreaks. Currently, no therapeutics or vaccines are approved for treatment or
prevention of SFTSV infection. The goal of this dissertation was to explore recombinant
vesicular stomatitis virus (rVSV) and mRNA vaccine platforms against SFTSV and to
determine the safety, immunogenicity, and efficacy of these exploratory vaccines in
small animal models.
In chapter 2, we assessed an rVSV-SFTSV vaccine in a single dose model. A
common concern with rVSV based vaccines is neuropathogenesis, which is commonly
observed in wild type VSV and sometimes reported in rVSVs98,109,110. To address this
safety concern, we performed intracerebral injections into 4-week old wild type mice.
None of the mice infected with rVSV-SFTSV developed any signs of neuropathy or
succumbed to infection. To further demonstrate safety, we showed that immunization of
the immunocompromised Ifnar-/- mouse strain was not lethal. This finding indicates that
an rVSV-SFTSV vaccine may be safe in immunocompromised humans. Immunogenicity
and challenge experiments showed that the rVSV-SFTSV vaccine induced high levels of
neutralizing antibodies and was protective from lethal SFTSV challenge. Antibodies
appear to be a correlate of protection from SFTSV infection as passive transfer of sera
from immunized mice to naïve mice was protective upon lethal challenge with SFTSV.
We then evaluated the ability of rVSV-SFTSV immunization to cross protect from lethal
challenge with a mouse adapted strain of the closely related Heartland virus (HRTV).
Despite a lack of detectable neutralizing antibodies, we found that rVSV-SFTSV
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immunization induced partial protection from lethal HRTV challenge. Taken together, this
work demonstrated the safety and efficacy of rVSV-SFTSV as a vaccine against SFTSV.
In chapter 3, we developed a novel mRNA based SFTSV vaccine and compared
it to our previously described rVSV-SFTSV vaccine both in single dose, and prime-boost
regimens. To assess the immunogenicity of our vaccines in an immunocompetent
animal model, we first used an a-IFNAR antibody blockade to make wild-type mice
susceptible to lethal SFTSV challenge. Once a working immunocompetent animal model
was developed, we began assessing the immunogenicity of our vaccine platforms. In
single dose immunizations we found that mRNA vaccines induced similar titers of total
IgG, and higher levels of neutralizing antibodies against the SFTSV glycoproteins Gn/Gc
than immunizations with rVSV-SFTSV. Interestingly, rVSV-SFTSV immunization induced
only weak T-cell responses while mRNA robustly activated both CD8+ and CD4+ Tcells. Despite the weaker immune response observed in rVSV-SFTSV immunized
animals relative to mRNA immunization, both groups were protected from lethal
challenge with SFTSV, showing no weight loss upon challenge.
In prime-boost studies, trends were consistent with those observed in single dose
immunizations. Animals receiving homologous mRNA vaccinations demonstrated higher
total IgG and neutralizing antibody titers than homologous rVSV-SFTSV immunized
animals. Similarly, homologous mRNA immunized animals had potent activation of
CD4+ and CD8+ T-cells while homologous rVSV-SFTSV receiving mice had mild cellular
responses. In a lethal SFTSV challenge model, both prime-boost regimens were equally
effective in protecting animals from death and preventing weight loss. Further analysis of
immune polarization showed that cellular responses from mRNA and rVSV-SFTSV
vaccines in both single dose and prime-boost models were skewed towards a type 1
cytokine profile with no detectable levels of type 2 cytokines. Interestingly, antibody
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isotype analysis indicated that rVSV-SFTSV vaccines drove a strong type 1 response
(with high titers of primarily IgG2c), while mRNA immunization drove a mixed type 1/2
response with high titers of IgG1 and IgG2c. When homologous immunizations were
compared to a heterologous (rVSV-SFTSV prime, mRNA boost) strategy, we found that
total IgG and neutralizing antibody titers were similar to homologous mRNA
immunization. T-cell response analysis showed heterologous immunization had similar
cytokine profile compared to homologous mRNA strategies. As with all other conditions,
no type 2 cytokines were detected in heterologous immunized animals; though, the type
2 associated antibody isotype IgG1 was detected at intermediate levels between those
seen with homologous mRNA and rVSV-SFTSV immunizations. Heterologous
immunization was protective from lethal challenge with no weight loss in challenged
mice. Ultimately, our data suggests that all tested vaccine platforms and strategies are
safe and immunogenic.
4.2 – General discussion and future directions
4.2.1 rVSV-SFTSV vaccine
Our studies in chapter 2 and 3 demonstrate that rVSV-SFTSV is protective but
does not induce cellular and humoral responses as robust as seen with mRNA
immunization. This finding was surprising as rVSV based vaccines have frequently been
shown to induce high levels of antibodies and good cellular responses102,106,107. While
good antibody responses were achieved, T-cell activity was limited in our studies. The
cause of this limited activity is likely due to rVSV-SFTSV being overly attenuated. We
and other groups have shown that while rVSV-SFTSV reaches similar titers to wild-type
VSV, it lags about 36 hours behind wild-type VSV112,190. The slower growth of rVSVSFTSV relative to wild-type VSV is clearly seen when comparing the much smaller
plaque sizes of rVSV-SFTSV relative to wild-type VSV112,190. This slowed growth
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combined with VSV’s sensitivity to IFN likely result in the rapid control of rVSV-SFTSV in
immunized animals preventing robust activation of T-cells. Several potential methods are
available to address the over-attenuation of rVSV-SFTSV.
It is well described that VSV buds at the plasma membrane, with budding
mediated by the matrix protein6. In contrast, SFTSV buds into the endoplasmic
reticulum-Golgi intermediate compartment (ERGIC) and Golgi, with SFTSV Gn/Gc
demonstrating strong Golgi localization signals6,195. This mislocalization of the
glycoprotein and the VSV proteins to different cellular locations is the likely cause of
rVSV-SFTSV attenuation. Our vaccine strain rVSV-SFTSV likely relies on SFTSV Gn/Gc
leaking from the Golgi to the plasma membrane, VSV components mislocalizing to the
Golgi and exiting the cell similarly to SFTSV, or a combination of these. The localization
signals maintaining SFTSV Gn/Gc in the ER/Golgi have not yet been fully mapped;
However, preliminary data from our lab and others, suggest that a coat protein complex I
(COPI) binding motif (RxxKxx) in the c-terminus of Gc may contribute to the observed
ERGIC/Golgi localization195. A single amino acid mutation (K-3A) to the COPI motif has
been shown to increase Gn/Gc localization to the plasma membrane thereby allowing us
to correct viral component mislocalization195. Indeed, preliminary work from our lab
shows that VSV pseudotype virus production with K-3A mutant Gn/Gc leads to much
higher virus titers than wild type SFTSV Gn/Gc. Future work is needed to characterize
whether an rVSV-SFTSV K-3A mutant would induce superior immunogenicity when
used as a vaccine.
An alternative solution to solve attenuation of rVSV-SFTSV is the manipulation of
the VSV genome. Wild type VSV has its genome organized from the 3’ end with the
nucleoprotein (N) encoded first, followed by the phosphoprotein (P), the matrix protein
(M), the glycoprotein (G), and finally the large RdRP (L). This organization is important
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as the RdRp transcribes mRNAs sequentially from the 3’ end with a probability of
dislodging from the template strand after each mRNA is produced6,203. This leads to a
higher quantity of N mRNA being produced than P, and more P than M and so on204.
Altering the gene order can alter the relative levels of protein produced204. Therefore,
changing the gene order for rVSV-SFTSV from it’s current N-P-M-Gn/Gc-L to Gn/Gc-NP-M-L may lead to increased production of SFTSV Gn/Gc, resulting in higher titers and a
less attenuated rVSV-SFTSV. Some studies have shown that genome alterations like
those described above can attenuate VSV, while other genetic modifications, such as
the addition of a fluorescent protein open reading frame, have resulted in minimal virus
attenuation205,206. If attenuation is observed, it may be possible to further manipulate
protein levels and restore virulence with 2A self-cleaving peptides. These peptides allow
2 proteins to be encoded by one mRNA by inducing ribosomal skipping at the 2A
sequence, which results in the release of the nascent protein. Once ribosomal
translation begins again, a second protein is produced207. Development of next
generation VSV platforms featuring altered genome organizations will require extensive
testing to assess effects on virulence. Next generation rVSVs may also be useful in
attenuating rVSVs that are too virulent. For example, the rVSV-EBOV vaccine virus that
is currently FDA approved for use in humans is lethal in Ifnar-/- mice and is known to
cause severe side effects in humans97,165. A next generation rVSV-EBOV vaccine could
potentially offer improved immunogenicity and safety. Importantly, development of an
rVSV-SFTSV K-3A or next generation rVSV-SFTSV platforms will require further
evaluation of vaccine safety. It is likely that as we attempt to increase virulence to
improve immunogenicity, we will in turn negatively impact safety, an ideal vaccine
candidate must balance safety and immunogenicity.
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Two alternatives to increase immunogenicity without altering our current rVSVSFTSV platform include increasing immunization dosage, and the use of adjuvants.
Immunizations in chapters 2 and 3 were done using 106 PFU inoculums. This is a high
dose of virus considering that the only rVSV vaccine currently approved for human use
has been found to have optimal immunogenicity at 2x107 PFU208,209. Using too high of a
dose may lead to inflammation and serious side effects. Furthermore, increasing
inoculum titer leads to a reliance on production of more virus, which takes longer to grow
and requires more resources, thereby making production inefficient. Adjuvants offer a
viable alternative to overcome issues surrounding dosing by stimulating the immune
system and thus amplifying immune responses upon vaccination. Unfortunately, most
adjuvants in use today drive a type 2 immune response, which is not well suited to
respond viral infections210. Type 1 response driving adjuvants have been developed in
research settings but are not yet approved for human use211,212. Further work is required
to determine whether novel adjuvants may improve rVSV-SFTSV immunogenicity and to
achieve approval of type 1 skewing adjuvants in humans.
A final consideration of rVSV based vaccines is their ability to elicit rapid nonspecific responses. In our Ifnar-/- studies, mice immunized with a single dose of rVSVSFTSV 7 days prior to lethal challenge were fully protected. Other studies have
demonstrated that immunization with rVSVs expressing Marburg glycoproteins provided
rapid protection from challenge when administered 3-7 days prior to challenge and even
when administered post-exposure103-105. One potential use for this property of rVSV
vaccines is in post-exposure prophylaxis. Laboratory needle sticks are a relatively
common source of infection, using an rVSV vaccine post-exposure may be protective in
some circumstances. Another interesting application of rVSV based vaccines was seen
in our a-IFNAR studies where we observed that rVSV-EBOV immunized animals were
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protected from lethal challenge in single dose, and when receiving mRNA luciferase
boosts. In contrast, vaccination with mRNA luciferase alone did not elicit protective
responses. Non-specific rapid protection has been observed in several vaccines such as
the live attenuated polio vaccine and the pertussis vaccine196-199. Similarly to what has
been observed in our own work, studies suggest this non-specific protection may last
over a month. Due to kinetics and functional characteristics of the adaptive immune
response, this protection cannot be mediated by B- and T-cells and is thus likely due to
upregulation of innate immune factors such as IFN stimulated genes (ISGs). ISGs are
known to have antiviral functions that act broadly and rapidly. A potential use of this
broad non-specific protection elicited by rVSVs is in remote and economically
disadvantaged areas where it is difficult to follow up with patients and/or maintain a cold
chain. Immunization with rVSV based vaccines (which can be lyophilized and maintain
infectivity) could potentially protect patients from infection against the immunogen
delivered and provide non-specific protection against other common pathogens108.
Taken together, rVSV is a powerful vaccine platform that may be effectively used against
many pathogens, and can be modified to provide the best possible responses.
4.2.2 mRNA SFTSV vaccine
Using the mRNA vaccine platform, we developed a novel SFTSV vaccine
candidate and demonstrated strong immunogenicity. In both single dose and primeboost regimens, mRNA SFTSV vaccination induced powerful cellular and humoral
responses. Interestingly, we observed mRNA vaccines generated powerful cellular type
1 immunity characterized by the type 1 cytokines IFN, TNF, and IL-2. We did not detect
CD4+ T-cells positive for the type 2 cytokines IL-4 and IL-5. Despite the lack of type 2
cytokines, mRNA immunization led to a mixed antibody response with both IgG2c (type
1 isotype), and IgG1 (type 2 isotype, IL-4 is required for class switch to IgG1). Other
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studies have reported similar findings of mixed antibody responses and largely type 1
skewed CD4+ responses124,127. These studies found that while CD4+ T-cells remain type
1 skewed, a subset of CD4+ cells called follicular helper T-cells (Tfh) shows mixed type
1/2 polarization124,127. This explains the discrepancy we observed in the skewing of
immune responses in antibodies and secreted cytokines. These same studies also
suggest that different antigens encoded by mRNA vaccines may impact the immune
polarization with some antigens skewing responses to type 1 while other antigens favor
a mixed response124,127. Further work is required to dissect the responses incurred by
our mRNA SFTSV vaccine to various cellular subsets.
mRNA vaccine technologies allow for the delivery of many potential
immunogens. In our studies we used SFTSV Gn/Gc, but other SFTSV targets may be
used alone or in conjunction to Gn/Gc. Protein subunit vaccine studies have
demonstrated that neutralizing antibodies may be made to either subunit of SFTSV
Gn/Gc, which highlights the possibility of mRNA vaccines encoding only Gn or Gc45.
Immunization with individual Gn/Gc subunits may drive immune responses to target
certain epitopes of SFTSV Gn/Gc more potently. Epitope mapping of SFTSV Gn/Gc
would also be beneficial in order to establish which epitopes may drive strong T-cell
responses allowing for targeted vaccine development. Targeting non-surface SFTSV
proteins, such as the nucleoprotein (N), is also an interesting proposition. With nonstructural targets, cellular responses such as CD8+ T-cells would be critical. We have
demonstrated that our mRNA vaccines drive strong CD8+ responses in mice though
other studies suggests this may not necessarily translate to other animal
models124,127,130. It is important to consider the impact that different immunogens may
have on the polarization of the immune response as previous work has demonstrated
that changes in mRNA vaccine immunogens may alter immune polarization.
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Nevertheless, exploring different mRNA immunogens against SFTSV warrants further
work.
4.2.3 Heterologous vaccines
Historically, heterologous vaccination strategies in humans have been avoided;
However, since the COVID19 pandemic, heterologous immunizations have received
renewed attention and emergency authorization has been granted to “mix-and-match”
COVID19 vaccines192. Few studies have done in depth analysis of immunologic
responses to heterologous immunizations140-142,192. Preliminary analyses show that
heterologous immunization induces similar to slightly inferior levels of antibodies as
homologous mRNA immunization, and equivalent to slightly superior cellular
responses140-142,192. These results are largely similar to what we have shown, though our
studies dive into more immunologic detail. We also compare rVSV+mRNA immunization
while other studies have studied an adenovirus prime in the context of COVID19.
Our studies demonstrated that heterologous immunization induces similar
immunogenicity to homologous mRNA immunization despite an attenuated rVSV prime.
Antibody responses in heterologous immunization demonstrated the highest fold
increase in neutralizing antibody titers. Increasing the virulence of the rVSV-SFTSV
prime may lead to higher antibody titers after prime and potentially superior titers to
homologous mRNA after boost. Similarly, T-cell responses with a single dose of rVSVSFTSV were lacking in comparison to responses in mice receiving a single dose of
mRNA SFTSV; However, upon boost, mice receiving heterologous immunizations had
slightly superior T-cell responses in CD4+ T-cells and CD8+ T-cell granzyme B
degranulation. These results are particularly interesting due to the relative lack of T-cell
stimulation observed upon immunization with rVSV-SFTSV. These results imply that
rVSV-SFTSV did prime T-cells to mount a robust response despite our results. Further
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characterization of the response to rVSV-SFTSV is necessary to determine whether
certain cellular subsets, organs, or response timing can explain the discrepancies
observed between the prime and boost immunizations. Taken together, increasing the
immunogenicity of the first dose may lead to heterologous immunization eliciting superior
antibody and T-cell responses.
Heterologous immunization demonstrated robust T-cell activation, however, Tcell contributions to protection from SFTSV currently remain unknown. Previous studies
have suggested that T-cells may contribute to protection from lethal challenge with
SFTSV while other studies have suggested CD8+ T-cells are not necessary45,54,146.
Currently, no studies have been done to directly determine the contribution of T-cells.
Further work is thus required in the form of adoptive transfers to conclusively assess Tcell contributions to protection from lethal SFTSV challenge. Further studies such as
these could be used to determine whether CD4+, CD8+ T-cells populations, both, or
neither are sufficient to impart protection from SFTSV. Currently, antibodies are the only
known correlate of protection for SFTSV, therefore, determining the impact of T-cells
would further our understanding of the correlates of protection for SFTSV infection and
inform future vaccine development.
Attaining approval for two vaccine platforms simultaneously presents one of the
primary obstacles to heterologous vaccines platforms. Vaccine approval requires that all
reagents in the vaccine exhibit favorable safety profiles and meet good manufacturing
practices. Having multiple platforms in a vaccine regimen would complicate safety trials
and impose more work on pharmaceutical companies than using a single platform. As
vaccine development is already relatively unprofitable for pharmaceutical companies,
they are unlikely to push for vaccine strategies that may impose further financial barriers
for approval unless governments impose incentives. The current COVID19 pandemic,
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however, demonstrates that governments may embrace heterologous immunizations in
times of vaccine shortages or emergency situations. Additionally, if evidence appears for
mRNA vaccination inducing superior responses to other platforms it is reasonable that
boosters may be given to individuals previously immunized with different vaccine
platforms. However, an enduring difficulty of mRNA vaccines is the necessity for cold
chains. The delivery of these vaccines to rural and hard to reach areas remains difficult
and further work is necessary to address cold chain requirements of mRNA vaccines.
4.2.4 Animal models & cross protection
A concession that must be made in developing vaccines is that animal models do
not accurately represent human immune responses. Nevertheless, it is necessary to
select a model that has a similar disease progression and immune system for vaccine
trials to occur. Most SFTSV work currently relies on the Ifnar-/- mouse which is
immunosuppressed; therefore, these mice are not representative of the immune
competent humans we would like to protect with vaccinations. The novel a-IFNAR
blockade model attempts to address these shortcomings by using mice that have
functional immune systems and are only temporarily immunosuppressed to sensitize
animals to lethal disease. Further work is necessary to validate other candidate SFTSV
vaccine platforms and assess whether immunogenicity of these vaccines is altered in
animals with fully competent immune systems. Additionally, validation of the a-IFNAR
blockade mouse model with other related bunyaviruses such as HRTV is required to
assess its suitability for research of other pathogenic bunyaviruses lacking adequate
mouse models.
We have demonstrated that rVSV-SFTSV immunization was cross-protective
from lethal challenge with HRTV. Neutralizing antibody data demonstrated only low titers
of cross-neutralizing antibodies, suggesting protection was mediated by cellular
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responses or other non-neutralizing antibody functions. This is contradictory to
previously published data where SFTSV/HRTV cross-neutralization was observed112. In
this previous study, a different strain of SFTSV Gn/Gc was delivered as an immunogen
than what was used in our studies, suggesting that cross-neutralization and maybe
cross-protection may be determined to some extent by the immunogen strain112. Further
work is necessary to assess SFTSV strain impacts upon cross-protection from HRTV or
other pathogenic bunyaviruses. In preliminary experiments we observed crossneutralization of the Puumala (PUUV) hantavirus upon immunization with rVSV-SFTSV.
This suggests that conserved epitopes may exist that could be targets for the
development of vaccines targeting highly divergent bunyaviruses. Further work is
necessary to determine whether such epitopes can be targeted and what vaccine
platforms and immunogens may effectively drive an immune response towards these
epitopes.
4.3 – Closing remarks
Overall, this work addresses the lack of SFTSV targeting vaccines by analyzing
the safety and immunogenicity of two vaccine platforms. Additionally, we explored novel
animal models for use in SFTSV research, and used a heterologous vaccine regimen
that proved to be effective at inducing robust immune responses. The two vaccine
platforms we explored have favorable immunogenicity and represent strong candidates
for the development of anti-SFTSV vaccines for human use. As evidenced by the recent
COVID19 pandemic, it is necessary to have easily modified vaccine platforms with well
described safety and immunogenicity to facilitate the rapid response to global disease
threats. Further work is necessary with both vaccine platforms to address safety,
immunogenicity, and delivery concerns; however, these platforms are strong options for
use against future emergent pathogens.
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